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Chapter 1  
Introduction 
 
1.1 Transition Metal-Catalyzed Asymmetric Hydrogenation: A Brief 
Introduction[1] 
 
After the pioneering work by Wilkinson and Coffey, who discovered that a phosphine-
based rhodium catalyst ([RhCl(PPh3)3]) was able to catalyze the reduction of unsaturated 
carbon-carbon bonds,[2] metal-catalyzed hydrogenation has attracted increasing interest 
and has been developed into an extremely powerful method in the organic chemist’s 
repertoire. In particular the preparation and deployment of chiral catalysts that enable 
the enantioselective hydrogenation of prochiral, unsaturated compounds to give highly 
enantioenriched molecules has been the object of numerous studies. The quest for chiral 
transition metal complexes to be used as homogeneous catalysts for hydrogenation 
started in the late 1960s. A milestone in this discovery process is the work of Knowles, 
who developed a chiral version of the Wilkinson catalyst by replacing the 
triphenylphosphine with a chiral phosphine (CAMP, Figure 1)[3] and, later on, with a 
bisphosphine ligand (DIPAMP) inspired by Kagan (DIOP).[4]  
 
 
Figure 1: Structure of the first generation phosphine and biphosphines used in rhodium-catalyzed 
asymmetric hydrogenation. 
 
Following these seminal studies, a plethora of chiral phosphine-based ligands were 
developed in a short period of time for the rhodium-catalyzed asymmetric hydrogenation 
of C=C bonds.[5] The substrate scope of this reaction though was limited to α-
dehydroamino acids,[4d] until the discovery that the BINAP-ruthenium system developed 
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by Noyori could be used to catalyze the asymmetric hydrogenation of a broader range of 
functionalized alkenes and, subsequently, ketones.[6] 
The fundamental work carried out by Knowles and Noyori in this field was awarded with 
the Nobel Prize for Chemistry in 2001.[6d,7] 
Besides the use of neutral rhodium complexes, like the Wilkinson’s catalyst, in transition 
metal-catalyzed hydrogenation, Schrock and Osborn[8] showed that also cationic species 
can catalyze this transformation. They found out that rhodium complex 1, bearing two 
phosphines and a diene as ligands, reacted under hydrogenation conditions in the 
presence of a coordinating solvent like acetone, methanol or tetrahydrofuran to afford 
bis-solvated species 2 (Scheme 1). Such species could be isolated and turned out to be 
catalytically active.  
 
 
Scheme 1: Study of the activity of cationic rhodium complexes by Schrock and Osborn.  
 
These experiments demonstrated that the dissociation of a solvent molecule from 
complex 2 is required to allow the coordination of the olefin substrate to the metal center 
and to start the catalytic cycle. This rate-determining step was found to be fast for these 
rhodium catalysts,[9] but it was not for the corresponding iridium analogs, which were 
almost inactive.[8a]  
The pioneering work of Schrock and Osborn[8] represents the first application of dienes, 
and in particular 1,5-cyclooctadiene (COD), as ligands for stabilizing the precatalyst. In the 
presence of hydrogen the COD ligand is reduced and leaves the coordination sphere of 
the complexes generating a cationic, coordinatively unsaturated catalyst precursor. 
 
Nowadays, asymmetric hydrogenation is a powerful tool for the stereoselective synthesis 
of chiral molecules which find widespread application in both academia and industry. In 
fact, this reaction is characterized by numerous advantages, such as very high 
enantioselectivities, low catalyst loading, perfect atom economy and high conversions. All 
these features can be observed in the archetypal rhodium-catalyzed asymmetric 
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hydrogenation depicted in Scheme 2, where the stereogenic center of 4 is installed by 
hydrogenation of 3 affording a key intermediate in the synthesis of L-DOPA,[10] a drug used 
in the treatment of Parkinson’s disease. 
 
 
Scheme 2: Key step in the synthesis of L-DOPA (Monsanto L-DOPA process). 
 
Another classic example of asymmetric hydrogenation is the synthesis of (R)-citronellol, 
an intermediate in the preparation of vitamin E, or (S)-citronellol starting from geraniol or 
nerol respectively and using Ru(S)-(BINAP)(OAc)2 as the catalyst (Scheme 3).[11] 
 
 
Scheme 3: Ru catalyzed asymmetric hydrogenation of allylic alcohols. 
 
The major drawback of Rh- and Ru- catalyzed asymmetric hydrogenation is the need for a 
coordinating group like an alcohol, a carboxylic acid, an amine or an ester, that directs the 
hydrogenation process, as shown in Scheme 2 and Scheme 3. This feature explains the 
chemoselectivity observed in Scheme 3, where the trisubstituted olefin adjacent to the 
alcohol is reduced, while the other double bond at C6 remains untouched. In fact, only a 
few Ru and Rh complexes bearing chiral bisphosphorous ligands gave successful results in 
the hydrogenation of unfunctionalized olefins.[12] This limitation could be overcome by 
the use of chiral catalysts based on other transition metals, like platinum,[13] zirconium or 
titanium. Indeed, after some pioneering work by Kagan,[14] Vollhardt[15] and Paquette,[16] 
Buchwald described the use of chiral titanium[17] and zirconium[18] cyclopentadienyl 
derivatives for the asymmetric hydrogenation of unfunctionalized olefins. Despite the 
high enantioselectivites and conversions achieved using this methodology, the catalysts 
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developed by Buchwald were not broadly used in either academia or industry. Such metal 
complexes indeed present several disadvantages as they are moisture- and air-sensitive, 
require harsh reaction conditions and are effective only with a low substrate/catalyst 
ratio.[17-18] Moreover, the catalyst precursors need activation by reaction with n-BuLi to 
generate the low-valent titanocene[17] and zirconocene[18] complexes. 
 
 
1.2 Iridium-Catalyzed Asymmetric Hydrogenation[1b,19] 
 
The first report of the use of iridium in hydrogenation reactions has been published by 
Crabtree,[20] roughly ten years after the discovery of the Wilkinson catalyst. At that time, 
the research community was not interested in applying iridium for such transformation, 
since the iridium analogs of the Wilkinson catalyst, [IrCl(PPh3)3] was known to react 
irreversibly with dihydrogen to form the stable [IrClH2(PPh3)3] complex. This species, 
unlike the Wilkinson catalyst, fails to undergo dissociation of a phosphine ligand to allow 
the binding of the olefin to the metal and thus starting the catalytic cycle.[9] Similarly, the 
cationic iridium complexes [Ir(COD)PR3]+ synthesized by Schrock and Osborn[8], showed 
weak activity toward hydrogenation of olefins in coordinating solvents (see Scheme 1). 
Crabtree and coworkers recognized that this low activity was related to the binding 
strength of the solvent molecules bound to the metal center. They postulated that the 
strong coordinating solvents used in these experiments inhibit the dissociation of the 
latter from the active catalyst species, avoiding the coordination of the olefin and thus 
impeding the catalytic cycle. In order to circumvent catalysts deactivation, Crabtree 
decided to investigate the activity of [Ir(COD)(PR3)2]PF6 complexes in a non-coordinating 
solvent. After discouraging results in benzene, toluene and hexane, the use of 
dichloromethane and chloroform resulted in high activities. It was somewhat surprising 
that chlorinated media were the solvent of choice, since it was known that they might 
oxidize and deactivate low-valent complexes used in hydrogenation and were therefore 
avoided in Rh- and Ru-catalyzed hydrogenation.[2a]  
Among many related complexes, [Ir(COD)PCy3(Py)]PF6, the so-called Crabtree catalyst, 
turned out to be the most active catalyst for the hydrogenation of di-, tri- and tetra-
substituted unfunctionalized olefins in non-coordinating solvents.[8b,21] The disadvantage 
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of such complex is the competitive degradation to inactive dimers or trimers during the 
course of the reaction, which explains the low levels of conversion observed in spite of 
the high initial turnover frequency (TOF) observed.[22] 
 
While the first chiral version of the Wilkinson catalyst was developed in a relatively short 
time,[3] it took almost 20 years before the first chiral version of the Crabtree catalyst was 
disclosed. In 1997, our group published the first iridium-catalyzed asymmetric 
hydrogenation using bidentate N,P-ligands as chirality source (Scheme 4).[23] 
 
Scheme 4: First example of iridium-catalyzed asymmetric hydrogenation. 
 
This catalyst class, named PHOX, is based on chiral oxazolines, which are derived from 
chiral amino acids and a tertiary phosphine.[24] These ligands have found application also 
in palladium[24a,24b,24d] and iridium[24c] catalyzed allylic substitution reactions as well as 
other transition metals-catalyzed reactions. 
In 1998 another reports by our group showed the power of this catalyst class in the 
hydrogenation of unfunctionalized olefins (Scheme 5).[25] 
 
 
Scheme 5: Application of PHOX ligand L2 in the asymmetric hydrogenation of unfunctionalized olefins. 
 
 
A variety of unfunctionalized olefins could be reduced with very good enantioselectivities 
but, unfortunately, high catalyst loading was required to achieve good conversions.[25] 
Despite the high initial TOF, the catalyst underwent deactivation in a short period of time. 
Addition of molecular sieves and the use of dry solvents resulted beneficial, although not 
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sufficient to reach full conversion. The cause of this deactivation, like in the case of 
Crabtree’s catalyst, was found to be the irreversible formation of an inactive trinuclear 
complex.[26] 
1.2.1 Counterion Effect 
 
When the hexa fluoro phosphate (PF6-) counteranion was replaced by the bulky 
tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BArF-),[27] only a very low catalyst loading 
(0.3 mol%) was necessary to achieve full conversion in the asymmetric hydrogenation of 
unfunctionalized olefins (compare Scheme 5 and Scheme 6).[25] 
 
Scheme 6: Counterion effect on the iridium-catalyzed asymmetric hydrogenation. 
  
The BArF anion is considerably less coordinating than the previously used counteranions 
and therefore does not compete with the substrate in binding to the metal center.[1b,19,28] 
This stabilizes the key intermediate in the catalytic process, a bishydride olefin complex, 
thus promoting the hydrogenation pathway over the deactivation process.[28a]  
Nowadays the vast majority of the catalysts used for asymmetric hydrogenation have a 
cationic iridium metal center, a COD ligand, a BArF counterion and an N,P-ligand (in some 
cases a C,P-ligand with and N-heterocyclic carbene is used, see Section 1.2.3). 
1.2.2 N,P-Ligands for Asymmetric Hydrogenation  
 
After the report of the phosphine-oxazolines as good N,P-ligands in the iridium-catalyzed 
asymmetric hydrogenation, a plethora of other catalysts has been synthesized. In most 
cases, a six membered ring is formed between the N,P-ligand and the iridium center. The 
phosphorus moiety is normally a phosphine[25,29] or a phosphinite[30] but also some 
phosphites[31] have been used.  
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Contribution by the Pfaltz group 
 
Since 1998 our group has developed a multitude of new N,P-ligands for the iridium-
catalyzed asymmetric hydrogenation, of which the most efficient are depicted in Figure 2. 
 
 
 
Figure 2: Selection of N,P-ligands developed in the Pfaltz laboratories. 
 
In 2002 the ThrePHOX ligands class was developed.[30b] This class is substantially different 
from the PHOX ligands. In fact, besides the use of a phosphinite as P-moiety, the 
stereogenic information was moved to the center of the backbone. A unique property of 
this ligand class is the presence of a second stereogenic center on the oxazoline moiety. 
The ThrePHOX ligands have been successfully applied to the reduction of terminal 
olefins,[30b] and later on of 4H-chromenes.[32] 
Some years later, the easily synthesized SimplePHOX family[30c] was applied to the 
asymmetric hydrogenation of functionalized olefins like acrylic esters, allylic alcohols, and, 
most importantly, cyclic substrates like 1-methyl-3,4-dihydronapthalene (Scheme 7).[30c] 
 
 
Scheme 7: Application of the SimplePHOX ligand L3 to the asymmetric hydrogenation of cyclic substrates. 
 
The success of this ligand structure paved the way to the synthesis of related ligand 
families, like the SimplePHIM[30f] and the NeoPHOX.[29d] The usefulness of the SimplePHIM 
ligands has been recently shown in the asymmetric hydrogenation of terminal vinyl 
Chapter 1  
8 
 
boronates[33] to yield chiral boronates, highly versatile building blocks in organic synthesis 
(Scheme 8). 
 
 
Scheme 8: Application of SimplePHIM ligand L4 to the asymmetric hydrogenation of terminal vinyl 
boronates. 
 
NeoPHOX ligands found application in the reduction of a broader range of substrates, 
among others in the synthesis of the precursors of some natural products. Noteworthy is 
the use of catalysts based on this ligand class in the synthesis of the key intermediate of 
Militarinone D,[34] a pyridone alkaloid isolated from a entomophatogenic fungi that shows 
general neuritogenic activity (Scheme 9).  
 
 
Scheme 9: Key step in the total synthesis of Militarinone D. 
 
All the ligands described so far form a six-membered chelate ring with the metal center. 
However, this property is not a must and indeed also five-membered chelate structures 
like phosphanyl-methyloxazoline[29b,35] have been shown to catalyze hydrogenation 
reactions in a very efficient way.[36] Using such catalyst class the asymmetric 
hydrogenation of unfunctionalized tetrasubstituted double bonds became more 
accessible (Scheme 10). [29b,36-37] 
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Scheme 10: Asymmetric hydrogenation of tetrasubstituted double bonds. 
 
In addition to ligands that possess an oxazoline moiety as a source of chirality, another 
N,P-ligand structure proved to be very useful for the iridium-catalyzed asymmetric 
hydrogenation of several substrates: the pyridine-phosphinite ligand class.[30g] Chiral 
molecules of this type were first synthesized in 2006 in our group and closely mimic the 
structure of the Crabtree catalyst. Moreover the rigid conformation given by the bicyclic 
core seems to be crucial for achieving high enantioselectivities.[30d] 
Nowadays this is one of the most powerful ligand classes in the field of iridium-catalyzed 
asymmetric hydrogenation, mainly due to their broad substrate scope. Indeed, not only 
unfunctionalized olefins, but also furan derivatives,[30g] α,β-unsaturated esters[38] and 
vinyl borates[33] could be reduced with excellent results using iridium catalysts based on 
this ligand class (Figure 3). 
 
 
 
Figure 3: Selection of substrates that can be reduced by a bicyclic pyridine phosphinite-derived iridium 
catalyst. 
 
In recent years these iridium complexes have found broad application in the asymmetric 
hydrogenation of key intermediates of many natural products.[34,39] 
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Contribution by other laboratories 
 
Besides our group, many other researchers have been interested in the synthesis of novel, 
powerful N,P-ligands for iridium-catalyzed asymmetric hydrogenation. The Andersson 
group focused its attention on the development of new PHOX-derived ligands, as well as 
bicyclic thiazole complexes for the asymmetric hydrogenation of functionalized[40] and 
unfunctionalized olefins[41] and imines.[42] 
The Ding and Zhou laboratories on the other hand showed that larger chelate rings with 
the metal center are also promising ligands for this transformation. More precisely, 
seven[43] (SpinPHOX, Ding), or even nine[44] (SiPHOX, Zhou) membered systems can act as 
catalysts in the reduction process of α,β-unsaturated carboxylic acids achieving excellent 
results.[44-45] The main characteristic of these ligands is given by the spirocyclic core which 
keeps the structure rigid allowing for efficient enantiodiscrimination (Figure 4). 
 
 
Figure 4: Structures of the spirocyclic ligands SpinPHOX and SIPHOX. 
 
Interestingly, SpinPHOX-derived catalysts are able, besides the hydrogenation of C=C, also 
to catalyze the asymmetric hydrogenation of imines with remarkably high yield and 
selectivity.[43]  
In general the asymmetric hydrogenation of C=N bonds, among others quinolines, can 
also be carried out with N,P-[46] and P,P-ferrocenyl-based[47] complexes. 
More rare is the enantioselective reduction of C=O bonds catalyzed by iridium complexes. 
Only in the last few years an efficient catalyst based on an N,P-ligand has been developed 
for this reaction by the Zhou group.[48] This methodology is noteworthy as it can be applied 
to the chemoselective reduction of carbonyl groups leaving olefins situated in close 
proximity untouched (Scheme 11).[49] 
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Scheme 11: Chemoselective carbonyl reduction in presence of an olefin. 
 
1.2.3 NHC Ligands for Asymmetric Hydrogenation  
 
N-Heterocyclic carbenes (NHCs) were developed independently by Wanzlick[50] and 
Öfele[51] in the 1960s. However, such complexes have not been used in transition metal 
catalysis until the mid 1990s, when NHC-based complexes were used as ligands in 
asymmetric reactions by Enders[52] and Herrmann.[53] These particular carbenes are 
known for stabilizing the low oxidation states of transition metals because of their strong 
σ-donating and weak pi-accepting properties which render the metal center more 
electron-rich compared to the corresponding phosphine complexes.[54] Another 
interesting property of NHC-based complexes is their stability toward air and 
moisture[54a,55] that, together with their high activity, makes this class of ligands very 
interesting for a multitude of different transformations, such as other alkene 
metathesis,[56] hydrogenations,[57] C-C[53a,58] and C-N[58e,59] bond formation. 
Despite the considerable potential of NHC-based metal complexes, there have been very 
few applications of them in asymmetric catalysis[53b,60] before 2001, when Burgess[54b,61] 
developed imidazolylidine-oxazoline-based NHC complexes such as L8d for iridium-
catalyzed asymmetric hydrogenation. This was the first report of high enantioselective 
induction using electron-rich carbene ligands in any catalytic process.[61] Best results were 
obtained using ligands containing a seven membered chelate ring, with the N-heterocyclic 
carbene replacing the phosphine of the classical N,P-ligands, and two bulky group, such 
as 1-adamantyl on the oxazoline moiety and 2,6-di-isopropylphenyl on the imidazolidine 
(Scheme 12). These ligands could be synthesized using a modular combination of 
imidazoles and oxazoline electrophiles, giving access to a large library of iridium 
catalysts.[54b] 
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Scheme 12: Hydrogenation of trans-methylstilbene using Burgess NHC ligand L8d. 
 
Ligand L8d found then broad application in the asymmetric hydrogenation of 
functionalized olefins[62] and in natural product synthesis.[63] Moreover, it has been 
demonstrated that the acidity of this catalyst class is lower compared to known iridium 
N,P-complexes. Therefore these catalysts are well suited for the hydrogenation of acid-
labile substrates like, for example, vinylethers.[64] 
Since the best results using N,P-ligands were obtained using six-membered chelate rings, 
our group became interested in evaluating the efficacy of oxazoline based NHC ligands 
forming a ring of the same size with the iridium center.[65] The results obtained were 
inferior, in terms of enantioselectivity and catalyst loading, compared to those achieved 
with the seven-membered catalyst developed by Burgess (Scheme 13).[65] 
 
 
Scheme 13: Hydrogenation of trans-methylstilbene using Pfaltz oxazoline-based NHC carbenes. 
1.2.4 Catalytic Cycle[66]  
 
The activation of iridium-catalysts bearing an N,P-ligand by hydrogenation of the 
cyclooctadiene moiety has been extensively studied[67] and the mechanism is nowadays 
unanimously accepted. In contrast, the exact mechanism of the iridium-catalyzed 
asymmetric hydrogenation is still under debate. Some researchers believe that an IrIII-IrV 
catalytic cycle is responsible for this reaction,[68] others believe that an IrI-IrIII cycle, like 
the one established in rhodium-catalyzed hydrogenations,[69] is more plausible.[70] The 
first hypothesisis is based on computational studies, the second on gas-phase reactivity 
data[70b] of a PHOX-catalyst, and polarization NMR spectroscopy.[70a]  
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Unfortunately, each experimental and theoretical study on this process has been carried 
out using various models, different catalysts, substrates and reaction conditions. 
Therefore, it is almost impossible to compare these results and state clearly which cycle 
is favored. It might be even possible that depending on the substrate, the conditions and 
the catalyst of choice, either an IrI-IrIII or an IrIII-IrV cycle can operate. 
 
 
 
Scheme 14: The IrI/IrIII (left) and IrIII/IrV (right) catalytic cycles for iridium catalyzed hydrogenation of 
olefins; S= solvent; Y= phosphine or carbene.[66] 
1.2.5 Drawbacks and Future Challenges in Iridium-Catalyzed Asymmetric Hydrogenation 
 
At the beginning of this chapter the advantages of the transition metal-catalyzed 
asymmetric hydrogenation were listed. However, some drawbacks for this reaction can 
still be found and represent important challenges in current research. Arguably, one of 
the major issues is the preferential use of dichloromethane as a solvent for the iridium-
catalyzed hydrogenation. Besides being a volatile and toxic solvent, it dissolves the fatty 
layer of the skin and can cause dermatitis.  
Since Crabtree’s findings[2a] only a few reports of iridium-catalyzed asymmetric 
hydrogenation in non-chlorinated solvents have been published[49,71] and for some of 
them additives were required to achieve high activity.[44] 
Although the field of iridium-catalyzed asymmetric hydrogenation has expanded vastly 
over the last fifteen years, there is still the need to improve catalyst efficiency by new 
ligand design in order to successfully reduce an even broader range of challenging 
Chapter 1  
14 
 
substrates for which there is currently no efficient asymmetric hydrogenation 
methodology available.  
1.2.6 Aim of This Work 
 
The main aim of the research presented in this thesis was to expand the current scope of 
the iridium-catalyzed asymmetric hydrogenation to challenging substrates. Chapter 2 
deals with the enantioselective reduction of vinylsilanes while the results of the 
asymmetric hydrogenation of maleic acid dimethyldiesters are the subject of Chapter 3.  
The second goal of the research presented herein was the deployment of environmentally 
advantageous solvents for iridium-catalyzed asymmetric hydrogenations. The outcome of 
the efforts made in this directions are described in Chapter 4, where ethereal solvents like 
THF and 2-MeTHF have been successfully used as solvents in the asymmetric 
hydrogenation of allylic alcohols. 
Additionally, some time was devoted to the development of new NHC ligands for the 
asymmetric hydrogenation of acid-labile substrates, as reported in Chapter 5. 
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Chapter 2 
Iridium-Catalyzed Asymmetric Hydrogenation of Vinylsilyl 
Derivatives 
 
2.1 Introduction 
 
Despite several similarities between silicon and carbon, these two elements are 
characterized by substantial differencies.[72] Besides the higher atomic weight and the 
reduced electronegativity, the higher lipophilicity of silicon compounds compared to 
related carbon analogs plays an important role in the in vivo effects of the molecules.[73] 
A small increase in lipophilicity can markedly increase the volume of distribution of the 
molecule reflecting increased tissue penetration, making the silicon-based drugs less 
prone to hepatic metabolism.[72] 
These properties together with non-toxicity of organosilanes, availability and cheapness 
have long stimulated the interest of scientists in silicon as a replacement for carbon, 
particularly in biologically active molecules.[74] This element has been mainly applied in 
the design of bioactive organosilanes starting with a molecule of known biological activity 
and replacing a carbon atom with a silicon atom or derivate. This procedure, called 
carbon-to-silicon switch,[74e,75] has found broad application in developing organosilane 
pesticides[74b,74c] and recently in the fine tuning of the pharmacological or 
pharmacokinetic properties of marketed drugs.[72,76] The two most common carbon-to-
silicon switches are depicted in Scheme 15. In the first case a quaternary carbon is 
replaced by a silicon atom in order to increase hydrophobicity,[77] whereas in the second 
example the unstable hydrate was replaced by a stable silicon analog exhibiting similar 
inhibitory effect as the parent compound (eq. 2).[74g,78] However, an important drawback 
in the use of silicon analog 6 as ACE inhibitor was represented by the long synthetic 
sequence required for its preparation and the use of expensive chiral reagents for the 
synthesis of the intermediate enantioenriched siladiol.[74g] 
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Scheme 15: Most common carbon-to silicon switches. 
 
In 2011, the research group of Prof. Sieburth solved this issue by developing an 
intramolecular asymmetric rhodium-catalyzed hydrosilylation of compound 7 to afford 
the cyclic enantioenriched silane 8 in good yield and selectivity. This intermediate could 
then be applied to the synthesis of the target molecule 6 (Scheme 16).[79] 
 
 
Scheme 16: Rhodium-catalyzed asymmetric hydrosilylation to afford compound 8 by Sieburth et al.[79] 
 
In general, the development of asymmetric methodologies aimed at affording 
enantioenriched silanes has been neglected for a long time. Only in recent years the need 
for more efficient synthetic routes to these molecules has stimulated the interest of 
various research groups.[80] Although the most frequently used transformations are 
undoubtedly represented by palladium-,[80a,80b] copper-,[80g-j] rhodium-[80c-e] or N-
heterocyclic carbene-catalyzed[80f] conjugated 1,4-additions as well as copper catalyzed 
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allylic substitutions,[80k-n] the first method applied to the synthesis of enantioenriched 
silanes was the asymmetric hydrosilylation of terminal olefins developed by Hayashi and 
coworkers (Scheme 17).[80o] This powerful reaction gives access to trichlorosilanes 9 in 
good yield and selectivity and using low catalyst loadings. Trichlorosilanes 9 can then be 
transformed into the corresponding vinylsiloxanes 10, that can subsequently undergo 
Tamao–Fleming oxidation[81] to the related enantioenriched alcohols 11. 
 
 
 
Scheme 17: First asymmetric hydrosilylation by Hayashi et al.[80o] 
 
The majority of the available methodologies for the synthesis of enantioenriched silanes 
involve the use of (dimethylphenylsilyl)boronic acid pinacol ester 12 as the silicon source, 
limiting the nature of the substituents on the silicon atom to the dimethylphenyl group (a 
representative example is shown in Scheme 18). 
 
 
Scheme 18: Application of reagent 12 in the synthesis of enantioenriched dimethylphenylsilanes.[80d] 
 
Reports of enantioenriched silanes bearing substituents other than the dimethylphenyl 
group are scarce.[80c,80r,82] One of such examples is represented by the iridium-catalyzed 
asymmetric hydrogenation of trisubstituted vinylsilanes to afford enantioenriched 
trimethylsilanes (Table 1).[80r] Despite the good conversion, this transformation suffered 
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from poor to moderate enantioselectivities (28-58% ee). Indeed only for the specific 
substrate 13 excellent enantiomeric excess could be achieved (Table 1).  
Given the lack of generality of the current methods for the preparation of enantioenriched 
silanes, our group became interested in broadening the substrate scope of the 
asymmetric hydrogenation of vinylsilanes using N,P-based iridium catalysts. Aie Wang, a 
former member of the Pfaltz group, started this project by comparing the performance of 
our catalysts with those of Andersson’s catalyst, [Ir(COD)L10]BArF (Table 2).[83] 
 
Table 1: Iridium-catalyzed asymmetric hydrogenation of trimethylvinylsilanes 13-18.[80r] 
 
 
 
After an extensive catalyst screening in which all the different ligand classes were tested, 
Wang figured out which ligands allowed to achieve best results in terms of selectivity and 
yield for every test substrate (Table 2). Unfortunately, none of the N,P-ligands tested 
resulted to be consistently the ligand of choice for a variety of substrates, but, in general 
ligands L3 and L11 performed best. Indeed, six out of the nine vinylsilanes depicted in 
Table 2 could be hydrogenated using catalysts bearing one of these two ligands. Despite 
the lack of a universal ligand for the asymmetric hydrogenation of vinylsilanes, the 
enantiomeric excesses obtained were promising and better than the reference values 
reported by Andersson using the phosphine/thiazole ligand L10 (compare Table 1 vs. 
Table 2). For example vinylsilane 15 could be reduced with full conversion and excellent 
enantiomeric excess in only two hours, whilst in the previous example of Andersson 
twelve hours were required to reach full conversion with a poor optical yield (28% ee). 
Moreover, outstanding results were achieved also in the hydrogenation of alkyl,alkyl 
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substituted trimethylvinylsilane 21, terminal trimethylvinylsilane 22 as well as dialkyl 
substituted dimethylphenylvinylsilane 23. 
 
Table 2: Asymmetric hydrogenation of various vinylsilanes using N,P-based iridium catalysts by Wang. 
 
 
[a]  Determined by GC analysis  of the reaction mixture after  removal of the cata lyst;  [b]  
Determined by GC or HPLC analys is  on a chiral  s tat ionary phase;  [c]  React ion carr ied out dur ing  
6 hours  us ing 1  mol% cata lyst loading;  [d]  Reaction t ime: 4  h;  [e]  carr ied out  at 1  bar H 2  pressure.  
 
Compared to Andersson’s report, this methodology represents a significant improvement, 
as it allows to achieve excellent enatiomeric excesses with substrates like 14, 22 or 23, 
bearing the silyl group on the sp2-hybridized prochiral carbon.  
After these promising initial results, it was decided to pursue the project by investigating 
a broader array of substrates, among others also vinyl siloxanes, siletanes, and 
trifluorosilanes.  
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2.2 Results and Discussion 
2.2.1 Vinylsilanes  
 
2.2.1.1 Synthesis of Vinylsilanes 
 
 
Figure 5: Synthesized vinylsilanes. 
 
Different synthetic pathways have been followed for the synthesis of 
dimethylphenylvinylsilanes, but only one method was used for the synthesis of the 
trimethylsilyl analogs, which were synthesized starting from commercially available 
terminal alkynes via palladium-catalyzed coupling reaction with iodotrimethylsilane and 
an organozinc reagent (Table 3).[84] 
 
Table 3 Synthesis of trimethylvinylsilanes following the procedure developed by Chatani et al.[84] 
 
 
 
Despite some problems of regioselectivity in the synthesis of vinylsilane 13, which 
resulted in moderate yield, substrates 24 and 25 could be prepared under the same 
reaction conditions in perfect stereo- and regioselectivity. 
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In order to expand the substrate scope of the hydrogenation and considering the 
considerable amount of trimethylsilanes already synthesized and tested by Wang, the 
focus of the project was moved to the related dimethylphenylvinylsilanes. The two step 
synthesis of α,β-unsaturated ester 26 started from vinylether 34, which was transformed 
into acylsilane 35. After Horner–Wadsworth–Emmons reaction and DIBAL-H reduction 
allylic alcohol 27 was afforded in good yield (Scheme 19). 
 
 
Scheme 19: Synthetic pathway to vinylsilanes 26 and 27. 
 
The isomeric allylic alcohol 28 was obtained through a four steps synthesis. Silylation of 
protected propargylic alcohol 36[85] followed by acidic cleavage of the tetrahydropyran 
protecting group[86] resulted in the formation of free alcohol 38, that was subjected to 
organocupration using methylmagnesium chloride to give allylic alcohol 28 in 83% yield 
and perfect regioselectivity. 
 
1) nBuLi (1.1 eq.)
78 °C, 30 min, THF
2) ClSiMe2Ph (1.1 eq.)
78 °C to 0 °C, 3 h, THF
37
90% yield
OTHP
OTHP
PhMe2Si
36
OH
PhMe2Si
38
83% yield
PPTS (20 mol%)
60 °C, o/n, EtOH
O
PhMe2Si OHPhMe2Si OAc
28
79% yield
29
85% yield
CuI (10 mol%)
MeMgCl (2.5 eq.)
reflux, o/n, Et2O
Ac2O (10 eq.)
60 °C, 2 h, Pyridine
THP =
 
Scheme 20: Synthesis of vinylsilanes 28 and 29. 
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Acetalization using acetic anhydride[87] yielded vinylsilane 29 (Scheme 20). Recent 
advances in the field of copper catalysis allowed for the synthesis of substrate 30 via a 
highly regioselective silylcupration of terminal alkyne 39 using 
(dimethylphenylsilyl)boronic acid pinacol ester 12 as a silicon source (Scheme 21).[88]  
 
 
Scheme 21: Synthesis of vinylsilane 30 following the procedure published by Loh et al. [88] 
 
One of the best known synthetic methods for synthesizing vinylsilanes is the Shapiro 
reaction. In this reaction, discovered in 1967,[89] a tosylhydrazone bearing an α-hydrogen 
reacts with an excess of n-butyllithium to generate a vinylanion that can be trapped by a 
broad variety of electrophiles, generating olefins which may be difficult to prepare by 
other means. Using this methodology, vinylsilane 31 could be obtained in good yield 
starting from propiophenone 40 in 2 steps (Scheme 22).[90] 
 
 
Scheme 22: Synthesis of vinylsilanes 31 via Shapiro reaction. 
 
Finally, vinylsilane 32 was obtained by palladium-catalyzed regio- and steroselective 
silaboration of 1-hexyne 42, using reagent 12 in good yield. This compound could then 
easily be transformed into compound 33 under Suzuki−Miyaura conditions (Scheme 
23).[91] 
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Scheme 23: Synthetic pathway to vinylsilanes 32 and 33.[91] 
 
2.2.1.2 Iridium-Catalyzed Asymmetric Hydrogenation of Vinylsilanes 
 
At the beginning the hydrogenation of trimethylvinylsilane 13 as a test compound was 
investigated. Various iridium catalysts bearing N,P-ligands were tested, including ligands 
L3, L11 and L13, which gave the best results in the reactions previously carried out by 
Wang under the same reaction conditions. Although poor enantioselectivities were 
achieved using iridium catalysts bearing an oxazoline-based ligand (L3, L15 and L18), 
excellent conversion and enantioselectivity were obtained with pyridine-phosphinite 
ligands (Table 4).  
 
Table 4: Ligand screening in the hydrogenation of vinylsilane 13. 
 
 
[a]  Determined by GC analysis  of the react ion mixture after removal of the 
cata lyst;  [b]  Determined by GC analys is  on a chira l  s tationary  phase.  
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The outcome of the reaction using this ligand class seemed to be rather independent of 
either the size of the carbocyclic ring and the substitutent on the phosphine moiety. 
Indeed, the results summarized in Table 4 show that stirring the substrate in the presence 
of 0.5 mol% catalyst under 50 bar hydrogen afforded silane 43 in similar 
enantioselectivities (90%-94% ee), independently of the pyridine phosphinite ligand used. 
Encouraged by the results obtained, the influence of the hydrogen pressure as well as the 
reaction temperature was examined using the best ligand out of the initial screening, L17.  
 
Table 5: Pressure and temperature screening in the hydrogenation of compound 13. 
 
 
Entry Pressure (bar ) Temperature (°C) Conv.[a] (%) ee[b] (%) 
1 50 rt >99 94 (−) 
2 50 −20 93 96 (−) 
3[c] 10 rt >99 95 (−) 
4[d] 10 −20 74 72 (−) 
[a]  Determined by GC analysis  of  the reaction mixture after removal  of 
the catalyst ;  [b]  Determined by GC analys is  on a chiral  stationary phase;  
[c]  Reaction time:  4 h;  [d]  React ion t ime: 7 h.  
 
As shown in Table 5, lowering either the reaction temperature to −20 °C resulted in a slight 
improvement of the enantioselectivity (96 vs. 94% ee) but incomplete conversion (entry 
2). On the other hand, with a reduced hydrogen pressure silane 43 could be obtained with 
95% ee while keeping full conversion (entry 3). However, lowering both parameters at the 
same time had a negative influence on both yield and selectivity (entry 4). Once 
established that pyridine-phosphinite ligands were the most suited for the hydrogenation 
of vinylsilanes, a further screening of a selection of such ligands was carried out using 
compound 14 as test substrate (Table 6). As expected, excellent results were obtained 
both in terms of yield and selectivity. An analysis of the performance of different catalysts 
showed that while the nature of phosphinite moiety in the five membered carbocyclic ring 
scaffolds exhibited little influence on the enantioselectivity of the reaction, six-membered 
  Vinylsilyl Derivatives 
25 
 
carbocyclic ring pyridine phosphinite ligands performed better with diarylphosphinites 
than dialkyl ones (cf. results with L13, L17 and L21, Table 6). 
 
Table 6: Ligand screening in the hydrogenation of vinylsilane 14. 
 
 
[a]  Determined by GC analys is  of the reaction mixture after removal of the  
cata lyst;  [b]  Determined by GC analys is  on a chira l  s tationary  phase.  
 
In the hydrogenation of alkyl/alkyl-disubstituted vinylsilane 25 the difference between the 
results achieved using catalysts bearing a pyridine-phosphinite ligand and the catalysts 
possessing other N,P-ligand classes was even more striking. 
Indeed, all the other N,P-ligand classes tested in the iridium-catalyzed asymmetric 
hydrogenation of substrate 25 yielded silane 45 in excellent yield but poor enantiomeric 
excess, whereas pyridine-phosphinites resulted the ligands of choice also for purely alkyl-
substituted substrates (Table 7). It should also be noted that the enantiomeric excess of 
silane 45 could be enhanced to 97% by carrying out the hydrogenations under 10 bar 
hydrogen pressure with catalyst [Ir(COD)L17]BArF, maintaining all other parameters fixed.  
 
 
 
 
Chapter 2  
26 
 
Table 7: Ligand screening in the hydrogenation of vinylsilane 25. 
 
 
[a]  Determined by GC analys is  of the reaction mixture after removal of the  
cata lyst;  [b]  Determined by GC analys is  on a chira l  s tationary  phase.  
 
Although good to excellent results could be obtained in the asymmetric hydrogenation of 
trimethylvinylsilanes, thus demonstrating the viability of vinylsilanes as substrates for this 
transformation with our catalysts, the products obtained find little application in organic 
synthesis. For instance, the trimethylsilyl- group cannot undergo Tamao–Fleming 
oxidation to the corresponding alcohols, as for this transformation the presence of an 
heteroatom, a hydrogen an aryl or heteroaryl-group on the silicon atom is required,[81] 
although some exceptions are known.[92] For this reason, the hydrogenation of easily 
oxidized dimethylphenylvinylsilanes became the main focus of the project. 
The first substrate of this kind that was tested in the iridium-catalyzed asymmetric 
hydrogenation was α,β-unsaturated ester 26 (Table 8). In contrast to the vinylsilanes 
evaluated earlier, for this specific compound various N,P-ligands yielded the desired 
product 46 with full conversion while catalysts bearing a pyridine-phosphinite ligand like 
L11, L13, L26 and L27 proved to be either poorly active or selective or both. 
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Table 8: Ligand screening for the hydrogenation of vinylsilane 26. 
 
 
[a]  Determined by GC analysis  of the reaction mixture after removal of the 
cata lyst;  [b]  Determined by HPLC analys is  on a chira l  s tationary phase.  
 
In particular the catalyst based on ligand L26 afforded the product 46 with poor 
conversion but 90% ee, the best enantioselectivity registered among the catalysts 
screened. Most surprisingly the related ortho-tolyl phosphine analog L27 gave opposite 
results with full conversion but giving silane 46 as a racemic mixture. 
In order to achieve full conversion of 26 with catalyst [Ir(COD)L26]BArF, the reaction was 
carried out for a prolonged time and with 1.0 mol% of catalyst. In this case the substrate 
was completely transformed into 46 with negligible erosion of enantioselectivity (Scheme 
24).  
 
 
Scheme 24: Optimized reaction conditions for the reduction of substrate 26. 
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The level of enantioselectivity obtained is slightly inferior to the benchmark of 95% ee 
achieved via copper-catalyzed asymmetric hydrosilylation, however, milder, more 
practical reaction conditions were required for the hydrogenation compared to the 
hydrosilylation reaction that had to be performed at −78 °C.[80q] 
From these first investigations it seemed that the reduction of trimethyl substituted 
vinylsilanes proceeded with better levels of enantioselectivity compared to the reduction 
of dimethylphenyl substituted analogs. This impression was also confirmed when alllyic 
alcohol 27 was used as a test substrate for the hydrogenation. Despite the good 
conversions only poor selectivities were achieved (Table 9). 
 
Table 9: Ligand screening in the asymmetric hydrogenation of vinylsilane 27. 
 
 
n.d.  =  not determined;  [a]  Determined by GC analys is  of the reaction mixture 
after removal of  the cata lyst;  [b]  Determined by HPLC analysis  on a chiral  
stationary phase.   
 
Since in general superior enantioselectivities were obtained with substrates bearing the 
silyl group at the less substituted carbon atom, the isomeric allylic alcohol 28 was 
synthesized and tested in the iridium-catalyzed asymmetric hydrogenation (Table 10). 
Interestingly, only a few complexes were able to catalyze in this case. Moreover, the 
results obtained with ligands L3 and L23 showed that the presence of ortho-tolyl 
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substituents in the phosphine was essential to achieve higher levels of enantioselectivity 
and yield.  
 
Table 10: Ligand screening in the hydrogeantion of vinylsilane 28. 
 
 
n.d.  = not  determined;  [a]  Determined by GC analys is  of the reaction mixture after 
removal of the cata lyst;  [b]  Determined by HPLC analysis  on a chira l  s tat ionary phase.   
 
In order to improve the enantioselectivity, the hydrogenation of alcohol 28 was carried 
out at lower temperature using the most promising ligands, L3 and L23 (Scheme 25). 
 
 
Scheme 25: Asymmetric hydrogenation of vinylsilane 28 at reduced temperature. 
 
Although performing the reaction at 0 °C rather than room temperature resulted in higher 
enatiomeric excess of silane 48, in particular when ligand L3 was used (cf. Table 10 and 
Scheme 25), the conversion was drastically diminished. However, a comparison of the 
enantiomeric excesses achieved in the reduction of vinylsilanes 27 and 28 confirmed the 
hypothesis that vinylsilanes having the silyl group adjacent to the prostereogenic center 
are better substrates than those bearing the silicon atom directly attached to the 
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prostereogenic center. It should be noted though that not all the vinylsilanes featuring 
this substitution pattern could be hydrogenated with satisfactory level of 
enantioselectivity, as shown in the reduction of acetate 29 (Table 11). 
 
Table 11: Ligand screening in the hydrogenation of vinylsilane 29. 
 
 
[a]  Determined by GC analys is  of the react ion mixture after  removal  of the cata lyst;  
[b]  Determined by HPLC analysis  on a  ch iral  s tat ionary phase;  [c]  5% of the (Z )- isomer 
of the start ing mater ia l  were detected;  [d]  10% of  the (Z) - isomer of the start ing 
mater ial  were detected.  
 
Indeed, despite the good yields, the enantioselectivities were not as high as for the free 
alcohol 28 (cf. Table 10 and Table 11). One possible reason for the moderate selectivity 
could be ascribed to partial cis/trans-isomerization of the starting material occurring 
during the hydrogenation process. This hypothesis was supported by the detection of 
some traces of (Z)-29 in cases where full conversion was not achieved, for example when 
ligands L24, L31 or L32 were employed. 
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After having tested some functionalized dimethylphenylvinylsilanes, the reduction of 
more unfunctionalized substrates such as 30-31 was investigated. 
The results summarized in Table 12 show that regardless of the ligands used for the 
hydrogenation of 30, the product 50 could be obtained only in poor enantiomeric excess 
although complete conversion was achieved in all cases using 0.5 mol% of any catalyst. 
 
Table 12: Ligand screening for the asymmetric hydrogenation of vinylsilane 30. 
 
 
[a]  Determined by GC analys is  of the react ion mixture after  removal  of the cata lyst;  
[b]  Determined by HPLC analys is  on a  ch iral  stat ionary phase.  
 
In an effort to achieve higher levels of enantioselectivity than those registered with 
vinylsilane 30, a trisubstituted substrate bearing a phenyl group directly bound to the 
prostereogenic center (31) was tested in the iridium-catalyzed asymmetric 
hydrogenation. However, no conversion into 51 was observed (Table 13). The use of 
higher hydrogen pressure (70 bar), additives (NaI, I2, KI, NBu4I), or different solvents (THF, 
MTBE or toluene) did not improve the results. 
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Table 13: Ligand screening for the hydrogenation of vinylsilane 31. 
 
 
[a]  Determined by GC analys is  of the react ion mixture after  removal  of the cata lyst.  
 
Only with 1.0 mol% catalyst loading, prolonged reaction time and higher reaction 
temperature traces of the desired product could be detected (Scheme 26). 
 
 
Scheme 26: Reduction of vinylsilane 31 at higher reaction temperature and prolonged reaction time. 
 
These results were discouraging since Wang[83] showed that compound 14, the 
trimethylsilylvinylsilane analog of 31 could be reduced in perfect yield and high 
enantioselectivity using ligand L11 (cf. Table 2 and Table 13). Such observations are 
consistent with the poor ability of the olefin to coordinate to the metal center, likely due 
to the steric bulk of the two phenyl groups in the substrates. 
 
Another interesting structural motif is represented by cis-β-silylalkenylborates such as 32, 
whose reduced product could give access to 1,2-diols after oxidation (Scheme 27). The 
interest for this type of compounds raised after the recent progress in the iridium-
catalyzed hydrogenation of vinylboronates and bisboronic esters[33] reported by our 
group.  
 
 
Scheme 27: Potential Applications of cis-β-silylalkenylborate 32. 
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Also in this occasion the steric bulk of the substrate proved to be too demanding, 
hampering the reactivity of the catalyst and yielding compound 32 with only poor 
conversion (Table 14).  
 
Table 14: Ligand screening for the hydrogenation of vinylsilaboronate 32. 
 
nBu
SiMe2Ph
Bpin
32
1.0 mol% [Ir(COD)L*]BArF
50 bar H2, rt, 15 h, CH2Cl2
Cy2P N
N
Ph
N
O
(tBu)2P
L29
12% conv.[a]
L28
0% conv.[a]
O
(o-Tol)2P N
O
L3
0% conv.[a]
nBu
SiMe2Ph
Bpin
52
Ph2P N
O
L22
3% conv.[a]
N
O
(tBu)2P
Ph
L11
0% conv.[a]
O
Ph2P N
O
Ph
Bn Bn
L12
0% conv.[a]
 
[a]  Determined by GC analys is  of  the reaction mixture after  
removal of  the catalyst .  
 
The best ligand for this transformation was found to be the phosphinomethyloxazoline 
ligand L29, which afforded compound 52 in 12% yield. Further attempts to achieve higher 
turnover using the catalyst based on such ligand and different reaction conditions were 
unsuccessful. Replacing the boronic ester moiety with an arguably less sterically hindered  
 
Table 15: Ligand screening for the hydrogenation of vinylsilane 33. 
 
 
[a]  Determined by GC analys is  of the reaction mixture after removal  of the cata lyst.  
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para-methoxyphenyl group did not show any influence on the conversion under forcing 
reaction conditions (100 bar H2), high catalyst loading and prolonged reaction time (Table 
15). In general the presence of a dimethylphenylsilyl group compared to the trimethylsilyl 
substituent seems to drastically reduce the range of substrates that are suitable for a 
successful hydrogenation using the iridium catalysts developed in our group. For example 
aryl groups on the C=C bond of trimethylvinylsilane substrates posed no particular 
challenge to the effective iridium-catalyzed asymmetric hydrogenation, while they were 
no longer tolerated on dimethylphenylvinylsilanes. This effect is likely to be attributed to 
the enhanced steric bulk caused by the presence of the phenyl group on the silicon atom. 
After these discouraging results in the hydrogenation of dimethylphenylvinylsilanes the 
effect of other silicon substituents at the C=C bond were investigated.  
2.2.2 Vinylsiloxanes  
 
After careful analysis, vinylsiloxanes were chosen as a valid alternative to 
dimethylphenylvinylsilane. Regarding the possible applications of the hydrogenation 
products, in addition to the aforementioned Tamao–Fleming oxidation, enantioenriched 
siloxanes can be transformed in one step into the corresponding trifluorosilanes. The 
latter hold particular interest as they represent the only silanes that can undergo an sp2-
sp3 Hiyama cross coupling (Scheme 28).[93] 
 
 
Scheme 28: Applications of enantioenriched vinylsiloxanes. 
 
2.2.2.1 Synthesis of Vinylsiloxanes 
 
 
 
Figure 6: Synthesized vinylsiloxanes. 
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While the preparation of dimethylphenylvinylsilanes required several different synthetic 
routes depending on the desired product, the ruthenium-catalyzed hydrosilylation of 
terminal alkynes[94] provided a general entry into vinylsiloxanes 54-57 (Table 16). Indeed, 
the use of commercially available RuCp*(MeCN)3PF6 allowed for the synthesis of the 
desired vinylsiloxanes in moderate to good yield after purification by column 
chromatography.  
 
Table 16: Hydrosilylation of terminal alkynes following the procedure developed by Trost et al.[94] 
 
 
 
2.2.2.2 Iridium-Catalyzed Asymmetric Hydrogenation of Vinylsiloxanes 
 
An initial catalyst screening was carried out using vinylsiloxane 54 as test substrate and 
three N,P-ligand classes under standard reaction conditions (50 bar H2, 0.5 mol% catalyst 
loading, Table 17). As a result, the desired siloxane 58 was formed together with a side 
product, whose structure was assigned as 59 on the basis of 1H-NMR and GC-MS analyses. 
Compound 59 could likely result from an acid promoted dimerization of product 58. The 
acidic species necessary for such a reaction to take place could be the iridium-hydrido 
intermediates formed in the course of the hydrogenation. Indeed Burgess et al.[64] showed 
that intermediates of N,P-ligand-based iridium catalysts are rather acidic. When 
phosphine-based ligands such as L22 are used, the corresponding iridium intermediates 
should be less acidic than those derived from catalysts bearing phosphinite-based ligands 
such as L11, L21 or L30. The fact that the catalyst based on phosphinoxazoline ligand L22 
afforded the lowest amount of side product compared to phosphinite complexes 
Chapter 2  
36 
 
underpinned this hypothesis (cf. entry 3 with entries 1, 2 and 4). 
 
Table 17: Ligand screening for the hydrogenation of vinylsiloxane 54. 
 
 
Entry L* Conv. to 58[a] (%) Conv. to side product[a] (%) 
1 L11 87 13 
2 L21 79 21 
3 L22 95 5 
4 L30 53 47 
 
[a]  Determined by GC analysis  of  the reaction mixture after removal  of 
the cata lyst.  
 
Unfortunately, the level of selectivity of the hydrogenation could not be determined by 
HPLC, since the side product 59 had the same retention time as the two enantiomers of 
58. In an attempt to circumvent the formation of undesired side products, three inorganic 
bases were added to the reaction mixture as additives (Table 18). 
 
Table 18: Use of inorganic bases in the hydrogenation of vinylsiloxane 54. 
 
  
 
Entry Base Conv. to 58[a] (%) ee[b] (%) 
1 K2CO3 >99 15 (+) 
2 Na2CO3 >99 15 (+) 
3 Cs2CO3 >99 15 (+) 
[a]  Determined by GC analys is  of  the reaction mixture after 
removal of the cata lyst;  [b]  Determined by HPLC analys is  
on a  ch ira l  stat ionary  phase.  
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The absence of the side product demonstrated that addition of a base was beneficial to 
the outcome of the reaction. Furthermore, this experiment showed that the nature of the 
carbonate counterion affected neither the yield nor the enantioselectivity of the reaction. 
The ligand screening in the hydrogenation of vinylsiloxane 54 was therefore repeated in 
the presence of 5 mol% of potassium carbonate, which was chosen as the base of choice 
for further tests (Table 19). Independently from the choice of the N,P-ligand, the reaction 
proceeded smoothly and vinylsiloxane 58 could be obtained as the only product. The best 
enantioselectivity level (70% ee) was achieved using ligands L30 and L35. 
 
Table 19: Further ligand screening in the hydrogenation of vinylsiloxane 54. 
 
  
 
[a]  Determined by GC analys is  of the reaction mixture after removal  of the catalyst;  [b]  
Determined by HPLC analys is  on a chira l  s tationary phase.  
 
To ascertain the influence of the alkoxy substituents on the silicon atom, the methoxy-
substituted analog of vinylsiloxane 54 was synthesized and tested in the iridium-catalyzed 
hydrogenation (Table 20). With the exception of ligand L35, all the ligands tested afforded 
enantioenriched siloxane 60 with full conversion. The alkoxy substituents on the silicon 
moiety were shown to have no major influence on the enantioselectivity of the 
transformation, as the results in Table 19 and Table 20 demonstrate. 
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Table 20: Ligand screening for the hydrogenation of vinylsiloxane 55. 
 
 
 
[a]  Determined by GC analys is  of the react ion mixture after removal of  the cata lyst;  
[b]  Determined by HPLC analys is  on a  ch iral  stat ionary phase.  
 
Ligands L35 and L30, which performed best in the hydrogenation of vinylsiloxane 54, 
yielded inferior results compared to ThrePhox ligand L12 in the hydrogenation of 55. In 
order to enhance the selectivity of the reaction a pressure and temperature screening was 
carried out using this ligand class (Table 21). 
 
Table 21: Pressure and temperature screening 55. 
  
 
 
Entry L* Pressure (bar) Temperature (°C) Conv.[a] (%) ee[b] (%) 
1 L25 5 rt >99 55 (–) 
2 L12 5 rt >99 80 (–) 
3[c] L12 1 rt >99 79 (–) 
4 L12 5 –20 >99 81 (–) 
[a]  Determined by GC analys is  of the reaction mixture after removal  of the catalyst;  [b]  
Determined by HPLC analys is  on a chira l  s tationary phase;  [c]  React ion time: 13 h.   
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Paralleling the observations made for the hydrogenation of vinylsilanes (see Subchapter 
2.2.1.2), no marked effect on the selectivity of the reduction of vinylsiloxane 55 was 
registered when the hydrogenation was carried out under 5 bar hydrogen pressure (entry 
2) or at lower temperature (entry 4). In contrast, the presence of aryl substitutents on the 
phosphorus atom proved to be crucial for the selectivity of the transformation (cf. entry 
1 and 2).  
To compare the reactivity of vinylsiloxanes with that of the related vinylsilanes in the 
hydrogenation reaction, compound 56 was synthesized and subjected to iridium-
catalyzed asymmetric hydrogenation. This compound was of particular interest as it 
represents the tris-methoxy analog of vinylsilanes 21 and 23. 
 
Table 22: Ligand screening for the hydrogenation of vinylsiloxane 56. 
 
 
Si(OMe)3
56
0.5 mol% [Ir(COD)L*]BArF
K2CO3 (5 mol%)
50 bar H2, rt, 2 h, CH2Cl2
61
Si(OMe)3
N
O
(tBu)2P
Ph
L11
>99% conv.[a]
28% ee[b] ( )
O
Ph2P N
O
Ph
Bn Bn
L12
>99% conv.[a]
44% ee[b] (+)
L3
>99% conv.[a]
14% ee[b] ( )
O
(o-Tol)2P N
O
O
(tBu)2P N
O
L30
>99% conv.[a]
89% ee[b] ( )
N
O
(tBu)2P
L29
>99% conv.[a]
34% ee[b] ( )
Cy2P N
N
Ph
L28
>99% conv.[a]
79% ee[b] ( )
Ph2P N
O
L22
>99% conv.[a]
53% ee[b] ( )
N
O
Ph2P
L24
>99% conv.[a]
64% ee[b] (+)
L36
>99% conv.[a]
51% ee[b] ( )
O
Ph2P N
O
L37
>99% conv.[a]
22% ee[b] ( )
O
Ph2P N
O
Ph
 
[a]  Determined by GC analys is  of  the react ion mixture after removal of  
the cata lyst;  [b]  Determined by GC analysis  on a ch ira l  stat ionary  phase.  
 
Chapter 2  
40 
 
Like in the previous ligand screening carried out with vinylsiloxanes, the ligands belonging 
to the SimplePHOX and PHIM classes, such as L30 and L28, gave the best 
enantioselectivities affording siloxane 61 with 89% and 79% ee respectively. As shown in 
Figure 7, while the best results were obtained in the hydrogenation of compound 21 the 
hydrogenation of vinylsiloxane 56 and dimethylphenylvinylsilane 22 still gave comparable 
high levels of enantioselectivity at full conversion, demonstrating the versatility of this 
methodology. 
 
 
Figure 7: Comparison of the outcome of the hydrogenation of compounds 21, 22 and 56.  
 
A further investigation of the iridium-catalyzed asymmetric hydrogenation of 
vinylsiloxanes was conducted using compound 57. Unfortunately, though, substrate 57 
was reduced to siloxane 62 with low conversion and low to moderate enantioselectivity 
under the conditions shown in Table 23. 
 
Table 23: Ligand screening for the hydrogenation of vinylsiloxane 57. 
 
Si(OMe)3
57
0.5 mol% [Ir(COD)L*]BArF
K2CO3 (5 mol%)
50 bar H2, rt, 2 h, CH2Cl2
62
Si(OMe)3
Cy2P N
N
Ph
L28
13% conv.[a]
36% ee[b] ( )
(o-Tol)2P N
N
Ph
L35
12% conv.[a]
64% ee[b] ( )
O
(o-Tol)2P N
N
Ph
L38
17% conv.[a]
53% ee[b] ( )
O
(tBu)2P N
O
L30
20% conv.[a]
56% ee[b] ( )
 
[a]  Determined by GC analys is  of the reaction mixture after removal of the  
cata lyst;  [b]  Determined by GC analys is  on a chira l  s tationary  phase.  
 
This lack of reactivity is likely due to the sterically demanding tert-butyl group in close 
proximity to the C=C bond, that hampers the coordination of the olefin to the iridium 
center.  
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2.2.3 Vinylsiletanes 
 
Since superior results were obtained using trimethylsilanes as test substrates (see Figure 
7), a search for alternative silicon groups having similar size was undertaken. In this regard 
vinylsiletanes represented a starting point. Although so far the use of siletanes for 
synthetic applications has been limited,[95] these compounds have the advantage over 
trimethylsilanes to be easily oxidized, and therefore more useful for subsequent chemical 
transformations such as, for instance, the preparation of alcohols as shown in Scheme 
29.[96] 
 
 
Scheme 29: Oxidation of siletanes by Dudley.[96] 
 
2.2.3.1 Iridium-Catalyzed Asymmetric Hydrogenation of Vinylsiletane 63 
 
The synthesis of strained, yet stable and easy to handle, silacycle 63 was achieved by 
Grignard substitution starting from α-bromostyrene in moderate yield (Scheme 30). This 
compound served as a test substrate for the hydrogenation reaction with several iridium 
catalysts. 
 
 
Scheme 30: Synthesis of vinylsiletane 63.[96] 
 
Given the impossibility to reduce vinylsiletane 63 to afford siletane 64 in a non-
enantioselective fashion using standard palladium on charcoal reduction, the iridium 
catalyst bearing achiral PHOX ligand L39 was employed. Hydrogenation with this metal 
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catalyst afforded a mixture of the desired racemic product and an unidentified side 
product (65) (Scheme 31).  
 
 
Scheme 31: Hydrogenation of vinylsiletane 63 with an achiral catalyst.(conversions determined by GC-MS 
analysis of the reaction mixture after removal of the catalyst). 
 
The structure of the by-product was not elucidated, but GC-MS (m/z 355) and 1H NMR 
analysis suggested that the compound was likely generated from the interaction of two 
product molecules. This result resembles the previous outcome of the hydrogenation of 
vinylsiloxanes 54 (cf. Table 17), where the addition of a base was crucial to circumvent by-
product formation. As a consequence many bases were screened as additives in order to 
avoid side product formation, but in this occasion the addition of 5 mol% of inorganic 
(K2CO3, Cs2CO3, KHCO3) or organic bases (DBU, DIPEA) resulted in a complete loss of 
catalytic activity. Last, the solvent was changed to THF or MTBE in the hope to avoid the 
formation of the undesired side product (Table 24). Unfortunately, in this case silane 64 
was formed as the minor component. 
 
Table 24: Use of ethereal solvents for the hydrogenation of vinylsiletane 63 with [Ir(COD)L39]BArF. 
 
Si Si
63 64 (rac)
Cy2P N
O
L39
1.0 mol% [Ir(COD)L39]BArF
50 bar H2, rt, 4 h, Solvent
+ by-product
65  
 
Entry Solvent (0.2 M) Conv. to 64[a] (%) Conv. to 65[a] (%) 
1 MTBE 26 52 
2 THF 7 22 
[a]  Determined by GC-MS analys is  of  the reaction mixture after 
removal of  the catalyst .  
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Given the low activity and the enhanced ratio of side product obtained in THF and MTBE, 
dichloromethane remained the solvent of choice for the further experiments.  
When vinylsiletane 63 was hydrogenated with other catalysts, in addition to the desired 
compound 64 and the previously detected side product 65, two further unidentified by-
products were observed. The formation of these two further by-products could be 
avoided only when PHOX ligands were applied (Table 25). 
 
Table 25: PHOX-ligands for the asymmetric hydrogenation of vinylsiletane 63. 
 
 
Entry L* Conv. to 64[a] (%) ee 64[b] (%) Conv. to 65[a] (%) 
1 L2 57 56 (–) 43 
2 L22 40 80 (–) 60 
3 L33 61 8 (–) 39 
4 L39 93 75 (–) 7 
5 L40 88 78 (–) 12 
Cy2P N
O
L33
Ph2P N
O
L22
(o-Tol)2P N
O
L40
(C6F5)2P N
O
L41
(o-Tol)2P N
O
L2  
[a]  Determined by GC-MS analys is  of the react ion mixture after removal of the cata lyst;  [b]  
Determined by HPLC analys is  on a chira l  s tationary phase.  
 
Although, as shown in Table 25, generation of by-product could not be completely 
avoided, when ligand L40 was applied only 7% conversion to 65 was detected, yielding 
the desired compound good yield and moderate enantiomeric excess. 
Attempts to decrease the formation of side product 65 and simultaneously enhance the 
enantioselectivity by lowering the reaction temperature only led to a modest increase of 
the enantioselectivity, but the side product was still formed to the same extent (Scheme 
32). 
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Scheme 32: Hydrogenation of vinylsiletane 63 at lower temperature. 
 
Since the formation of side product 65 could not be completely avoided and the level of 
enantioselectivity was not excellent, the focus of the project turned to 
trifluorovinylsilanes. 
2.2.4 Trifluorovinylsilanes 
 
To conclude the survey of possible vinylsilyl derivatives to be reduced in the presence of 
chiral iridium catalysts, the suitability of fluorine as a substituent on the silicon atom was 
considered. The small size of this halogen atom should enable facile substrate 
coordination to the metal center, allowing for the reduction of sterically demanding 
substrates. Moreover, as mentioned already earlier, the resulting trifluorosilanes are 
interesting target compounds, since they could be used in the modular synthesis of 
different building blocks via Hiyama cross-coupling (see Scheme 28).[93] 
 
2.2.4.1 Iridium-Catalyzed Asymmetric Hydrogenation of Trifluorovinylsilane 67 
 
The synthesis of trifluorovinylsilane 67 was achieved starting from commercially available 
diphenylacetylene in two synthetic steps. Hydrosilylation[97] followed by fluorination[98] 
with boron trifluoride diethyl etherate afforded the desired compound in moderate yield 
(Scheme 33). 
 
 
Scheme 33: Synthesis of trifluorovinylsilane 67. 
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The substrate synthesized was then tested in the iridium-catalyzed hydrogenation using a 
selection of N,P-ligands as summarized in Table 26. Despite the forcing reaction conditions 
(100 bar H2, 1 mol% catalyst loading, 14 hours) no reaction took place. Given the absence 
of reactivity, no further trifluorovinylsilane was investigated. 
 
Table 26: Ligand screening for the hydrogenation of trifluorovinylsilane 67. 
 
 
 
Entry L* Conv. to 68[a] (%) 
1 L3 0 
2 L11 0 
3 L22 0 
4 L24 0 
 
[a]  Determined by 1H NMR analys is  of the reaction mixture after removal  
of the cata lyst.  
 
 
2.3 Summary 
 
To conclude, various compounds bearing a vinylsilyl moiety were prepared in moderate 
to good yields. While the synthesis of a series of trimethylvinylsilanes required several 
different synthetic routes, dimethylphenyl- and trialkoxy- vinylsilanes were synthesized 
following only one synthetic pathway for each substitutent pattern.  
These subtrates were then subjected to iridium-catalyzed asymmetric hydrogenation 
using N,P-ligands. The outcome of this transformation confirmed that, as shown in Wang’s 
preliminary results (Table 2),[83] trimethyl-substituted vinylsilanes performed better than 
the corresponding dimethylphenyl and trialkoxy analogs (see Figure 7). Adding the results 
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of Wang[83] to the ones achieved in the course of this investigation, 12 trimethyl- and 
dimethylphenyl-vinylsilanes could be hydrogenated affording the desired compounds 
with up to full conversion and enantiomeric excesses ranging between 83% and 99% ee. 
These levels of enantioselectivity exceeded the benchmark set by Andersson et al. in 2006 
(see Table 1).[80r] 
The hydrogenation of vinylsiloxanes yielded a mixture of the desired product and an 
unidentified side product, which could be circumvented by adding 5 mol% of potassium 
carbonate to the reaction mixture. In this way 3 vinylsiloxanes were reduced with full 
conversion and good enantiomeric excesses (70-89% ee).  
Despite the generally good levels of enantioselectivity obtained, the major drawback of 
this process was represented by the lack of an universal iridium complex able to 
successfully catalyze the hydrogenation of this substrate class. Indeed, for each substrate 
a ligand screening had to be carried out in order to figure out the most promising ligand 
scaffold. 
At the end of the project the hydrogenation of vinylsiletanes and trifluorovinylsilanes was 
considered, but due to unavoidable formation of side products and the absence of 
reactivity, the substrate scope was not investigated further. 
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Chapter 3 
Iridium-Catalyzed Asymmetric Hydrogenation of Maleic 
Acid Dimethylesters 
 
3.1 Introduction 
 
Prochiral fumarates and maleates, as well as the corresponding anhydrides, represent an 
interesting class of unsaturated compounds for iridium-catalyzed asymmetric 
hydrogenation. The enantioselective hydrogenation of such compounds would provide 
access to highly valuable 2-substituted succinic acid derivatives that find applications as 
chiral building blocks and whose basic structure can be found in a variety of biologically 
active molecules like matrix metalloproteinase inhibitors (MMP, 69 and 70), caspase 1 
inhibitors (71) and mitiglinide (72), a drug used in the treatment of diabetes[99] (Figure 8).  
 
 
Figure 8: Structures of biologically active compounds containing the 2-substituted succinic acid moiety. 
 
In addition, the versatility of the functional groups that are present in the reduced 
products allows a broad array of subsequent chemical transformations (see section 3.2.3) 
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3.1.1 State of the Art 
 
Several reports on the asymmetric hydrogenation of itaconic acid derivatives have been 
published over the last decades[1a,100] but none of these deals with the hydrogenation of 
the corresponding isomeric fumarates or maleates. Similarly, only one example of 
asymmetric hydrogenation of an α-alkylidene succinic anhydride has been reported in the 
literature,[101] while asymmetric hydrogenations of 2-substituted maleic anhydrides are 
extremely rare. Indeed, only one method for the Rh-catalyzed hydrogenation of citraconic 
anhydride 73a has been published and, although excellent conversion could be achieved 
for this substrate, the enantioselectivity achieved was very poor (26% ee).[102] According 
to the results of Shimoda and Kubota, currently the most efficient method for the 
enantioselective reduction of citraconic anhydride is an enzymatic reduction using a 
reductase from Marchantia polymorpha.[103] This methodology has not been applied to 
more complex maleic anhydrides and therefore, it seems evident that more general 
methods that allow for the efficient and selective preparation of 2-substituted succinic 
anhydrides or acid derivatives are of interest.  
Arguably, the lack of enantioselective reductions of fumarates, maleates and substituted 
maleic anhydrides is a consequence of their poor reactivity toward hydrogenation, due to 
the conjugation of the C=C bond with the two carboxylic groups. Therefore, 
enantioenriched 2-substituted succinic acid derivatives have been synthesized via the 
rhodium-catalyzed asymmetric hydrogenation of the parent β-substituted itaconic 
acid,[104] or its methyl ester,[104b,105] or by organocatalytic parallel kinetic resolution of 
monosubstituted succinic anhydrides[106] (Scheme 34).  
 
 
Scheme 34: Enantioselective routes to chiral 2-substituted succinic acid derivatives. 
 
While the latter method is limited to a maximum yield of 50%, the hydrogenation of 
itaconic acid derivatives cannot be performed efficiently when the target C=C bond is 
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tetrasubstituted, as would be required for the synthesis of 70 and 71 (Figure 8). Moreover, 
the reduction of itaconic acid derivatives does not allow to access 2-aryl-succinic acid 
derivatives. 
 
3.2 Results and Discussion 
3.2.1 Iridium-Catalyzed Asymmetric Hydrogenation of Maleic Anhydrides 
 
Initial investigations focused on the iridium-catalyzed asymmetric hydrogenation of 
maleic anhydrides. As a test substrate, commercially available citraconic anhydride 73a 
was chosen and its hydrogenation carried out with several catalysts that have been 
developed in the past in the Pfaltz research group. The results of such catalyst screening 
are summarized in Table 27. 
 
Table 27. Ligand screening for the hydrogenation of citraconic anhydride 73a. 
 
 
[a]  Determined by GC analysis  of  the reaction mixture after removal  of  the cata lyst;  [b]  
Determined by GC analys is  on a ch ira l  stat ionary  phase.  
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In the initial screening all the different ligand classes were tested. Under standard 
conditions (50 bar H2, rt, 18 h, CH2Cl2), the ligands which performed best were L23 and 
L24, belonging to the NeoPHOX family.[29d] The presence of an aryl moiety on the 
phosphine as well as a bulky tert-butyl group on the oxazoline seemed necessary to 
achieve good results in terms of both conversion and selectivity, as the results with ligands 
L42, L43 and L44 show. 
The opposite effect can be observed when using the pyridine-phosphinite based catalysts. 
Ligand L20 bearing a diphenylphosphine gave worse results compared to the ditert-butyl 
phosphine analogs L11, which yielded the desired product with 59% conversion and 89% 
ee. Among the other complex classes, only a few catalysts gave full conversion, and usually 
moderate enantioselectivities were observed (L34b, L35). 
These initial results were very encouraging since, as mentioned earlier, only one example 
of metal-catalyzed asymmetric hydrogenation of citraconic anhydride was known in the 
literature, affording 74a in only 26% ee.[102] To further improve the results outlined in 
Table 27, the effect of temperature and pressure was scrutinized using the three most 
 
Table 28: Pressure and temperature screening for the hydrogenation of citraconic anhydride 73a. 
 
 
 
Entry L* Pressure (bar) Temperature (°C) Conv.[a] (%) ee[b] (%) 
1 L11 50 –10 11 87 
2 L11 10 r.t. 22 86 
3 L23 50 –10 27 83 
4 L23 10 r.t. >99 88 
5 L24 50 –10 35 88 
6 L24 10 r.t. 99 93 
 
[a]  Determined by GC analys is  of  the reaction mixture after  removal  of  the cata lyst;  
[b]  Determined by GC analys is  on a  ch ira l  stat ionary  phase.  
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promising catalysts of the ligand screening (L11, L23, L24). A decrease of the reaction 
temperature did not furnish the expected results. In fact only poor conversion could be 
achieved after 18 hours at –10 °C (Table 28, entries 1, 3, 5). A slightly positive influence 
on the enantiomeric excess was observed when the hydrogenation reaction was carried 
out at 10 bar hydrogen pressure (Table 28, entries 4 and 6). With a promising selection of 
catalysts for the hydrogenation of citraconic anhydride, it was decided to test the 
substrate scope of the reaction on a series of more sterically hindered compounds. 
Therefore, the compounds shown in Scheme 35 were synthesized in two steps in 
moderate yields by copper-catalyzed Michael addition of Grignard reagents to 
dimethylacetylenedicarboxylate (DMAD), followed by condensation of the corresponding 
maleic acid dimethylesters using an aqueous solution of lithium hydroxide.  
 
 
Scheme 35: Synthesis of maleic anhydrides. 
 
Given the foreseen lower reactivity of maleic anhydrides 73b-d compared to citraconic 
anhydride, it was decided to test them first under the conditions outlined in Table 27 (50 
bar H2), seeing that probably more forcing conditions would be needed to drive the 
hydrogenations to completion. Indeed, even carrying out the hydrogenation of 73c under 
50 bar of hydrogen full conversion could not be achieved, as shown in Scheme 36. 
 
 
Scheme 36: Results of the hydrogenation of substrates 73b-d using ligand L24. 
 
In the case of maleic anhydrides 73b and 73d some solubility issues were also 
encountered. These substrates were poorly soluble in dichloromethane, resulting in only 
poor results in the catalytic reaction (Scheme 36). For this reason a solvent screening 
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(Table 29) was carried out in order to enhance the solubility of the substrates without 
affecting the solubility of the catalyst and ideally achieving good levels of conversion and 
enantioselectivity. Polar solvents did not furnish the desired effects (Table 29, entries 1 to 
4), while in methyl-tert-butyl ether the maleic anhydrides were well soluble, but the 
catalyst was not.  
In an attempt to dissolve both the substrate and the catalyst, a 1:1 mixture of 
dichloromethane and methyl-tert-butyl ether was employed as solvent. In this case 40% 
conversion and 79% enantiomeric excess were achieved for the reduction of 73b. Carrying 
out the reaction at 40 °C improved the conversion to 64% while keeping almost the same 
enantioselectivity (77% vs. 79% ee, entries 6 and 7). 
Given the moderate levels of enantioselectivity observed in the case of 73b and to 
circumvent the solubility issues observed with this substrate, it was chosen to use maleic 
acid dimethyldiesters as alternative substrates. These compounds are even easier to 
prepare than maleic anhydrides, as they are precursors in the synthesis of the maleic 
anhydrides. 
 
Table 29: Solvent screening for the hydrogenation of maleic anhydride 73b. 
 
OO
O
Cy
OO
O
1.0 mol% [Ir(COD)L24]BArF
50 bar H2, rt, 18 h, Solvent Cy
73b 74b  
 
 
Entry Solvent (0.2 M) Conv.[a] (%) ee[b] (%) 
1 Ethylacetate 10 n.d. 
2 Methanol 9 n.d. 
3 Propylene Carbonate 0 - 
4 Acetone 9 n.d. 
5 MTBE 12 n.d. 
6 MTBE:CH2Cl2 (1:1) 40 79 
7[c] MTBE:CH2Cl2 (1:1) 64 77 
[a]  Determined by GC analys is  of  the react ion mixture after  
removal  of the cata lyst;  [b]  Determined by GC analysis  on a 
chira l  s tationary  phase;  [c]  The react ion was carried out  at  40 
°C.   
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3.2.2 Iridium-Catalyzed Asymmetric Hydrogenation of Maleic Acid Dimethyldiesters 
 
To investigate the suitability of maleic acid dimethylesters as substrates for iridium-
catalyzed asymmetric hydrogenation, a series of these compounds was synthesized via a 
one-step procedure starting from dimethylacetylenedicarboxylate (DMAD).[107] This 
copper-catalyzed Michael addition reaction gave access to a broad array of maleic acid 
dimethyldiester by simple variation of the Grignard reagent. The yield of the 
transformation was often low due to the difficult separation of the two stereoisomers 
formed by flash chromatography (yields reported in Table 30 are based on the amount of 
pure E- or Z-isomers isolated from the purification process). 
 
Table 30. Substrates synthesized via organocupration reaction starting from DMAD. 
 
 
 
Entry R Yield (%) Entry R Yield (%) 
1  (Z), Me (76a) 15 11 (Z), 2-Me-C6H4 (76j) 9 
2 (E), Me (76a) 17 12 (Z), 4-OMe-C6H4 (76k) 24 
3 (Z), Cy (76b) 50 13 (Z), 4-F-C6H4 (76l) 28 
4 (Z), iPr (76c)  77 14 (Z), 3-F-C6H4 (76m) 13 
5  (Z), tBu (76d) 38 15 (Z), 4-Cl-C6H4 (76n) 8 
6 (Z), nBu (76e) 88 16 (Z), 4-CF3-C6H4 (76o) 4 
7 (Z), iBu (76f) 31 17 (Z), 4-Ph-C6H4 (76p) 12 
8 (Z), Ph (76g) 24 18 (Z), 4-TMS-C6H4 (76q) 5 
9 (Z), 4-Me-C6H4 (76h) 14 19 (Z), 4-SMe-C6H4 (76r) 15 
10 (Z), 3-Me-C6H4 (76i) 15 20 (Z), 3-thiophenyl (76s) 15 
 
To find out the most promising catalyst class for the iridium-catalyzed asymmetric 
hydrogenation of maleic acid dimethyldiesters, a ligand screening was carried out 
employing compound 76b as the test substrate (Table 31). 
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Like for the related anhydrides, not many complexes were able to catalyze such 
transformation to completion. Ligands L23 and L24, which previously performed best, 
gave good enantioselectivity but poor conversion. For this transformation the best ligands 
were those belonging to the pyridine phosphinite class. Important features for this class 
of ligands to perform well are the size of the carbocyclic ring fused to the pyridine and the 
substituents on the phosphinite moiety. As shown in Table 29 ligand L11 bearing a five 
membered carbocyclic ring performed much better than its six membered analog L21, 
and the use of a di-tert-butyl-phosphinite was crucial for both conversion and selectivity 
(compare the results obtained with L11 and L20 in Table 31).  
 
Table 31: Ligand screening for the hydrogenation of maleic acid dimethyldiester 76b. 
 
 
[a]  Determined by GC analysis  of  the react ion mixture after removal of the catalyst ;  [b]  
Determined by GC analys is  on a ch ira l  stat ionary  phase.  
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With the excellent results obtained with L11 in hand, further catalysts from this family 
were tried (L26, L45, L46). The particularities of these ligands are the different electronic 
and steric properties of the pyridine ligand-core. Small changes on the pyridine ring (L45) 
and bulky substituents on the phenyl ring in proximity to the pyridine (L26) do have only 
a small influence on selectivity and conversion, but when the phenyl ring on the pyridine 
was exchanged for a 2,6-difluorophenyl group, the results achieved were outstanding 
(>99% conversion and ee using L46).  
Ligand L46 has been recently synthesized in our laboratory[108] reasoning that the 2,6-
difluorophenyl moiety could play an important role in preventing the C-H insertion 
process that often occurs with complexes of iridium and ligands bearing a phenyl 
substituent on the pyridine ring. In fact, such a C-H insertion is an undesirable side 
reaction that is known to reduce the catalyst activity.[109] 
Encouraged by the results obtained with substrate 76a, other 2-alkyl-substituted maleic 
acid dimethyldiesters were tested in the iridium-catalyzed asymmetric hydrogenation 
reaction (Table 32). 
 
Table 32: Substrate scope of the hydrogenation of 2-Alkyl substituted maleic acid dimethyldiester 76a,c-f. 
 
  
 
Entry Substrate (R) Conv.[a] (%) ee[b] (%) 
1 (Z)-76a (Me) >99  97 (+) 
2 (E)-76a (Me) >99 98 (+) 
3[c] 76a (Me) >99 98 (+) 
4 (Z)-76c (iPr)  >99 99 (+) 
5 (Z)-76d (tBu)  99 98 (+) 
6 (Z)-76e (nBu) 97 96 (+) 
7 (Z)-76f (iBu) >99 95 (+) 
[a]  Determined by GC analys is  of  the reaction mixture after 
removal of the catalyst;  [b]  Determined by GC analys is  on 
a chiral  s tationary  phase;  [c]  A  1.5:1  mixture of  (Z)-76a  and 
(E )-76a  was used in  th is  case.  
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Interestingly, either reducing or increasing the steric bulk of the substituent on the C=C 
bond had no major impact on the outcome of the hydrogenation. In fact, substrates 
bearing either linear and branched alkyl substituents such as (Z)-76a, c-f were reduced 
with excellent conversion and with enantiomeric excesses ranging from 95 to 98% under 
the same conditions used for the hydrogenation of 76b. Remarkably, the reduction of the 
fumarate derivative (E)-76a with the catalyst used for this study led to the formation of 
77a which has the same configuration as that deriving from maleate (Z)-76a (cf. entries 1 
and 2). Therefore, even mixtures of maleates and fumarates could be hydrogenated in an 
enantioconvergent fashion (entry 3). This represents a highly desirable feature for the 
reaction, especially when the separation of the two geometric isomers of the starting 
material is difficult. More sterically demanding substituents as those present on substrate 
(Z)-76c and (Z)-76d were reduced with very high level of conversion and nearly perfect 
enantioselectivity (98-99% ee). 
To further explore the generality of this method aryl-substituted dimethyl maleates, were 
examined. Compound 76g was chosen as the test substrate for these investigations and 
its hydrogenation was attempted with iridium catalysts based on ligands L11, L25, L45 and 
L46 (Table 33). 
 
Table 33: Ligand screening in the hydrogenation of maleic acid dimethyldiester 76g. 
 
 
 
 
Entry L* Conv.[a] (%) ee[b] (%) 
1 L11 16 92 (+) 
2 L25 >99 79 (−) 
3 L45 14 89 (+) 
4 L46 95 96 (+) 
[a]  Determined by GC analysis  of the react ion 
mixture after  removal  of the cata lyst;  [b]  
Determined by GC analysis  on a  ch iral  
stationary phase.  
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The novel pyridyl phosphinite ligand L46 outperformed the first generation ligand L11. 
While both catalysts reduced 76g to 77g with similar enantioselectivities (95% vs. 92% ee), 
the new generation catalyst achieved much higher conversion (95% vs. 16%, cf. entries 1 
and 4). These results are consistent with the hypothesis that the 2,6-difluorophenyl 
moiety decreases the poisoning rate of the catalyst, allowing a longer catalyst activity. In 
addition, like for the 2-alkyl substituted maleates, it was found that the methyl group on 
the pyridyl ring in L45 has no major influence on the outcome of the reaction (cf. entries 
1 and 3).  
Further to these encouraging results, a broader set of substrates was tested using catalyst 
[Ir(COD)L46]BArF (Table 34).  
At the beginning, in order to gain an insight on the steric and electronic effects of the 
substituents on the outcome of the reaction, different tolyl-substituents were considered 
(entries 1-3). The reaction proceeded smoothly for 76h with complete conversion and 
excellent enantioselectivity. Moving the methyl group of the tolyl substituent to the meta 
(76i) and then to the ortho position (76j) resulted in decreased reactivity of the substrates 
toward hydrogenation. In fact, in the case of 76i the catalyst loading had to be increased 
to 2 mol% to achieve full conversion (entry 3), whilst sterically hindered 76j was essentially 
not active under the same reaction conditions. With regard to the electronic effect of the 
substituents, both electron-rich and electron-poor aromatic groups at the C=C bond were 
well tolerated (entries 5-10), and no clear trend in either reactivity or selectivity could be 
observed. The presence of a trimethylsilyl group at the para position of the aromatic 
substituent was somehow problematic, requiring a higher catalyst loading (2.0 mol%) to 
achieve full conversion of 75q into 76q (entries 11 and 12). In terms of functional group 
compatibility, while the presence of a thioether in the molecule (entry 13) was not 
tolerated, 3-thiophenyl dimethyl maleate could be hydrogenated in good conversion 
(88%, entry 14) and selectivity (84% ee), showing the broad substrate scope of this 
methodology. 
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Table 34: Substrate scope of the hydrogenation of 2-Aryl substituted maleic acid dimethyldiester 76h-s. 
 
 
 
 
 
Entry Substrate (R) Conv.[a] (%) ee[b] (%) 
1 76h (4-Me-C6H4) >99 97 (+) 
2 76i (3-Me-C6H4) 52 95 (+) 
3[c] 76i (3-Me-C6H4) >99 96 (+) 
4 76j (2-Me-C6H4) 2 n.d. 
5 76k (4-OMe-C6H4) >99 94 (+) 
6 76l (4-F-C6H4) >99 96 (+) 
7 76m (3-F-C6H4) 99 95 (+) 
8 76n (4-Cl-C6H4) >99 92 (+) 
9 76o (4-CF3-C6H4) >99 91 (+) 
10 76p (4-Ph-C6H4) >99 97 (+) 
11 76q (4-TMS-C6H4) 30 n.d.[d] 
12[c] 76q (4-TMS-C6H4) >99 96 (+) 
13 76r (4-SMe-C6H4) 0 - 
14 76s (3-thiophenyl) 88 84 (+) 
n.d.  = not determined; [a]  Determined by GC analys is  of the 
react ion mixture after  removal of  the catalyst;  [b]  Determined by 
GC or HPLC analys is  on a ch iral  s tationary phase;  [c]  2  mol% of  
cata lyst loading were used;  [d ]  Enantiomeric excess could not be 
determined because of the over lapping  peaks  of unreacted 76q  
and one of the enant iomers of the product in the HPLC 
chromatogram. 
3.2.3 Synthetic Applications of the Hydrogenation Products 
 
As mentioned in the introduction of this chapter, the products of the iridium-catalyzed 
hydrogenation of maleic acid dimethyldiesters 77 or maleic anhydrides 74 are useful 
building blocks as they can be transformed into a variety of interesting compounds in a 
few synthetic steps (Scheme 37). 
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Scheme 37: Possible applications of maleic acid dimethyldiester 77 and maleic anhydrides 74. 
 
As is known both succinic diesters and anhydrides can be readily converted into the 
corresponding diols 78[110] and diacids 79[111] without loss of enantioselectivity. 
Fortunately, since the hydrogenation of anhydrides was not as general as hoped for, 
products 74 can be anyway accessed from 79.[111] Such succinic anhydrides are highly 
versatile compounds, since they can be used as starting materials for the synthesis of γ-
aminoacids 80,[112] succinimide (81)[113] and pyrrolidine derivatives (82).[113] It should be 
noted that, some succinimide derivatives were so far accessible via iridium-catalyzed 
asymmetric hydrogenation of α-alkylidene succinimides,[113b] but this transformation 
does not allow to access enantiopure 2-aryl succinimides. These can now be synthesized 
with the methodology presented herein. In fact, 2-aryl succinimide derivatives can be 
easily prepared from the enantioenriched succinic anhydrides.[114] 
Furthermore, in order to serve as useful intermediates in the synthesis of the biologically 
active molecules like 69 to 72, the succinic dimethyldiester should undergo a selective 
saponification of one ester moiety. One example on this transformation was reported in 
2003 by Helmchen and co-workers.[115] In this report dimethyl 2-methylsuccinate 
underwent an enzyme-catalyzed semi-saponification to give mono ester 83 in 
quantitative yield and excellent regioselectivity (Scheme 38). 
 
 
Scheme 38: Enzyme-catalyzed semisaponification of 77a. 
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This transformation gives access to the important building block class of the chiral C5-
bifunctional compounds that are widely used in the synthesis of terpenoid natural 
products (Scheme 39).  
 
 
 
Scheme 39: Preparation of C5-building blocks.[115]  
 
In order to expand the range of applications of succinic diesters 77 b-s to the synthesis of 
these enantioenriched C5-synthons, the semisaponification reaction of 77f was 
attempted. Despite the previous report,[115] the employment of Mucor javanicus lipase as 
an enzyme failed to provide the desired product. Instead a complex mixture of both mono 
esters as well as succinic acid was obtained. Similar results were obtained when treating 
77f with sterically hindered bases like tBuOK. Unfortunately, the enzyme-catalyzed semi-
saponification reaction seemed to be very substrate-specific, impeding a broader 
substrate scope. Due to these disappointing results, the selective hydrolysis of succinic 
diesters 77 b-s was shelved. 
 
3.3 Summary 
 
In summary, the preparation of alkyl- and aryl-substituted maleic acid dimethyldiesters as 
well as some alkyl-substituted maleic anhydrides was achieved in moderate yield starting 
from commercially available dimethylacetylenedicarboxylate (DMAD). 
The compounds prepared were tested as novel substrates for the iridium-catalyzed 
asymmetric hydrogenation.  
The initial idea of enantioselectively reducing substituted maleic anhydrides met with only 
partial success due to major solubility problems of these substrates. For this reason the 
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focus of the project moved to the hydrogenation of the parent maleic acid 
dimethyldiesters. Such compounds proved to be more suited to this transformation, 
reacting smoothly in the presence of pyridine-phosphinite based iridium complexes to 
afford the desired succinic dimethyldiesters in good yields and selectivities.  
Within this class of catalysts, the most active was that based on ligand L46, bearing a di-
tert-butyl phosphinite and a 2,6-difluorophenyl group on the pyridine ring. The latter is 
thought to play an important role in preventing deactivation of the catalyst. Indeed, as 
already mentioned earlier, pyridine phosphinite iridium complexes bearing a phenyl 
substituent on the pyridine ring are known to undergo C–H insertion that lowers the 
catalyst activity.  
The iridium-catalyzed asymmetric hydrogenation presented in this chapter features a 
broad substrate scope (Scheme 40), as alkyl-, hetereoaryl- and aryl groups were tolerated 
as substituents of the maleic acid diesters. In total 20 examples of these new substrates 
could be reduced with excellent yields (up to full conversion) and enantioselectivities 
(from 84 up to 99% ee). 
 
 
Scheme 40: iridium-catalyzed asymmetric hydrogenation of maleic acid dimethyldiesters 76a-s. 
 
The products of this process can be used for a variety of transformations to afford succinic 
acids,[111] diols,[110] γ-aminoacids derivatives[112] as well as succinic anhydrides,[111] 
succinimides,[113] pyrrolidines.[113] 
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Chapter 4 
Iridium-Catalyzed Asymmetric Hydrogenation of 3,3-
Disubstituted Allylic Alcohols in Etheral Solvents 
 
4.1 Introduction 
 
During the last decades the asymmetric hydrogenation of many functionalized olefins 
such as α-substituted acrylic acids,[45,116] enamides,[117] α,β-unsaturated carboxylic 
acids[44,118] and esters[37,62,119] could be successfully achieved using ruthenium-, rhodium- 
or iridium-based complexes. More recently, further examples of unsaturated carbonyl 
compounds, like enones, have been successfully chemoselectively reduced at the C=C 
bond in good yield and enantioselectivity.[37,101,120] These reactions show that in the field 
of transition metal-catalyzed hydrogenation in general higher reactivity is observed for 
C=C compared to C=O bonds.[6d,121] Some important exceptions are the iridium catalysts 
developed in the Takaya[122] and Zhou[48-49] group (see Chapter 1, Scheme 11) as well as 
Noyori’s ruthenium-based catalyst,[123] which preferentially reduce C=O bonds in the 
presence of C=C bonds. 
Despite the recent progress in this field, the chemoselective, metal-catalyzed asymmetric 
hydrogenation of the C=C bonds of α,β-unsaturated aldehydes is unexplored. The major 
issue with this kind of transformation is the enhanced reactivity of the C=O bond which 
favors over-reduction, yielding the saturated alcohols rather than the saturated aldehydes 
as final products.[124] 
An alternative synthetic approach to α- and β-substituted chiral aldehydes is represented 
by the transfer hydrogenation of the parent enals. In recent years many organocatalysts 
have been reported[125] to catalyze such reaction in good yield and chemoselectivity but 
unfortunately relatively low levels of enantiomeric excesses and high catalyst loading 
render this synthetic route less attractive for large scale syntheses.  
The need for a general method for the highly enantioselective reduction of enals occurring 
selectively at the C=C bond set a challenge that could potentially be tackled using iridium-
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catalyzed asymmetric hydrogenation by judicious choice of catalyst and reaction 
conditions.  
Unfortunately, this goal could not be attained. Generally a mixture of the desired product, 
the related allylic alcohol and the corresponding saturated alcohol were obtained (see 
subsection 4.2.1). Nonetheless, the latter was formed in excellent enantioselectivity when 
β,β-disubstituted enals were employed as a substrates. This observation and the 
impossibility to selectively reduce the C=C bond of α,β-unsaturated aldehydes under the 
reaction conditions investigated, shifted the focus of the study on the reduction of allylic 
alcohols. It was discovered that, under similar reaction conditions to those tested for 
enals, the corresponding 3,3-disubstituted allylic alcohols could be reduced to afford the 
same product in similar yield and enantioselectivity, indicating that the aldehyde moiety 
is not crucial for the outcome of the reaction.  
The interest in prochiral allylic alcohols in the field of asymmetric hydrogenation started 
with Noyori’s first report in 1987, when the use of Ru-BINAP catalysts for the asymmetric 
hydrogenation of geraniol and nerol was unveiled.[126] Since then, many studies have been 
reported on the selective hydrogenation of 2,3-disubstituted allylic alcohols and, in 
particular, α-methyl cinnamyl alcohol has become a standard substrate for the evaluation 
of new metal complexes for asymmetric hydrogenation. Nevertheless, the currently 
available methodologies for the enantioselective reduction of this substrate class, lack in 
generality.[1b,127] 
For instance, the hydrogenation of their 3,3-disubstituted allylic alcohols proved 
considerably more difficult to achieve with high degrees of stereoselectivity and for a wide 
range of substrates,[1b,127] and only a few specific compounds could be successfully 
deployed for this reaction.[126,128] Therefore, state-of-the-art asymmetric methodologies 
for the preparation of 3,3-disubstituted chiral primary alcohols are mainly based on multi-
step syntheses that rely on a first enantioselective transformation carried out on a 
functionalized substrate, followed by an adjustment of the oxidation state of the resulting 
product. As summarized in Scheme 41 asymmetric SN2’ allylic alkylation,[129] 1,4-addition 
onto α,β-unsaturated carbonyl compounds,[130] asymmetric isomerization of allylic 
alcohols to aldehydes,[131] asymmetric hydrogenation of α,β- unsaturated carboxylic 
acids,[132] esters[132] and aldehydes[125] all afford products that require further redox 
transformations to yield the target molecules.  
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Scheme 41: Synthetic routes to enantioenriched 3,3-disubstituted primary alcohols. 
 
Therefore, a more direct approach to the synthesis of these alcohols, that affords the 
product in the right oxidation state with no need for further functional group 
manipulation would be highly desirable. 
 
4.2 Results and Discussion 
4.2.1 Substrate Synthesis 
 
The substrates needed for the investigations shown in this Chapter were easily obtained 
in a three steps synthetic sequence. While ester 85a was commercially available, 
compound 85b was synthesized via Horner–Wadsworth–Emmons reaction of iso-
butyrophenone with triethyl phosphonoacetate yielding the desired α,β-unsaturated 
ester in good yield. Subsequent DIBAL-H reduction led to 3,3-disubstituted allylic alcohols 
86a-b, which could then be oxidized under Swern conditions[133] to the related aldehydes 
87a (Scheme 42). 
 
 
 
Scheme 42: Synthesis of allylic alcohols 86a,b and α,β-unsaturated aldehyde 87a. 
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The synthesis of tertiary alcohol 88 was achieved following the procedure described by 
Weinreb et al.[134] Methyllithium addition to ester 85a, yielded the desired compound 88 
in 84% yield (Scheme 43). 
 
 
Scheme 43: Synthesis of tertiary allylic alcohol 88. 
 
4.2.2 Attempted Iridium-Catalyzed Chemoselective Asymmetric Hydrogenation of α,β-
Unsaturated Aldehydes 
 
As mentioned earlier, the original aim of the project described in this Chapter was the 
chemoselective reduction of the C=C bond of α,β-unsaturated aldehydes. Initial 
experiments were aimed at identifying the most promising class of chiral iridium catalysts 
for the hydrogenation of commercially available trans-α-methyl-cinnamaldehyde 89 
(Table 35). The results outlined in Table 35 show that, regardless of the catalyst used, 
under screening conditions (50 bar H2, rt, CH2Cl2), the major product observed was the 
saturated alcohols 91, resulting from the reduction of both C=C and C=O bonds. In 
contrast, the desired aldehyde 90 could only be detected in some cases and always as the 
minor product. Among the catalysts tried, those based on ligands L29 and L47, belonging 
to the phosphinomethyloxazoline family, proved to be the most active (entries 4 and 5), 
whereas poor activity was observed for other iridium N,P-ligand complexes (Table 35, 
entries 1-3). The phosphinomethyloxazoline ligand class has proven particularly effective 
for the hydrogenation of tetrasubstituted olefins[29b,36,135] but so far has not found use for 
the hydrogenation of other substrate classes. Catalysts derived from L29 or the likes of 
are attractive because the chiral ligands are readily accessible through several short 
synthetic routes[29b,35-36,135] (See also Section 1.2.2). In the examples reported in Table 35, 
the presence of a sterically hindered tert-butyl group on the phosphine and an alkyl group 
on the oxazoline seemed necessary to achieve full conversion, as the results with ligands 
L48, L49 and L50 show (entries 6-8). 
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Table 35: Ligand screening in the chemoselective hydrogenation of aldehyde 89. 
 
 
 
Entry L* Conversion to 90[a] (%) Conversion to 91[a] (%) ee 91[b] (%) 
1 L3 5 9 n.d. 
2 L11 2 2 n.d. 
3 L22 0 0 - 
4 L29 0 >99 26 (−) 
5 L47 0 >99 28 (−) 
6 L48 4 39 19 (+) 
7 L49 9 27 15 (−) 
8 L50 6 2 n.d. 
 
n.d.  = not determined;[a]  Determined by GC analysis  of  the react ion mixture after  removal of  
the cata lyst;  [b]  Determined by GC analys is  on a chiral  s tat ionary  phase.   
 
The outcome of this series of experiments clearly indicated that the olefin and the 
aldehyde moiety possess similar reactivity, rendering the chemoselective hydrogenation 
of such substrates with the catalysts developed in the Pfaltz group difficult to achieve. 
Given the poor enantiomeric excess obtained with aldehyde 89, and in order to explore 
the generality of this method, its β,β-disubstituted isomer 87a was synthesized and tested 
in the catalytic process (Table 36). Like in the previous example, only the catalysts based 
on L29, L47 and L51 were able to promote the hydrogenation. While catalysts bearing L47 
and L51 gave only traces of the corresponding allylic alcohol 86a, ligand L29 afforded a 
mixture of allylic alcohol 86a, saturated alcohol 93a and the desired product 92a. It is 
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worth highlighting that, despite the low conversion, very high enantiomeric excess (98%) 
for aldehyde 92a was achieved. This is remarkable since, as mentioned earlier, the 
asymmetric reduction of β,β-disubstituted α,β-unsaturated aldehydes has been proven 
to be more challenging in terms of selectivity and substrate scope than the corresponding 
α,α-disubstituted analogs.[1b,127] On the other hand, the results summarized in Table 36 
confirm the difficulty in developing a chemoselective reduction of substrates like 87a or 
89. In this regard it seems that little changes on the ligand structure have a major impact 
on the outcome of the catalysis. Indeed, when catalysts bearing L47 or L51 were used, 
C=O bond reduction was faster than olefin reduction. The opposite effect was observed 
with ligand L29.  
 
Table 36. Ligand screening for the chemoselective hydrogenation of 87a. 
 
 
 
Entry L* Conv. to 92a[a] (%) Conv. to 86a[a] (%) Conv. to 93a[a] (%) 
1 L11 0 0 0 
2 L13 0 0 0 
3 L29 12 (−98% ee)[b] 8 5 
4 L47 0 9 0 
5 L50 0 0 0 
6 L51 0 19 0 
 
[a]  Determined by GC analys is  of the react ion mixture after  removal  of  the catalyst;  [b]  Determined by GC 
analys is  on a  ch iral  stat ionary phase.  
 
In an attempt to improve the results obtained with the most successful iridium complex 
bearing ligand L29, the effect of the solvent was scrutinized as summarized in Table 37.  
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Unfortunately, the solvents tested did not improve the conversion to the saturated 
aldehyde 92a. In contrast, in toluene exclusive reduction of the C=O bond took place, 
leaving the olefin untouched (Table 37, entry 1). A similar outcome could be observed in 
etheral solvents such as methyl-tert-butyl-ether or diethylether, with the C=O reduction 
being considerably faster than the hydrogenation of the C=C bond (entries 2 and 3). 
 
Table 37: Solvent screening in the chemoselective hydrogenation of 87a. 
 
 
 
Entry Solvent Conv. 92a[a] (%) Conv. 86a[a] (%) Conv. 93a[a] (%) ee 93a[b] (%) 
1 Toluene 0 21 0 - 
2 MTBE 1 34 12 95 (−) 
3 Et2O 2 52 14 96 (−) 
4 THF 0 0 >99 97 (−) 
5 PhCl 0 0 >99 98 (−) 
[a]  Determined by GC analysis  of the reaction mixture after removal of the cata lyst;  [b]  Determined 
by GC analys is  on a chira l  s tationary phase.   
 
In tetrahydrofuran (THF) as well as in chlorobenzene (entries 4 and 5 respectively), full 
conversion to the saturated alcohol 93a was detected. Despite the lack of 
chemoselectivity, it was surprising to notice that the transformation could be carried out 
with high degrees of enantioselectivity in several solvents. In fact, enantiomeric excesses 
above 95% were achieved regardless of the solvent used (entries 2-5). Several reports on 
the iridium-catalyzed hydrogenation in dichloromethane[19] or methanol[116c,136] have 
been published, but none of them documents the use of THF for such transformation. In 
fact, this solvent has been avoided for iridium-catalyzed asymmetric hydrogenations since 
it is known to coordinate to the metal center, thus deactivating the catalyst (See Chapter 
1.2).[137] However, the use of THF would have several advantages over the routinely used 
dichloromethane, in particular, low toxicity and higher boiling point play in favor of 
tetrahydrofuran. 
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The excellent enantiomeric excesses obtained in THF for the asymmetric reduction of 87a, 
as well as the lack of chemoselectivity of this transformation, rose the question about the 
importance of the aldehyde moiety for the outcome of the catalysis. To answer this 
question, related 3,3-disubstituted allylic alcohols 86a,b were synthesized and tested as 
substrates for the iridium-catalyzed asymmetric hydrogenation. 
4.2.3 Iridium-Catalyzed Asymmetric Hydrogenation of 3,3-Disubstituted Allylic Alcohols in 
Ethereal Solvents 
 
The results of the iridium-catalyzed asymmetric hydrogenation of substrates 86a,b using 
various phosphinomethyloxazoline ligands are outlined in Table 38. Similarly to what was 
observed previously, the electronic and steric properties of the ligand were found to have 
a major impact on the activity and selectivity of the catalyst. The presence of an alkyl 
phosphine was crucial for good performances (L51 and L29). Indeed, despite the lower 
catalyst loading (0.5 vs. 1.0 mol% for the related α,β-unsaturated aldehydes), alcohols 93a 
and 93b were obtained in excellent enantiomeric excesses using ligand L51 and L29. In 
contrast, ligands bearing aryl-phosphines yielded reduced activity as well as poor 
enantioselectivities (entries 5-8).  
 
Table 38: Phosphinomethyloxazoline ligands in the hydrogenation of 3,3-disubstituted allylic alcohols 
86a,b.[a,b] 
 
 
n.d.  =  not determined; [a]  Conversions  determined by GC analysis  of the reaction mixture after removal of  
the cata lyst;  [b]  Enantiomeric  excesses determined by GC analys is  on a  chira l  stationary  phase;  [c]  3% of  the 
(Z)- isomer of the start ing material  was detected.   
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A comparison between the results summarized in Table 37 and Table 38, shows that, 
under these reaction conditions, the aldehyde moiety has no major influence on the 
outcome of this transformation. The iridium catalysts bearing a 
phosphinomethyloxazoline ligand are able to catalyze the hydrogenation of α,β-
unsaturated aldehydes as well as allylic alcohols with excellent conversion and 
enantiomeric excesses. Therefore, the focus of the project shifted toward the asymmetric 
hydrogenation of the related 3,3-disubstituted allylic alcohols.  
By careful analysis of the results from the reduction of substrate 86a, an unexpected 
reactivity was discovered. Indeed, the reaction catalyzed by ligands L29, L31 and L52, 
afforded traces of the (Z)-regioisomer of the starting material (Table 38). This observation 
raised some concerns regarding the mechanism of the transformation. Instead of the 
classical hydrogenation mechanism (see Chapter 1.2.4), it was envisaged that another 
reaction pathway related to that recently proposed by Mazet et al.[131] could take place 
(Figure 9).  
 
 
Figure 9: Proposed mechanism for the isomerisation of allylic alcohols by Mazet.[131] 
 
Mazet and co-workers demonstrated that, under similar reaction conditions to those used 
in this study, phosphinemethyloxazoline-based catalysts can promote the isomerization 
of allylic alcohols to the corresponding saturated aldehydes.[1b,127] 
In order to ascertain what reaction pathway did take place in the case of the 
hydrogenation described herein, the reduction of tertiary allylic alcohol 88, was 
investigated under similar reaction conditions to those described in Table 38. Surprisingly, 
when catalysts bearing ligands L29 and L51 were applied to this transformation in addition 
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to the product, a mixture of three unidentified side products could be observed. The latter 
could not be assigned to side product derived from any isomerization reactions or from 
an elimination process. Nevertheless, judicious choice of the iridium catalyst made it 
possible to achieve full conversion and 69% ee for the formation of 94, avoiding the 
formation of any unidentified by-products (Scheme 44).  
 
 
Scheme 44: Asymmetric hydrogenation of allylic alcohol 88 using an iridium catalyst bearing ligand L32. 
 
The outcome of the experiment shown in Scheme 44 supports the hypothesis that direct 
hydrogenation of the C=C bond occurs, since alcohol 88 could not react according to the 
mechanism proposed by Mazet and thus forming an aldehyde. However, the different 
behavior of the substrate with different catalysts and the formation of unidentified by-
products in some cases called for further investigations aimed to clarify the reaction 
mechanism. 
Vincenzo Ramella[138] and Paolo Tosatti[139] from our group, carried out further 
experiments which support the proposition that, under these reaction conditions, the 
classical hydrogenation pathway is favored. Ramella[138] showed that when the reduction 
of substrate 86a was ran under 50 bar of D2, complete deuterium incorporation (>90%) at 
the C2 and C3 positions was obtained, whereas no deuteration occurred at the C1 position 
(Scheme 45).  
 
 
Scheme 45: Deuteration experiment on allylic alcohol 86a carried out by Vincenzo Ramella. 
 
Furthermore, homoallylic alcohols 96a and 96b could be successfully reduced to give the 
saturated alcohols 97a and 97b with full conversion and excellent enantioselectivities 
(Scheme 46). The hydrogenation of this specific substrate class could not be explained 
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using Mazet’s proposed catalytic cycle, since homoallylic alcohols cannot isomerize under 
these conditions to the corresponding aldehydes. 
 
 
 
Scheme 46: Asymmetric hydrogenation of homoallylic alcohols achieved by Vincenzo Ramella and Paolo 
Tosatti. 
 
The asymmetric hydrogenation of homoallylic alcohols of this type bears considerable 
potential for application in organic synthesis. In fact, the reduction of 96b to 97b is a key 
step in the synthesis of four natural products, namely curcumene, nuciferal, nuciferol and 
erogorgiaene. All these bisabolane sesquiterpenes can be accessed starting from 97b via 
the corresponding aldehyde 98.[140] Thus the sequence leading to highly enantioenriched 
aldehyde 98 shown in Scheme 47 represents a formal synthesis of these natural products.  
 
 
Scheme 47: Formal total synthesis of natural products through alcohol 97b. 
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Homoallylic alcohol 96b was synthesized by Tosatti[139] starting from commercially 
available cyclopropyl methyl ketone 99 and yielding the desired compound after a two-
step transformation involving Grignard addition followed by acid-catalyzed 
rearrangement of the tertiary alcohol 100. After iridium-catalyzed asymmetric 
hydrogenation of 96b, the resulting chiral alcohol 97b was converted to aldehyde 98 via 
Parikh−Doering oxidation[141] in 97% yield. Compared to the most efficient published 
route to 98, which is based on the enantioselective cyclopropanation of para-
methylstyrene,[142] the sequence shown in Scheme 47 was shorter and the overall yield of 
98 was higher (68% vs. 30−36%).[143] 
In order to broaden the substrate scope of the asymmetric hydrogenation of allylic 
alcohols, Vincenzo Ramella synthesized, in the course of his master thesis,[138] various 
aryl/alkyl and alkyl/alkyl 3,3-disubstituted allylic alcohols and tested them in the iridium-
catalyzed asymmetric hydrogenation. During this study, following a suggestion by Tosatti, 
he found that similar results in the asymmetric hydrogenation of allylic alcohol 86c were 
obtained using 2-MeTHF, a “greener” solvent alternative to THF (Scheme 48). 
 
 
 
Scheme 48: Hydrogenation of allylic alcohol 86c in THF and 2-MeTHF achieved by Vincenzo Ramella.[138] 
 
2-MeTHF is considered an ecofriendly solvent, as it can be obtained from renewable 
sources[144] and has several advantages such as low miscibility with water, high stability 
under acid/basic conditions, formation of an effective azeotrope with water and a higher 
boiling point than THF, that render it particularly attractive for application in both industry 
and academia.[145] 
Consequently the hydrogenation of several allylic alcohols 86c-l in THF and 2-MeTHF were 
examined. Table 39 summarizes the results obtained with [Ir(COD)L29]BArF and related 
catalysts derived from phosphinomethyloxazoline ligands. In general, slightly better 
results were observed in THF, although in most cases comparable levels of conversion and 
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enantioselectivity were achieved in the two solvents (entries 2-7). Yet in one case (entry 
11) the reaction in 2-MeTHF gave significantly higher enantioselectivity than in THF. 
(E)-3-Methylcinnamyl alcohol 86b and related aryl/methyl-substituted derivatives reacted 
with excellent enantioselectivities (ee 95-98%, entries 1-4) except for the 4-chlorophenyl 
derivative 86g, which gave a slightly lower ee (entry 6).  
 
Table 39: Asymmetric hydrogenation of allylic alcohols 86 achieved by Vincenzo Ramella.[138] 
 
 
 
Entry R1, R2 
THF 2-MeTHF 
L*, Conv.(%), ee[a] (%) L*, Conv.(%), ee[a] (%) 
1 Ph, Me (b) L51, >99, 95, (−)-(R) L51, >99, 90 
2 4-MeOC6H4, Me (c) L29, >99, 98, (−)-(R) L29, >99, 97 
3 4-MeC6H4, Me (d) L51, >99, 95, (−)-(R) L51, >99, 95 
4 2-MeC6H4, Me (e) L51, >99, 97, (−) L51, 41, 93 
   L51, >99, 95[b] 
5 2-Naphthyl, Me (f) L47, 97, 95, (−) L47, 98, 93 
6 4-ClC6H4, Me (g) L48, >99, 92, (+) L48, >99, 90 
7 Ph, Cy (h) L48, 94, 92, (+) L48, >99, 90 
8 tBu, Ph (i) L48, 43, 96, (+)-(R) L48, 10, n.d. 
   L48, 68, 90[c] 
9 tBu, Me (j) L48, >99, >99, [b] (−)-(S) L48, >99, 95[b] 
10 Cy, Me (k) L53, >99, 88,[b] (+)-(R) L31, >99, 60[b] 
11 iBu, Me (l) L48, >99, 80,[b] (+) L51, >99, >99,[b] (−) 
 
[a]  Convers ions were determined by GC analysis  of the crude react ion mixtures whi le  
enantioselect iv i t ies were determined by HPLC analys is  on a chira l  s tat ionary phase;  [b]  
1 mol% of catalyst used;  [c]  React ion carr ied out  for 20  h with 2 mol% of cata lyst.  
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The sterically hindered ortho-tolyl derivative 86e required a higher catalyst loading of 1.0 
mol% instead of 0.5 mol% to reach full conversion in 2-MeTHF. While high conversion and 
good enantioselectivity could be achieved for the phenyl/cyclohexyl-substituted substrate 
86h (entry 7), a substantial decrease of conversion but excellent ee (99% in THF) was 
observed for the phenyl/tert-butyl derivative 86i (entry 8). The tert-butyl/methyl analog 
86j, on the other hand, gave full conversion at 1 mol% catalyst loading (entry 9). The 
dialkyl-substituted substrates 86k and 86l proved to be less reactive than the 
corresponding aryl/alkyl-substituted compounds, but at 1.0 mol% catalyst loading full 
conversion was achieved. While the enantioselectivity was only moderate for the 
cyclohexyl/methyl derivative 86k, up to 99% ee was recorded for 86j and 86l using the 
appropriate catalyst and solvent (entries 9 and 11). Overall the results show that the 
proper choice of the phosphinomethyloxazoline ligand and the solvent (THF or 2-MeTHF) 
is crucial to obtain optimal results for a particular substrate. 
 
 
4.3 Summary 
 
In summary, the feasibility of a chemoselective asymmetric hydrogenation of α,β-
unsaturated aldehydes was investigated using iridium catalysts developed in the Pfaltz 
group. This ambitious transformation, due to the similar reactivity of the C=C and C=O 
bonds, suffered from over-reduction yielding a mixture of the desired saturated aldehyde, 
the related allylic alcohol as well as the saturated alcohol. Nonetheless, the latter could 
be obtained in excellent enantiomeric excess in the reduction process of β,β-disubstituted 
enals using catalysts based on phosphinomethyloxazoline ligands.  
Such ligands performed best also in the iridium-catalyzed asymmetric hydrogenation of 
the corresponding 3,3-disubstituted allylic alcohols, a type of substrate that cannot be 
efficiently hydrogenated in an enantioselective manner with current methodologies. In 
addition, the required ligands are structurally simple and readily accessible from 
enantiopure aminoalcohols via several short syntheses,[29b,35-36,135] adding attractiveness 
to the reaction presented herein. Importantly, reactions could be carried out in either THF 
or 2-MeTHF, which are ecologically advantageous and better suited for industrial 
applications than the commonly used dichloromethane. In order to explore the scope of 
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this transformation a broad set of aryl/alkyl and alkyl/alkyl 3,3-disubstituted allylic 
alcohols (Scheme 49) were tested by Vincenzo Ramella, affording the desired saturated 
alcohols in excellent yields (up to full conversion) and enantioselectivities (from 60 to 99% 
ee). 
 
 
 
Scheme 49: Iridium-catalyzed asymmetric hydrogenation of allylic alcohols 86a-l by Vincenzo Ramella.[138] 
 
Furthermore, the work carried out by Vincenzo Ramella and Paolo Tosatti on analogs 
homoallylic alcohols broadened the application of this methodology to homoallylic 
alcohols (Scheme 50). The potential of this method was illustrated by a short and efficient 
synthesis of a highly enantioenriched precursor that had been used for the synthesis of 
several bisabolane sesquiterpenes. 
 
 
 
Scheme 50: Iridium-catalyzed asymmetric hydrogenation of homoallylic alcohols 96a-b by Vincenzo 
Ramella and Paolo Tosatti. 
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Chapter 5 
Chiral N-Heterocyclic Carbene/Pyridine Ligands for the 
Iridium-Catalyzed Asymmetric Hydrogenation of Olefins 
 
5.1 Introduction: N-Heterocyclic Carbenes in Transition Metal Catalysis[146] 
 
Despite early work on N-heterocyclic carbenes carried out by Öfele[51] and Wanzlick,[50] in 
the 1960s, it was not until 1991 that these molecules started to attract the attention of 
several scientists. The turning point in this revived interest was represented by the 
discovery that some carbenes can be isolated and easily handled using classical inert 
atmosphere techniques.[147] From this moment on, the number of reports dealing with 
the application of NHC carbenes as ligands in homogeneous catalysis grew 
significantly.[148] 
Nowadays the most common NHC ligands have five-membered scaffolds, namely 
imidazolylidenes, imidazolinylidenes or a triazolylidenes (Figure 10). While the latter is 
widely used in organocatalysis,[149] the first two structure classes are widely employed in 
transition metal catalysis, with elements of the d-block from group 7 to group 11.[58d,146,150] 
 
 
Figure 10: Structures of most common N-Heterocyclic Carbenes.[146] 
 
Classic applications of NHC-ligands in transition metal catalysis are represented by 
ruthenium-based olefin metathesis[150] and palladium,[151] nickel,[152] copper[153] or iron-
catalyzed[154] cross coupling reactions. In addition, a variety of other transformations like, 
for instance, cyclization,[155] cycloaddition[156] or cycloisomerization[157] reactions have 
been shown to be catalyzed efficiently by NHC-metal complexes. Recently, this ligand class 
has also been deployed for reduction reactions, in particular, hydrosilylation,[148b,158] 
borrowing hydrogen[159] or more classical hydrogenation[57b,61,160] reactions.  
In general, the enhanced σ-electron-donating properties[161] of the carbene ligands result 
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in strong carbene-metal bonds[162] which render the catalyst structure robust, preventing 
complex decomposition. 
5.1.1 N-Heterocyclic Carbenes in Asymmetric Hydrogenation Reactions 
 
Although the first applications of NHC ligands to different asymmetric metal-catalyzed 
reactions were reported in the late 1990s and early 2000s,[52,53b,60b] only poor to moderate 
enantioselectivites could be achieved. A breakthrough in this field is certainly represented 
by the work carried out in 2001 by Burgess et al.[61] who found out that an iridium catalyst 
bearing a bulky bidentate imidazolylidine-oxazoline-based NHC ligand allowed for the 
enantioselective hydrogenation of various unfuctionalized olefins in very good yields and 
selectivities. In particular, excellent results in terms of activity and selectivity were 
obtained in the asymmetric hydrogenation of trans-methyl stilbene using ligand L8d, 
bearing a sterically demanding adamantyl-group on the imidazolydine moiety and a 2,6-
di-isopropylphenyl group on the oxazoline ring (Scheme 51).[61] 
 
 
Scheme 51: Asymmetric hydrogenation of trans-methyl stilbene using various NHC ligands L8. 
 
After Burgess’ initial investigations,[61] other research groups,[163] including our own,[65,164] 
became interested in using bidentate NHC carbenes as ligands for iridium catalysts (Figure 
11). Despite considerable efforts, none of the new complexes afforded better results than 
ligand L8d. Building on the success of their ligand in the hydrogenation of trans-methyl 
stilbene, the Burgess group[165] broadened the substrate scope of the hydrogenation to 
functionalized olefins,[165] demonstrating the versatility of NHC based ligands, that 
became valid alternatives to phosphines in iridium-catalyzed asymmetric hydrogenation 
in some cases. 
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Figure 11: Iridium catalysts bearing NHC ligands applied to asymmetric hydrogenation. 
 
Indeed, one advantage of iridium catalysts possessing a bidentate imidazolylidine-
oxazoline-based NHC ligand is the lower acidity of the corresponding hydrides compared 
to their N,P-analogs,[64] that renders these catalysts particularly suited for acid-sensitive 
substrates.[64] 
Given the utility of Burgess catalyst [Ir(COD)L8d]BArF and, on the other hand, the paucity 
of alternative ligands to L8d for iridium-catalyzed asymmetric hydrogenation, our group 
continued its efforts to find alternative NHC-based ligands which could be complementary 
to the Burgess system, so to broaden even more the current substrate scope of the 
hydrogenation. 
In this context and considering the successful applications of pyridine phosphinite 
ligands,[30g,166] Andreas Schumacher, prepared a series of NHC-pyridine analogs L34a-c to 
be tested as chiral ligands for iridium-catalyzed asymmetric hydrogenation (Figure 12).[167]  
 
 
 
Figure 12: NHC-pyridine-based ligands synthesized by Schumacher for iridium-catalyzed asymmetric 
hydrogenation. 
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He started the preparation of ligands L34a-c from previously synthesized, enantiopure, 
bicyclic pyridyl alcohols having a five, six, or seven-membered carbocyclic ring. These 
alcohols were converted into the corresponding amines 102 by mesylation and 
subsequent reaction with sodium azide, followed by hydrogenation with Pd/C.[168] The 
coupling of primary amines 102 with the imidazolium salt 103 was achieved following the 
method of Fürstner et al.,[169] yielding the enatiomerically pure ligands 104 as perchlorate 
salts. Treatment with lithium tert-butoxide in THF and complexation with [Ir(COD)Cl]2 in 
the presence of NaBArF resulted in the formation of the desired iridium complexes 
[Ir(COD)L34a-c]BArF in moderate to good yields (Scheme 52).[167] 
 
 
Scheme 52: Synthesis of catalysts [Ir(COD)L34a-c]BArF carried out by Andreas Schumacher.[167] 
 
Evaluation of the new NHC/pyridine ligands L34a-c in the iridium catalyzed asymmetric 
hydrogenation of six typical test substrates was started by Andreas Schumacher, who 
compared their results with those obtained with analogs pyridine phosphinite ligands L11 
and L13 (Scheme 53).[167] With two exceptions (L34c with substrate 105 and L34a with 
107), the new complexes showed high catalytic activity and led to full conversion within 2 
hours at 50 bar hydrogen pressure and 1.0 mol% catalyst loading. In general, 
enantioselectivites were comparable to those obtained with analogs pyridine phosphinite 
ligands L11 and L13 or Burgess’ oxazoline-NHC ligand L8d,[61,170] with the exception of 
terminal alkene 108. In this case ligand L8d yielded superior results compared to ligands 
L34a-c (89 vs. 63% ee).[170a] 
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The opposite effect was observed in the reduction of (Z)-alkene 109, with ligands L34a-c 
performing better than ligand L30 (92-94 vs. 80% ee).[170a] This result indicates that the 
pyridine-derived ligands L34a-c are an useful addition to the oxazoline derived ligand L8, 
and enhance the application range of NHC-based iridium catalysts. 
Further to the success of the catalysts based on ligands L34, the next step was to test their 
performance in the reduction of acid-labile substrates. An example of such compounds is 
represented by protected allylic alcohols,[64] which can be hydrogenated with only poor 
results with standard N,P-ligand-based iridium catalysts.[36] In addition, the activity of 
these new iridium complexes at lower catalyst loading needed to be investigated. 
 
 
Scheme 53: Iridium-catalyzed asymmetric hydrogenation of substrates 105-110 performed by 
Schumacher;[167] [a] Reaction carried out at 1.0 bar H2. 
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5.2 Results and Discussion 
5.2.1 Iridium-Catalyzed Asymmetric Hydrogenation of Acid-Labile Substrates 
 
Methoxymethyl ether (MOM) protected allylic alcohol 111 was chosen as an initial test 
substrate for iridium-catalyzed asymmetric hydrogenation, since methoxymethyl ethers 
are known to be labile under acidic conditions[171] and therefore represent an interesting 
substrate class for this investigation. Compound 111 was easily synthesized in moderate 
yield following Okahara’s procedure[172] starting from allylic alcohol 107 (Scheme 54).  
 
 
Scheme 54: Synthesis of protected allylic alcohol 111. 
 
Despite the excellent enantiomeric excesses achieved using N,P-based ligands (Table 40, 
entries 1-2), the formation of an unidentified side product could not be avoided. 
 
Table 40: Iridium-catalyzed asymmetric hydrogenation of 111. 
 
 
Entry L* Conversion to 112[a] (%) ee 112[b] (%) 
1[c] L11 83 93 (+) 
2[c] L13 83 96 (+) 
3 L34a >99 30 (+) 
4 L34b >99 52 (−) 
 
[a]  Determined by GC analysis  of  the reaction mixture after removal  of  the cata lyst;  [b]  
Determined by HPLC analysis  on a chira l  s tat ionary phase;  [c]  17% of an unidenti f ied 
product was observed.   
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This undesired product did not form when the transformation was catalyzed by NHC 
ligands, although lower enantioselectivities were detected (cf. entries 1-2 with 3-4). 
Another acid-sensitive substrate that was used to test the performance of the catalyst 
based on ligand 34b, was the tert-butyloxycarbonyl (Boc) protected allylic alcohol 113, 
synthesized in one step[173] starting from allylic alcohol 107 (Scheme 55). 
 
 
Scheme 55: Synthesis of protected allylic alcohol 113. 
 
As summarized in Table 41, the difference between the N,P-based and NHC-pyridine-
based ligands was even more striking than in the previous example. Indeed, when the 
catalyst bearing ligand L13 was applied to this transformation, in addition to the product, 
a mixture of many unidentified side products could be observed. In contrast, with ligands 
L34b substrate 113 underwent clean hydrogenation to afford the Boc-protected saturated 
alcohol 114 with 69% ee in essentially quantitative yield.  
 
Table 41: Iridium-catalyzed asymmetric hydrogenation of 113. 
 
 
n.d.= not determined; [a]  Conversion to compound 114 ,  determined by 
GC analys is  of the reaction mixture after removal of the catalyst;  [b]  
Determined by HPLC analys is  on a chira l  s tationary phase.   
 
Lastly, ester 115 was chosen as an additional test substrate to compare the performance 
of the NHC/pyridine ligands with the classic N,P-analogs. In previous investigations[119] on 
the asymmetric hydrogenation of Aliskiren derivative 115, the tert-butyl group on the 
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ester moiety was found to undergo cleavage in the presence of N,P-based iridium 
complexes, affording the corresponding saturated carboxylic acid as the major product. 
The high Brønsted acidity of the iridium hydrides formed in the course of the reaction is 
assumed to be responsible for the observed ester cleavage.[64,119] 
In order to avoid this undesired reaction, the novel, less acidic NHC/pyridine based ligand 
L34b was employed in the iridium-catalyzed hydrogenation of α,β-unsaturated ester 115 
(Table 42). In the presence of [Ir(COD)L13]BArF the saturated carboxylic acid of 116 was 
formed in 86% yield.[119] In contrast, the use of an iridium catalyst bearing the 
NHC/pyridine ligand L34b, allowed for the smooth hydrogenation of coumpound 115 to 
yield the desired tert-butyl ester 116 in full conversion and moderate enantioselectivity, 
confirming the reduced acidity of these new NHC/pyridine based complexes compared to 
the classical catalysts bearing N,P-ligands. 
 
Table 42: Iridium-catalyzed asymmetric hydrogenation of 115. 
 
 
[a]  Conversion to  compound 116 ,  determined by GC analysis  of the react ion 
mixture after  removal  of the catalyst;  [b]  Determined by HPLC analys is  on a  chira l  
stationary phase;  [c]  86% conversion to the corresponding saturated carboxyl ic  
acid  was  detected.   
5.2.2 Catalyst Loading Screening in the Asymmetric Hydrogenation of trans-Methyl 
Stilbene 
 
Another goal of this project was to study the activity of the new iridium complexes by 
investigating the impact of lower catalyst loadings on the outcome of the hydrogenation 
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reaction. For this purpose trans-methyl stilbene 105 was chosen as the substrate of choice 
in combination with the most promising NHC/pyridine ligand, L34b (Table 43).  
 
Table 43: Catalyst loading screening in the asymmetric hydrogenation of 105 using [Ir(COD)L34b]BArF. 
 
 
 
 
Entry Catalyst loading (mol%) Conversion[a] (%) ee[b] (%) 
1 1.00 >99 97 
2 0.75 >99 96 
3 0.5 >99 96 
4 0.25 28 83 
[a]  Determined by GC analysis  of the react ion mixture after  removal 
of the cata lyst;  [b]  Determined by HPLC analysis  on a chira l  s tationary 
phase.   
 
As shown in Table 43, the catalyst loading could be reduced down to 0.5 mol% without 
affecting either the yield or the enantioselectivity of the transformation (entries 1-3). 
However, when the amount of catalyst was lowered to 0.25 mol%, a significant drop in 
activity and selectivity was observed (entry 4). 
 
5.3 Summary[167] 
 
In summary, the newly synthesized NHC/pyridine based ligands developed by Andreas 
Schumacher showed that replacement of the phosphinite group in classical pyridine-
based iridium complexes by a NHC unit leads to efficient and highly enantioselective 
hydrogenation catalysts. In the hydrogenation of various olefins the phosphinite- and the 
NHC-based catalysts showed similar selectivities. However, as a result of the lower acidity 
of the iridium hydride intermediates produced from the NHC-based complexes, these 
catalysts are better suited for the hydrogenation of acid-sensitive substrates like 111, 113 
and 115. Moreover, the reaction proceeded with complete conversion even with reduced 
catalyst loadings (down to 0.5 mol%) confirming the high reactivity of this new ligand 
class. 
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Chapter 6 
Experimental Section 
 
6.1 General Information 
6.1.1 Working techniques 
 
Commercially available reagents were purchased from Acros, Aldrich, Alfa-Aesar and used 
as received. The solvents were collected from a purification column system (PureSolv, 
Innovative Technology Inc.)[174] or purchased from Aldrich or Fluka in sure/sealedTM 
bottles over molecular sieves. Column chromatographic purifications were performed on 
Merck silica gel 60 (particle size 40–63 nm) according to the procedure published by Still 
and Mitra.[175] The eluents were of technical grade and distilled prior to use. The 
hydrogenation experiments were prepared under air, unless otherwise specified. 
6.2.1 Analytical methods 
 
Thin Layer Chromatography (TLC): TLC plates were obtained from Merck (Silica gel 60 
F254). UV light (254 nm) or basic permanganate solution were used to visualize the 
respective compounds. 
 
NMR Spectroscopy: NMR spectra were measured on either a Bruker DPX-NMR (400 MHz) 
or a Bruker Avance DRX-NMR (500 MHz) spectrometer equipped with BBO broadband 
probe heads. Chemical shifts (δ) are reported in parts per million (ppm) and coupling 
constants (J) are reported in Hertz (Hz). Deuterated NMR solvents were obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). The measurements were 
performed at 25 °C. The chemical shift (δ) values were corrected to 7.26 ppm (1H NMR) 
and 77.16 ppm (13C NMR) for CHCl3, or to 2.54 ppm (1H NMR) and 40.45 ppm (13C NMR) 
for DMSO. 13C and 19F spectra were recorded 1H-decoupled. Multiplicities are reported as 
follows: s=singlet, d=doublet, t=triplet, q=quartet, quin=quintet, sext=sextet, sept=septet, 
m=multiplet. 
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Infrared Spectroscopy (IR): IR spectra were recorded on a Shimadzu FTIR-8400S Fourier 
Eform spectrometer with ATR/Golden Gate technology. The absorption bands are given 
in wave numbers ṽ (cm−1). The peak intensity is reported as follows s (strong), m (medium) 
and w (weak). The index br stands for broad. 
 
Optical Rotations ([α]D20): Optical rotations were measured on a Perkin Elmer Polarimeter 
341 (1 dm cylindrical cell) or on a Jasco P-2000 Polarimeter (1 dm cylindrical cell) at 589 
nm. The concentration (c) is given in g/100 mL. 
 
High Resolution Mass Spectrometry (HRMS): High resolution mass spectra (ESI) were 
measured by Dr. H. Nadig (Department of Chemistry) on a Bruker MaXis 4G. 
 
Elemental Analysis (EA): Elemental analyses were measured by Mr. Kirsch (Department 
of Chemistry, University of Basel) on a Leco CHN-900 (C-, H-, N-detection). The data are 
indicated in mass percent. 
 
Melting Points (m.p.): Melting points were determined on a Büchi B-545 apparatus and 
were not corrected. 
 
High Performance Liquid Chromatography (HPLC): HPLC analyses were performed with 
Shimadzu Class-VP Version 5.0 systems with SCL-10A system controller, LC-10AD pump 
system, SIL-10AD auto injector, CTO-10AC column oven, DGU-14A degasser and SPD-
M10A diode array- or UV/VIS detector. Chiral columns Chiralcel IC, OJ and OD-H (4.6 mm 
× 250 mm) from Daicel Chemical Industries were used. For enantioenriched samples, the 
retention time (tR) of the major enantiomer is reported in boldface. 
 
Gas Chromatography (GC): Gas chromatograms were recorded on Carlo Erba HRGC 
Mega2 Series 800 (HRGS Mega2) instruments. Achiral separations were performed on a 
Restek Rtx®-1701 column (30 m × 0.25 mm × 0.25 μm) using helium as carrier gas. For the 
separations of enantiomers Chiraldex G-TA, γ–cyclodextrin TFA column (30 m × 0.25 mm 
× 0.25 μm), Brechbühler SE54 β-cyclodextrin DEtTButSil column (25 m × 0.25 mm × 
0.25 μm) were used with H2 as carrier gas. For enantioenriched samples, the retention 
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time (tR) of the major enantiomer is reported in boldface. 
 
Gas Chromatography-Mass Spectrometry (LRMS): A Shimadzu GCMS-QP2010 SE 
equipped with a Restek Rtx®-5MS column (30 m × 0.2 mm × 0.2 μm) was used. The carrier 
gas pressure (He) was set to 100 kPa with a 10:1 split ratio.  
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6.2 Iridium-Catalyzed Asymmetric Hydrogenation of Vinylsilyl Derivatives 
6.2.1 Synthesis and analytical data of trimethylsilyl- and dimethylphenyl- substituted 
vinylsilanes 
 
6.2.1.1 Synthesis of Vinylsilanes 13, 24 and 25 
 
Vinylsilanes 13, 24 and 25 were synthesized via Pd-catalyzed coupling reaction of 
acetylenes, iodotrimethylsilane and an organozinc reagent according the procedure 
published by Murai.[84] 
In a flame-dried, argon flushed Schlenk tube a solution of the relevant alkyne (5 mmol, 
1.0 eq.) in dioxane (10 mL) and Pd(PPh3)4 (0.1 mmol, 0.02 eq.) were added. After careful 
addition of the dialkylzinc reagent (5 mmol, 1.0 eq.), the solution was cooled down to 0 
°C prior to dropwise addition of iodotrimethylsilane (10 mmol, 2.0 eq.). A very exothermic 
reaction was observed and the resulting mixture was allowed to stir at rt until no starting 
material could be detected anymore by TLC (1–6 h). After addition of H2O (ca. 10 mL), the 
mixture was filtered through a plug of celite, extracted with n-hexane (2×10 mL), washed 
with brine, dried over Na2SO4, filtered and evaporated in vacuo to afford the crude 
product. Purification by column chromatography (SiO2, pentane) or by Kugelrohr 
distillation yielded the pure product. 
 
(E)-Trimethyl(2-phenylprop-1-en-1-yl)silane (13) 
 
Purification: column chromatography (SiO2, 2 cm × 18 cm, pentane); 
Appearance: colorless liquid; Rf: 0.70 in pentane (visualization: UV, 
KMnO4); Yield: 46%; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.47–7.44 (m, 
2H), 7.41–7.20 (m, 3H), 5.92 (s, 1H), 2.22 (s, 3H), 0.19 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 151.8, 144.5, 128.2, 127.4, 126.5, 125.6, 21.1, 0.2; LRMS (EI, 70 eV) m/z (%) 
190 (13) [M+], 176 (11), 175 (64), 159 (18), 135 (100); IR (neat): ṽ = 2954 (m), 2362 (w), 
2345 (w), 1597 (w), 1441 (w), 1248 (s), 846 (s), 758 (s); GC (achiral phase), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 13.1 min. 
The 1H and 13C NMR data were consistent with the literature data.[176] 
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(E)-Trimethyl(2-phenylbut-1-en-1-yl)silane (24) 
 
Purification: column chromatography (SiO2, 2 cm × 19 cm, pentane); 
Appearance: colorless oil; Rf: 0.65 in pentane (visualization: UV, KMnO4); 
Yield: 70%; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.45–7.41 (m, 2H), 7.38–
7.27 (m, 3H), 5.75 (s, 1H), 2.65 (q, J = 7.6 Hz, 2H), 1.00 (t, J = 7.6 Hz, 3H), 0.20 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δC (ppm) = 159.4, 143.7, 128.5, 127.6, 127.6, 126.6, 28.3, 14.5, 0.6; 
LRMS (EI, 70 eV) m/z (%) 204 (11) [M+], 73 (100); IR (neat): ṽ = 2955 (m), 2896 (w), 2361 
(w), 1594 (m), 1570 (m), 1493 (w), 1453 (w), 1247 (s), 929 (w), 853 (s), 834 (s), 759 (s), 693 
(s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 13.6 min. 
The 1H and 13C NMR data were consistent with the literature data.[176] 
 
(E)-(2-Cyclohexylprop-1-en-1-yl)trimethylsilane (25) 
 
Purification: Kugelrohr distillation (0.15 mbar at 90°C); Appearance: 
colorless liquid; Rf: 0.95 in pentane (visualization: UV, KMnO4); Yield: 83%; 
1H NMR (400 MHz, CDCl3) δH (ppm) = 5.16 (s, 1H), 1.85–1.77 (m, 1H), 1.76–1.65 (m, 7H), 
1.28–1.13 (m, 6H), 0.09 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 160.7, 120.3, 49.9, 
32.2, 26.9, 26.6, 20.3, 0.3; LRMS (EI, 70 eV) m/z (%) 196 (12) [M+], 181 (32), 141 (13), 139 
(20), 122 (43), 99 (12), 79 (14), 73 (100); IR (neat): ṽ = 2924 (m), 2852 (m), 2360 (w), 1611 
(m), 1447 (m), 1246 (s), 835 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min: tR = 10.7 min. 
The 1H and 13C NMR data were consistent with the literature data.[84] 
 
6.2.1.2 Synthesis of Vinylsilanes 26 and 27 
 
The synthesis of the title compounds was achieved according to the procedure published 
by Hoveyda.[80k]  
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1-(Dimethyl(phenyl)silyl)ethan-1-one (35) 
 
To a cold (–78 °C) solution of ethyl vinyl ether (34) (5 mL, 52.2 mmol, 1.9 eq.) 
in THF (40 mL), a tert-BuLi solution (1.6 M in heptane, 20 mL, 32.6 mmol, 1.2 
eq.) was added dropwise. Upon addition, the reaction was allowed to warm up to 0 °C 
within 20 min and stirred for 30 min. The resulting yellow solution was cooled again to –
78 °C prior to dropwise addition of dimethylphenylchlorosilane (4.6 mL, 27.1 mmol, 1.0 
eq.). The reaction was then stirred for 15 h at room rt and then quenched by addition of 
a HCl (1 M aq., 30 mL). The layers were separated and the aqueous phase was extracted 
with Et2O (2×30 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo to give a pale yellow liquid, which was 
dissolved in CH3CN (120 mL) and H2O (40 mL). To this solution p-TsOH (1.0 g, 5.1 mmol, 
0.2 eq.) was added and the reaction stirred for 1 h at rt. The mixture was then extracted 
with EtOAc (2×30 mL) and the combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo to give a pale yellow liquid which was 
purified by column chromatography (SiO2, 4 cm × 17 cm, pentane/EtOAc, 40:1) to afford 
4.5 g (93% yield) of the title compound as a pale yellow liquid. 
 
Rf: 0.42 in pentane/EtOAc 30:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.57–7.54 (m, 2H), 7.43–7.35 (m, 3H), 2.24 (s, 3H), 0.50 (s, 6H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 245.6, 134.4, 134.1, 130.1, 128.3, 36.1, –4.8; LRMS (EI, 70 eV) m/z 
(%) 177 (16) [M+], 136 (15), 135 (100), 105 (12); IR (neat): ṽ = 3065 (w), 2962 (w), 2361 
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(m), 2333 (m), 1742 (w), 1643 (s), 1425 (w), 1340 (w), 1252 (m), 1111 (m), 835 (w), 814 
(m), 737 (m). 
The 1H and 13C NMR data were consistent with the literature data.[177] 
 
Ethyl (E)-3-(dimethyl(phenyl)silyl)but-2-enoate (26) 
 
To a cold (0 °C) solution of NaH (288 mg, 12.0 mmol, 1.2 eq.) in THF (25 
mL), triethylphosphonoacetate (2.3 mL, 11.5 mmol, 1.2 eq.) was added 
dropwise. The mixture was stirred at 0 °C for 30 min before adding dropwise acylsilane 35 
(1.78 g, 10.0 mmol, 1.0 eq.). The reaction was allowed to warm up to rt within 20 min, 
stirred for 12 h and subsequently quenched by the addition of NH4Cl (sat. aq., 20 mL). The 
layers were separated and the aqueous phase was extracted with Et2O (2×20 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo to give a colorless liquid which was purified by column 
chromatography (SiO2, 3 cm × 23 cm, pentane/EtOAc, 60:1) to afford 1.8 g (73% yield) of 
the title compound as a colorless liquid. 
 
Rf: 0.35 in pentane/EtOAc, 50:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.50–7.36 (m, 5H), 6.09 (q, J = 1.2 Hz, 1H), 4.16 (q, J = 5.6 Hz, 2H), 2.18 (d, J = 1.2 
Hz, 3H), 1.29 (t, J = 5.6 Hz, 3H), 0.41 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 165.8, 
160.0, 136.3, 134.2, 129.6, 128.1, 127.9, 59.9, 17.6, 14.5, –3.8; LRMS (EI, 70 eV) m/z (%) 
233 (8) [(M–Me)+], 205 (15), 203 (19), 171 (11), 170 (70), 143 (14), 142 (69), 137 (20), 136 
(14), 135 (100), 127 (10), 121 (10), 107 (14), 105 (29), 77 (13); EA: calc. (%) for C14H20O2Si, 
C 67.70, H 8.12; found C 67.70, H 8.29; IR (neat): ṽ = 2959 (w), 2361 (m), 2336 (m), 1715 
(s), 1254 (w), 1182 (s), 1115 (w); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min: tR = 20.5 min.  
The 1H and 13C NMR data were consistent with the literature data.[80k] 
 
(E)-3-(Dimethyl(phenyl)silyl)but-2-en-1-ol (27) 
 
A solution of ester 26 (1.4 g, 5.6 mmol, 1.0 eq.) in CH2Cl2 (15 mL) was 
added dropwise to DIBAL-H (1.7 M in toluene, 7.0 mL, 11.8 mmol, 2.1 
eq.) in CH2Cl2 (10 mL) at –78 °C. After 4 h the reaction mixture was allowed to warm to rt, 
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stirred for 13 h and quenched by addition of a NaHCO3 (sat. aq. 20 mL) at –78 °C. The 
mixture was stirred at rt for 15 min and filtered through a plug of celite. The combined 
organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give a pale 
yellow liquid which was purified by column chromatography (SiO2, 2 cm × 20 cm, 
pentane/EtOAc, 7:1) to afford 775 mg (67% yield) of the title compound as a colorless 
liquid. 
 
Rf: 0.35 in pentane/EtOAc, 7:1 (visualization: UV, KMnO4);1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.53–7.47 (m, 2H), 7.38–7.32 (m, 3H), 6.01–5.90 (m, 1H), 4.30 (d, J = 5.8 Hz, 2H), 
1.74–1.66 (m, 3H), 1.31 (s, 1H), 0.36 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 139.8, 
138.0, 137.7, 134.1, 129.2, 127.9, 60.0, 15.2, –3.5; LRMS (EI, 70 eV) m/z (%) 206 (1) [M+], 
170 (43), 145 (11), 142 (45), 137 (29), 136 (17),135 (100), 121 (12), 107 (15), 105 (30), 77 
(17); EA: calc. (%) for C12H18O1Si, C 69.85, H 8.79; found C 69.65, H 8.73; IR (neat): ṽ = 3304 
(brs), 2957 (w), 2531 (w), 2154 (w), 1249 (m), 1109 (w), 825 (m), 672 (s); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 19.4 min. 
The 1H and 13C NMR data were consistent with the literature data.[80k] 
 
6.2.1.3 Synthesis of Vinylsilanes 28 and 29 
 
Alkyne 36 has been synthesized by Larissa Pauli from the corresponding propargylic 
alcohol. 
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Dimethyl(phenyl)(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl)silane (37) 
 
nBuLi (1.6 M in hexane, 55.4 mmol, 1.05 eq.) was added dropwise to 
a cold (–78 °C) solution of alkyne 36 (7.4 g, 52.7 mmol, 1.0 eq.) in 
THF (50 mL). The resulting mixture was stirred for 30 min and 
dimethylphenylchlorosilane (9.7 mL, 57.8 mmol, 1.1 eq.)was added. The reaction mixture 
was stirred for additional 30 min at –78 °C and then warmed to rt and stirred for 3 h. The 
solution was quenched by addition of H2O (40 mL) and the aqueous phase extracted with 
pentane (2×35 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo to afford 13.0 g (90% yield) of the title 
compound as an orange liquid that was used without further purification. 
 
Rf: 0.80 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.66–7.59 (m, 2H), 7.42–7.33 (m, 3H), 4.84 (t, J = 3.4 Hz, 1H), 4.31 (d, J = 6.8 Hz, 
2H), 3.90–3.80 (m, 1H), 3.57–3.49 (m, 1H), 1.90–1.47 (m, 6H), 0.43 (s, 6H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 136.9, 133.8, 129.6, 128.0, 103.5, 96.9, 89.0, 62.1, 55.0, 30.4, 25.5, 
19.2, –0.8; IR (neat): ṽ = 2943 (m), 2919 (m), 2849 (m), 2176 (w), 1430 (w), 1343 (w), 1253 
(m), 1203 (w), 1118 (s), 1061 (w), 1028 (s), 902 (w), 838 (w), 817 (s), 781 (w), 702 (m). 
The 1H and 13C NMR data were consistent with the literature data.[178] 
 
3-(Dimethyl(phenyl)silyl)prop-2-yn-1-ol (38) 
 
To a solution of alkyne 37 (4.0 g, 14.6 mmol, 1.0 eq.) in ethanol (20 mL), 
was added pyridinium p-toluenesulfonate (550 mg, 2.2 mmol, 0.15 eq.). 
After stirring the solution overnight at 60 °C, solid NaHCO3 (ca. 1 g) was added, ethanol 
was removed in vacuo and the resulting mixture partitioned between Et2O (20 mL) and 
H2O (15 mL). The aqueous phase was extracted with Et2O (2×15 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo to give a pale yellow liquid which was purified by column chromatography (SiO2, 3 
cm × 25 cm, pentane/EtOAc, 12:1) to afford 2.3 g (83% yield) of the title compound as a 
colorless liquid. 
 
Rf: 0.27 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
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(ppm) = 7.67–7.60 (m, 2H), 7.43–7.35 (m, 3H), 4.31 (d, J = 6.1 Hz, 2H), 1.86–1.73 (m, 1H), 
0.44 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 136.6, 133.8, 129.7, 128.1, 105.6, 88.9, 
51.8, –0.9; LRMS (EI, 70 eV) m/z (%) 190 (1) [M+], 175 (21), 147 (24), 135 (12), 131 (11), 
115 (26), 105 (12), 91 (22); IR (neat): ṽ = 3301 (brs), 2961 (m), 2361 (m), 2176 (m), 1426 
(w), 1253 (m), 1114 (m), 1041 (s), 982 (m), 820 (s), 781 (m), 733 (s), 701 (w). 
The 1H and 13C NMR data were consistent with the literature data.[80k] 
 
Ethyl (E)-3-(dimethyl(phenyl)silyl)but-2-enoate (28) 
 
The synthesis of the title compound was performed according to the 
procedure published by Spino.[179] In a flame-dried, argon flushed two-
neck round bottom flask a solution of 3-(dimethyl(phenyl)silyl)prop-2-yn-1-ol 38 (1.5 g, 
7.8 mmol, 1.0 eq.) in Et2O (25 mL) was added to CuI (150 mg, 0.78 mmol, 0.1 eq.). After 
dropwise addition of methylmagnesium chloride (3.0 M in THF, 6.5 mL, 19.5 mmol, 2.5 
eq.) the mixture was stirred at reflux overnight.  
The solution was quenched by addition of NH4Cl (sat. aq., ca. 10 mL) and the aqueous 
layer extracted with Et2O (2×15 mL). The combined organic layers were washed with 
brine, dried over Na2SO4, filtered and the solvent was evaporated in vacuo to yield the 
crude product, which was purified by column chromatography (SiO2, 2 cm × 25 cm, 
pentane/EtOAc, 10:1) to afford 1.27 g (79 % yield) of the title compound as a pale yellow 
liquid. 
 
Rf: 0.37 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.56–7.54 (m, 2H), 7.36–7.32 (m, 3H), 5.69 (s, 1H), 4.06 (s, 2H), 1.70 (s, 3H), 1.60 
(brs, 1H), 0.42 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 155.1, 139.7, 133.9, 129.0, 
127.9 118.8, 69.0, 18.8, –0.9; LRMS (EI, 70 eV) m/z (%) 191 (9) [(M–Me)+], 173 (13), 145 
(18), 137 (31), 135 (34), 129 (11), 113 (25), 105 (17), 91 (11), 75 (100); EA: calc. (%) for 
C12H18O1Si, C 69.85, H 8.79; found C 69.38, H 8.71; IR (neat): ṽ = 3281 (brs), 2955 (m), 2365 
(w), 1628 (m), 1427 (w), 1250 (s), 1111 (m), 826 (s); GC (achiral phase), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min: tR = 19.3 min. 
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(E)-3-(Dimethyl(phenyl)silyl)-2-methylallyl acetate (29) 
 
To a solution of (E)-3-(dimethyl(phenyl)silyl)-2-methylprop-2-en-1-ol 
28 (516 mg, 2.5 mmol, 1.0 eq.) in pyridine (5 mL) was added acetic 
anhydride (2.4 mL, 25 mmol, 10 eq.). After stirring the solution during 2 h at 60 °C, the 
solution was quenched by addition of HCl (1 M aq., ca. 5 mL) and the aqueous layer 
extracted with Et2O (2×15 mL). The combined organic layers were washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo to yield the crude product, which 
was purified by column chromatography (SiO2, 1 cm × 19 cm, pentane/EtOAc, 20:1) to 
afford 530 mg (85% yield) of the title compound as a pale yellow liquid. 
 
Rf: 0.50 in pentane/EtOAc, 25:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.60–7.48 (m, 2H), 7.40–7.31 (m, 3H), 5.64 (d, J = 0.8 Hz, 1H), 4.52 (s, 2H), 2.12 (s, 
3H), 1.71 (s, 3H), 0.39 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 170.8, 149.8, 139.4, 
133.9, 129.0, 128.0, 122.9, 70.1, 21.1, 19.1, –1.0; LRMS (EI, 70 eV) m/z (%) 248 (1) [M+], 
173 (35), 145 (28), 137 (25), 135 (41), 129 (13), 117 (53), 113 (13), 105 (16), 91 (14), 75 
(72), 61 (15), 43 (100); EA: calc. (%) for C14H20O2Si, C 67.70, H 8.12; found C 67.61, H 8.11; 
IR (neat): ṽ = 2958 (brs), 1744 (s), 1629 (w), 1247 (m), 1227 (m), 832 (w); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 20.0 min. 
 
6.2.1.4 Synthesis of vinylsilane 30 
 
Dimethyl(phenyl)(3-phenylprop-1-en-2-yl)silane (30) 
 
The title compound was synthesized via regioselective silycupration of 
terminal alkynes according to the procedure published by Loh.[88] Inside 
a glovebox, a flame-dried, argon flushed Schlenk tube was charged with CuCl (20 mg, 0.2 
mmol, 0.1 eq.), NaOtBu (21 mg, 0.2 mmol, 0.1 eq.), Johnphos (60 mg, 0.2 mmol, 0.1 eq.) 
and THF (8 mL). The resulting mixture was stirred for 20 min and Ph(Me)2SiBpin (0.6 mL, 
2.2 mmol, 1.1 eq.) was added. The reaction mixture was removed from the glovebox and 
cooled to 0 °C. After 30 min the corresponding terminal alkyne (0.25 mL, 2 mmol, 1.0 eq.) 
and methanol (0.16 mL, 4 mmol, 2.0 eq.) were added to the reaction mixture. The reaction 
was stirred overnight at 0 °C prior to be diluted with CH2Cl2, filtered over a plug of Celite 
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and concentrated in vacuo. Purification by column chromatography (SiO2, 1 cm × 26 cm, 
pentane) to afforded 340 mg (68 % yield) of the title compound as a colorless liquid. 
 
Rf: 0.41 in pentane (visualization: UV/KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.50–
7.44 (m, 2H), 7.38–7.29 (m, 3H), 7.24–7.20 (m, 2H), 7.20–7.13 (m, 1H), 7.10–7.04 (m, 2H), 
5.58–5.54 (m, 1H), 5.51–5.48 (m, 1H), 3.42 (s, 2H), 0.26 (s, 6H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 149.8, 140.0, 138.1, 134.1, 129.5, 129.1, 128.3, 127.9, 127.9, 126.1, 42.7, –2.8; 
LRMS (EI, 70 eV) m/z (%) 252 (1) [M+], 237 (19), 175 (12), 174 (69), 159 (85), 136 (15), 135 
(100), 121 (31), 107 (10), 105 (21), 91 (12); EA: calc. (%) for C17H20Si, C 80.89 H 7.99; found 
C 80.52, H 8.02; IR (neat): ṽ = 2955 (m), 2362 (w), 1428 (m), 1250 (m), 1111 (m), 929 (w), 
831 (s), 816 (s), 776 (m), 738 (m), 700 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 
°C/min, 250 °C, 10 min: tR = 22.1 min. 
The 1H and 13C NMR data were consistent with the literature data.[88] 
 
6.2.1.5 Synthesis of vinylsilane 31 
 
(E)-4-Methyl-N'-(1-phenylpropylidene)benzenesulfonohydrazide (41) 
 
To a solution of benzenesulfonyl hydrazide (5.4 g, 31 mmol, 1.0 eq.) in ethanol 
(40 mL), propiophenone (4.0 mL, 30 mmol, 1.0 eq.) and p-toluenesulfonic acid 
(ca. 50 mg) were added and the resulting mixture was stirred at 55 °C for 5 h. 
After this time the solution was concentrated in vacuo to half its volume and stored in the 
fridge (4 °C) overnight. A white precipitate was formed, filtered off and dried under high 
vacuum overnight to afford 6.28 g (69% yield) of the title compound as a white crystalline 
solid as a 8:1 mixture of trans and cis isomers. 
 
m.p.: 111–114 °C; Rf: 0.18 in pentane/EtOAc, 6:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.95–7.88 (m, 2H), 7.69 (s, 1H), 7.67–7.61 (m, 2H), 7.39–7.32 (m, 
4H), 7.31 (s, 1H), 2.58 (q, J = 7.8 Hz, 2H), 2.42 (s, 3H), 1.10 (t, J = 7.7 Hz, 3H).  
The 1H NMR data were consistent with the literature data.[180] 
 
 
 
Ph
N
NH
Ts
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(Z)-Dimethyl(phenyl)(1-phenylprop-1-en-1-yl)silane (31) 
 
The title compound was synthesized via Shapiro reaction according to the 
procedure published by Chan.[90] In a flame-dried, argon flushed two-neck 
round bottom flask TMEDA (10 mL) was added to 41 (800 mg, 2.75 mmol, 
1.0 eq.) and the resulting mixture was cooled to –78 °C. n-BuLi (1.6 M in hexane, 6.8 mL, 
11 mmol, 4.0 eq.) was added dropwise and the mixture gently allowed to warm up to rt. 
Strong gas evolution was observed. The mixture was stirred for 45 min before addition of 
dimethylphenylchlorosilane (0.5 mL, 3.1 mmol, 1.1 eq.). After 4 h the mixture was 
quenched by careful addition of HCl (6% aq., ca. 10 mL). The aqueous layer was extracted 
with pentane (2×20 mL), washed with brine, dried over Na2SO4, filtered and concentrated 
in vacuo to afford the crude product. Purification by column chromatography (SiO2, 1 cm 
× 19 cm, pentane) afforded 493 mg (72% yield) of the title compound as a colorless liquid. 
 
Rf: 0.93 in pentane (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.53–
7.48 (m, 2H), 7.39–7.33 (m, 3H), 7.26–7.21 (m, 2H), 7.19–7.12 (m, 1H), 6.89–6.83 (m, 2H), 
6.12 (q, J = 6.6 Hz, 1H), 1.58 (dd, J = 6.5, 1.2 Hz, 3H), 0.31 (d, J = 1.2 Hz, 6H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 144.0, 142.1, 138.5, 137.9, 134.3, 129.0, 128.2, 128.1, 127.8, 
125.5, 16.2, –2.8; LRMS (EI, 70 eV) m/z (%) 252 (32) [M+], 238 (10), 237 (39), 197 (33), 159 
(13), 136 (15), 135 (100), 121 (23), 107 (13), 105 (21), 91 (12); IR (neat): ṽ = 3014 (w), 2957 
(m), 2361 (m), 1489 (w), 1250 (s), 1111 (m), 702 (s); GC (achiral phase), 60 kPa He, 100 °C, 
2 min, 7 °C/min, 250 °C, 10 min: tR = 20.8 min. 
The 1H and 13C NMR data were consistent with the literature data.[181] 
 
6.2.1.6 Synthesis of vinylsilanes 32 and 33 
 
(Z)-Dimethyl(phenyl)(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hex-1-en-2-
yl)silane (32) 
 
The title compound was synthesized according to the procedure published 
by Ito[91] and Suginome.[182] A flame-dried, argon flushed Young tube was 
charged with Pd(OAc)2 (18 mg, 0.08 mmol, 0.04 eq.) and 1,1,3,3-
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tetramethylbutylisocyanide (0.25 mL, 1.2 mmol, 0.6 eq.). The color of the reaction mixture 
turned red. Toluene (1.0 mL) and 1-hexyne (0.7 mL, 6 mmol, 3.0 eq.) were added and the 
mixture was heated at reflux for 2 h. The solvent was then removed in vacuo and the 
crude product was purified by column chromatography (SiO2, 1 cm × 16 cm, 
pentane/EtOAc, 50:1) to afford 1.15 g (88% yield) of the title compound as a red liquid. 
 
Rf: 0.44 in pentane/EtOAc, 50:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.57–7.48 (m, 2H), 7.34–7.27 (m, 3H), 6.18 (s, 1H), 2.22 (td, J = 7.4, 1.0 Hz, 2H), 
1.40–1.19 (m, 4H), 1.06 (s, 12H), 0.82 (t, J = 7.2 Hz, 3H), 0.49–0.38 (m, 6H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 166.7, 140.6, 134.2, 128.5, 127.5, 121.4, 83.2, 42.4, 32.0, 24.8, 
22.7, 14.1, –0.7; LRMS (EI, 70 eV) m/z (%) 329 (6) [(M–Me)+], 287 (29), 202 (25), 145 (14), 
137 (15), 135 (100), 121 (15), 119 (10), 107 (14), 85 (13), 84 (70), 83 (49); IR (neat): ṽ = 
2977 (w), 2956 (w), 2927 (m), 2856 (w), 1585 (m), 1459 (w), 1428 (w), 1371 (s), 1352 (s), 
1333 (s), 1245 (s), 1144 (s), 1110 (m), 968 (w), 835 (s), 816 (s), 775 (s), 700 (s); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 28.8 min. 
 
(Z)-(1-(4-Methoxyphenyl)hex-1-en-2-yl)dimethyl(phenyl)silane (33) 
 
(Z)-Dimethyl(phenyl)(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)hex-1-en-2-yl)silane 32 (517 mg, 1.5 mmol, 1.0 eq.) and p-
bromoanisole (0.21 mL, 1.65 mmol, 1.1 eq.) were added to a suspension of PdCl2(dppf) 
(25 mg, 0.03 mmol, 0.02 eq.) and K3PO4 (955 mg, 4.5 mmol, 3.0 eq.) in THF (10 mL). 
Degassed H2O (0.29 mL, 16 mmol, 10 eq.) was added and the resulting mixture was stirred 
at 80 °C for 15 h. After extraction with CH2Cl2, the organic phase was dried over Na2SO4. 
Filtration, in vacuo removal of the solvent and subsequent purification by column 
chromatography (SiO2, 2 cm × 25 cm, pentane/EtOAc, 50:1) afforded 400 mg (82% yield) 
of the title compound as an orange liquid. 
 
Rf: 0.39 in pentane/EtOAc, 50:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.50–7.45 (m, 2H), 7.34–7.27 (m, 3H), 7.22 (s, 1H), 7.02 (d, J = 8.6 Hz, 2H), 6.68 (d, 
J = 8.6 Hz, 2H), 3.76 (s, 3H), 2.29–2.21 (m, 2H), 1.49–1.39 (m, 2H), 1.39–1.28 (m, 2H), 0.89 
(t, J = 7.3 Hz, 3H), 0.18 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 158.6, 143.1, 141.3, 
140.4, 134.0, 132.4, 130.0, 128.7, 127.8, 113.2, 55.3, 39.1, 33.0, 22.7, 14.1, –0.7; LRMS (EI, 
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70 eV) m/z (%) 324 (26) [M+], 232 (12), 231 (55), 165 (13), 136 (15), 135 (100), 121 (13); 
EA: calc. (%) for C21H28OSi, C 77.72, H 8.70; found C 77.45, H 8.76; IR (neat): ṽ = 2954 (m), 
2926 (w), 2372 (w), 1609 (w), 1506 (s), 1246 (s), 1175 (w), 1108 (w), 1036 (w), 818 (m); GC 
(achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 31.5 min. 
6.2.2 Synthesis and analytical data of vinylsiloxanes 
 
Vinylsiloxanes were synthesized via hydrosilylation of the corresponding terminal alkynes 
according the procedure published by Trost.[183] In a flame-dried, argon flushed Schlenk 
tube a solution of the alkyne (5 mmol, 1.0 eq.) and RuCp*(MeCN)3 (0.005 mmol, 0.01 eq.) 
were dissolved in CH2Cl2 (10 mL). To the resulting black solution the corresponding 
siloxane (6 mmol, 1.2 eq.) was added dropwise and the mixture was allowed to stir at rt 
for 2 h. The solvent was then evaporated in vacuo and the desired compound was purified 
by column chromatography (SiO2, pentane/EtOAc) or Kugelrohr distillation. 
 
Triethoxy(4-phenylbut-1-en-2-yl)silane (54) 
 
Purification: column chromatography (SiO2, 2 cm × 29 cm, pentane); 
Appearance: colorless liquid; Rf: 0.41 in pentane/EtOAc, 25:1 
(visualization: UV, KMnO4); Yield: 57%; 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.32–7.27 (m, 2H), 7.24–7.15 (m, 3H), 5.79–5.74 (m, 1H), 5.70–5.65 (m, 1H), 3.85 
(q, J = 7.0 Hz, 6H), 2.83–2.74 (m, 2H), 2.50–2.41 (m, 2H), 1.25 (t, J = 7.0 Hz, 9H); 13C NMR 
(100 MHz, CDCl3) δC (ppm) = 143.3, 142.6, 129.7, 128.6, 128.4, 125.8, 58.7, 38.2, 35.5, 
18.4; LRMS (EI, 70 eV) m/z (%) 294 (12) [M+], 265 (12), 203 (13), 164 (12), 163 (98), 159 
(21), 135 (33), 130 (31), 129 (12), 128 (14), 119 (51), 115 (10), 107 (20), 103 (11), 91 (100), 
79 (70), 77 (13); HRMS (ESI) exact mass calculated for C16H26O3SiNa [(M+Na)+], 317.1543, 
found 317.1542; IR (neat): ṽ = 2972 (s), 2922 (w), 2357 (m), 1549 (w), 1447 (w), 1387 (w), 
1163 (w), 1072 (s), 949 (s), 781 (m), 737 (m); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 
7 °C/min, 250 °C, 10 min: tR = 19.7 min. 
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Trimethoxy(4-phenylbut-1-en-2-yl)silane (55) 
 
Purification: column chromatography (SiO2, 2 cm × 24 cm, pentane); 
Appearance: colorless liquid; Rf: 0.36 in pentane/EtOAc, 30:1 
(visualization: UV, KMnO4); Yield: 70%; 1H NMR (400 MHz, CDCl3) δH 
(ppm)= 7.31–7.26 (m, 2H), 7.23–7.14 (m, 3H), 5.83–5.76 (m, 1H), 5.69–5.63 (m, 1H), 3.60 
(s, 9H), 2.82–2.72 (m, 2H), 2.51–2.41 (m, 2H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 142.3, 
141.9, 130.3, 128.6, 128.4, 125.9, 50.8, 38.0, 35.4; LRMS (EI, 70 eV) m/z (%) 252 (10) [M+], 
220 (16), 130 (41), 121 (96), 117 (12), 91 (100); EA: calc. (%) for C13H20O3Si, C 61.87, H 7.99; 
found C 62.01, H 7.93; IR (neat): ṽ = 2941 (brs), 2839 (m), 2361 (m), 2338 (w), 1603 (w), 
1452 (m), 1188 (m), 1074 (s), 939 (m), 804 (s), 737 (s), 698 (m); GC (achiral phase), 60 kPa 
He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 18.0 min. 
 
(1-Cyclohexylvinyl)trimethoxysilane (56) 
 
Purification: column chromatography (SiO2, 2 cm × 30 cm, pentane/EtOAc, 
60:1); Appearance: yellow liquid; Rf: 0.45 in pentane/EtOAc, 40:1 
(visualization: UV, KMnO4); Yield: 38%; 1H NMR (400 MHz, CDCl3) δH 
(ppm)= 5.77 (dd, J = 2.7, 1.2 Hz, 1H), 5.62 (d, J = 2.8 Hz, 1H), 3.56 (s, 9H), 2.13–2.00 (m, 
1H), 1.83–1.71 (m, 4H), 1.71–1.61 (m, 1H), 1.37–1.05 (m, 5H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 148.17, 128.07, 50.69, 43.84, 32.82, 26.92, 26.36; LRMS (EI, 70 eV) m/z (%) 230 
(4) [M+], 198 (22), 122 (10), 121 (100), 108 (17), 91 (52), 79 (10); EA: calc. (%) for 
C11H22O3Si, C 57.35, H 9.62; found C 57.05, H 9.46; IR (neat): ṽ = 2923 (m), 2842 (m), 1450 
(w), 1190 (m), 1077 (s), 940 (m), 798 (s), 770 (m); GC (achiral phase), 60 kPa He, 100 °C, 2 
min, 7 °C/min, 250 °C, 10 min: tR = 13.2 min. 
 
(3,3-Dimethylbut-1-en-2-yl)trimethoxysilane (57) 
 
Purification: column chromatography (SiO2, 2 cm × 25 cm, pentane/EtOAc, 
90:1); Appearance: colorless liquid; Rf: 0.46 in 60:1 pentane/EtOAc 
(visualization: KMnO4); Yield: 53%; 1H NMR (400 MHz, CDCl3) δH (ppm) = 5.82 (d, J = 2.0 
Hz, 1H), 5.64 (d, J = 2.1 Hz, 1H), 3.56 (s, 9H), 1.10 (s, 9H); 13C NMR (100 MHz, CDCl3) δC 
(ppm) = 152.2, 127.0, 50.6, 36.0, 30.1; LRMS (EI, 70 eV) m/z (%) 204 (5) [M+], 121 (100), 
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91 (37); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 7.2 
min; EA: calc. (%) for C9H20O3Si, C 52.90, H 9.86; found C 53.10, H 9.61; IR (neat): ṽ = 2945 
(m), 2840 (m), 1461 (w), 1362 (w), 1190 (m), 1078 (s), 925 (m), 794 (s), 703 (s). 
 
(E)-(1,2-Diphenylvinyl)trimethoxysilane (66) 
 
Purification: Kugelrohr distillation (0.12 mbar at 230°C); Appearance: pale 
yellow liquid; Rf: 0.83 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 
Yield: 95%; 1H NMR (400 MHz, CDCl3) δH (ppm)= 7.32–7.11 (m, 9H), 7.06–
7.02 (m, 2H), 3.58 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 143.0, 
140.6, 136.8, 135.8, 130.0, 128.8, 128.3, 128.1, 127.8, 126.4, 51.1; LRMS (EI, 70 eV) m/z 
(%) 300 (56) [M+], 238 (11), 180 (16), 179 (22), 178 (60), 177 (13), 152 (10), 121 (100), 107 
(18), 91 (88); HRMS (ESI) exact mass calculated for C17H20O3SiNa [(M+Na)+], 323.1074, 
found 323.1074; IR (neat): ṽ = 2943 (m), 2841 (m), 2363 (m), 2334 (m), 1742 (w), 1450 
(w), 1192 (m), 1084 (s), 968 (w), 806 (m), 700 (m).  
6.2.3 Synthesis and analytical data of vinylsiletane 63 
 
1-Methyl-1-(1-phenylvinyl)siletane (63) 
 
The title compound was synthesized according the procedure published by 
Dudley.[96] A solution of α-styrenylmagnesium bromide (1 M in Et2O, 10.0 mL, 
10 mmol, 1.0 eq.) was added to a solution of 1-chloro-1-methylsilacyclobutane 
(1.35 mL, 11 mmol, 1.1 eq.) in Et2O (6 mL). The reaction mixture was then heated at reflux 
for 15 h. The solution was then allowed to cool down to rt and quenched by addition of 
NH4Cl (sat. aq., ca. 10 mL). The aqueous layer was extracted with pentane (2×10 mL) and 
the combined organic layers were then washed with brine, dried over Na2SO4, filtered and 
evaporated in vacuo. Purification by column chromatography (SiO2, pentane, 50:1) 
afforded 800 mg (43% yield) of the title compound as an orange liquid. 
 
Purification: column chromatography (SiO2, 2 cm × 22 cm, pentane); Rf: 0.96 in pentane 
(visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.32–7.26 (m, 2H), 7.26–
7.16 (m, 3H), 6.02 (d, J = 2.6 Hz, 1H), 5.69 (d, J = 2.6 Hz, 1H), 2.17–2.02 (m, 2H), 1.30–1.16 
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(m, 2H), 1.16–1.04 (m, 2H), 0.34 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 151.2, 143.1, 
128.5, 127.2, 126.9, 126.6, 18.2, 14.8, -1.2; LRMS (EI, 70 eV) m/z (%) 188 (16) [M+], 160 
(30), 159 (17), 147 (11), 146 (25), 145 (100), 143 (10), 131 (10), 121 (12), 105 (15); IR (neat): 
ṽ = 3051 (m), 2968 (w), 1939 (m), 1501 (s), 1406 (s), 1173 (w), 1088 (w), 818 (m). 
The 1H and 13C NMR data were consistent with the literature data.[96] 
6.2.4 Synthesis and analytical data of trifluorovinylsilane 67 
 
(E)-(1,2-Diphenylvinyl)trifluorosilane (67) 
 
The title compound was synthesized from the corresponding vinylsiloxane 
according to the procedure published by Young.[98] A solution of boron 
trifluoride etherate (0.4 mL, 3.2 mmol, 1.05 eq.) in Et2O (3 mL) was added 
dropwise to vinylsiloxane 66 (900 mg, 3 mmol, 1.0 eq.) in Et2O (3 mL) at rt. After 12 h the 
solvent was evaporated in vacuo and the resulting black oil purified by Kugelrohr 
distillation (0.40 mbar at 160 °C) to afford 327 mg (41% yield) of the title compound as a 
yellow liquid. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)= 7.51–7.22 (m, 11H); 13C NMR (100 MHz, CDCl3) δC 
(ppm) = 147.9, 136.4, 135.0, 130.4, 129.5, 129.4, 128.4, 128.3, 128.0, 126.7 (q, JCF = 22.6 
Hz); 19F NMR (376 MHz, CDCl3) δF (ppm) = –143.4; LRMS (EI, 70 eV) m/z (%) 264 (53) [M+], 
180 (15), 179 (100), 178 (74), 177 (13), 176 (12), 165 (11), 152 (13), 89 (12); IR (neat): ṽ = 
3055 (w), 3022 (w), 2359 (w), 1603 (m), 1572 (w), 1491 (m), 1445 (s), 1150 (s), 1030 (w), 
982 (s), 922 (s), 885 (m), 864 (s), 847 (s), 810 (w), 760 (s), 717 (w), 690 (s), 662 (m). 
 
6.2.5 Analytical data for hydrogenation compounds 
 
General procedure for the iridium-catalyzed hydrogenation 
 
A 2 mL glass vial was charged with a cylindrical stirring bar (0.7 cm in length), the relevant 
iridium catalyst (0.5–1.0 mol%) and the substrate (100 μmol). The mixture was dissolved 
in CH2Cl2 (0.5 mL, 0.2 M) and placed in an autoclave.  
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The autoclave was attached to a high pressure hydrogen line and purged with H2 three 
times before being sealed under the appropriate H2 pressure. The mixture was stirred for 
the appropriate reaction time at rt. After release of H2, the solution was concentrated 
under a stream of nitrogen and the catalyst was removed by filtration of the crude mixture 
through a plug of SiO2 in a Pasteur pipette. After washing with ca. 5 mL of a 4:1 n-
hexane:MTBE mixture, the solvent was concentrated in vacuo to yield the hydrogenation 
product. 
 
(–)-Trimethyl(2-phenylpropyl)silane (43) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.29–
7.14 (m, 5H), 2.88 (sext, J = 8.0 Hz, 1H), 1.28 (d, J = 8.0 Hz, 3H), 0.99 (dd, J 
= 14.4, 7.8 Hz, 1H), 0.90 (dd, J = 14.4, 7.8 Hz, 1H), –0.11 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 150.0, 128.4, 126.8, 125.9, 36.6, 27.1, 26.5, –0.9; LRMS (EI, 70 eV) m/z (%) 192 
(3) [M+], 177 (32), 135 (57), 118 (10), 105 (11), 73 (100); IR (neat): ṽ = 3027 (w), 2954 (m), 
2897 (w), 2359 (w), 1451 (w), 1247 (s), 834 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 
min, 7 °C/min, 250 °C, 10 min: tR = 10.6 min; GC (chiral phase, Chiraldex G-TA, Gamma CD-
trifluoroacetyl column (30 m × 0.25 mm × 0.25 μm), 50 kPa He, 50 °C, 50 min, 0.5 °C/min, 
70 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 80.2min (–), tR = 81.0 min (+), 98% ee; [α]D20 
= –5.2 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[184]  
 
(–)-Trimethyl(2-phenylbutyl)silane (44) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.28–7.25 
(m, 2H), 7.18–7.15 (m, 3H), 2.60–2.47 (m, 1H), 1.69–1.53 (m, 2H), 0.96–
0.93 (m, 2H), 0.74 (t, J = 7.4 Hz, 3H), –0.18 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 147.9, 128.5, 128.0, 126.2, 44.3, 34.0, 25.3, 12.6, –0.7; LRMS (EI, 70 eV) 
m/z (%) 206 (1) [M+], 73 (100); EA: calc. (%) for C13H22Si, C 75.65, H 10.74; found C 75.50, 
H 10.62; GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 11.8 
min; GC (chiral phase, Chiraldex G-TA, Gamma CD-trifluoroacetyl column (30 m × 0.25 mm 
× 0.25 μm), 90 kPa He, 60 °C, 35 min, 10 °C/min, 160 °C, 5 min): tR = 38.1min (+), tR = 38.3 
min (–), 99% ee; [α]D20 = –7.2 (c = 1.50, CHCl3). 
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(+)-(2-Cyclohexylbutyl)trimethylsilane (45) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 1.79–1.55 
(m, 6H), 1.51–1.40 (m, 1H), 1.28–1.05 (m, 5H), 0.83 (t, J = 6.9 Hz, 3H), 0.62 
(dd, J = 14.6, 4.0 Hz, 1H), 0.34 (dd, J = 14.8, 9.8 Hz, 1H), –0.01 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 45.7, 34.7, 30.3, 27.1, 27.0, 21.9, 19.4, –0.5; LRMS (EI, 70 eV) m/z (%) 
198 (1) [(M)+], 115 (30), 74 (10), 73 (100); IR (neat): ṽ = 2953 (m), 2923 (m), 2852 (m), 1610 
(w), 1246 (s), 834 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 
min: tR = 11.2 min; GC (chiral phase, Chiraldex G-TA, Gamma CD-6-Methyl-2,3-pentyl 
PS086 column (30 m × 0.25 mm × 0.25 μm), 50 kPa He, 50 °C, 80 min, 10 °C/min, 180 °C, 
5 min): tR = 68.8 min (+), tR = 69.9 min (–), 98% ee; [α]D20 = +8.8 (c = 0.60, CHCl3). 
 
(+)-Ethyl 3-(dimethyl(phenyl)silyl)butanoate (46) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.53–7.47 (m, 2H), 7.39–7.32 (m, 3H), 4.11 (q, J = 7.1 Hz, 2H), 2.38 (dd, 
J = 15.2, 4.1 Hz, 1H), 2.04 (dd, J = 15.2, 11.3 Hz, 1H), 1.51–1.37 (m, 1H), 1.23 (t, J = 7.1 Hz, 
3H), 0.97 (d, J = 7.3 Hz, 3H), 0.28 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 174.1, 
137.5, 134.1, 129.2, 127.9, 60.3, 37.0, 16.6, 14.6, 14.4, –4.9, –5.2; LRMS (EI, 70 eV) m/z 
(%) 250 (1) [M+], 235 (11), 163 (12), 145 (24), 137 (22), 136 (15), 135 (100), 129 (11), 107 
(10), 105 (19); EA: calc. (%) for C14H22O2Si, C 67.15, H 8.85; found C 67.20, H 8.76; IR (neat): 
ṽ = 3254 (m), 2904 (s), 1732 (s), 1254 (m), 1208 (m), 1151 (w), 815 (m); GC (achiral phase), 
60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 19.7 min; HPLC (chiral, Daicel 
Chiracel OD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 0.5 mL/min, 20 °C): tR = 11.9 
min (+), tR = 13.3 (–), 89% ee; [α]D20 = +4.2 (c = 0.50, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[185] 
 
(−)-3-(Dimethyl(phenyl)silyl)butan-1-ol (47) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.54–7.47 (m, 2H), 7.40–7.32 (m, 3H), 3.75–3.65 (m, 1H), 3.64–3.54 (m, 
1H), 1.82–1.68 (m, 1H), 1.43–1.29 (m, 1H), 1.17 (s, 1H), 1.07–0.99 (m, 1H), 0.96 (d, J = 6.0 
Hz, 3H), 0.27 (d, J = 1.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 138.3, 134.1, 129.1, 
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127.9, 61.9, 34.7, 15.4, 14.0, –4.7, –5.1; LRMS (EI, 70 eV) m/z (%) 193 (22) [(M–Me)+], 152 
(10), 137 (100), 136 (11), 135 (55), 105 (15), 43 (14); EA: calc. (%) for C12H20OSi, C 69.17, H 
9.67 found C 68.90, H 9.39; IR (neat): ṽ = 3370 (brs), 2953 (m), 2867 (w), 1723 (m), 1426 
(w), 1249 (s), 1111 (s), 1047 (m), 831 (s), 813 (s), 770 (m), 733 (s), 701 (s); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 19.0 min; HPLC (chiral, 
Daicel Chiracel AD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 0.5 mL/min, 20 °C): 
tR = 41.4 min (+), tR = 44.1 (–), 37% ee; [α]D20 = −1.8 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data. [80n] 
 
(–)-3-(Dimethyl(phenyl)silyl)-2-methylpropan-1-ol (48) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.55–7.49 (m, 2H), 7.37–7.33 (m, 3H), 3.40 (dd, J = 10.4, 5.8 Hz, 1H), 
3.33 (dd, J = 10.4, 6.8 Hz, 1H), 1.87–1.72 (m, 1H), 1.27 (s, 1H), 0.91 (d, J = 6.7 Hz, 4H), 0.60 
(dd, J = 14.8, 9.1 Hz, 1H), 0.31 (d, J = 0.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
139.8, 133.6, 129.0, 127.9, 70.8, 32.5, 20.2, 19.7, –1.8, –2.1; LRMS (EI, 70 eV) m/z (%) 193 
(10) [(M–Me)+], 138 (18), 137 (100), 136 (13), 135 (82), 131 (13), 105 (11); EA: calc. (%) for 
C12H20OSi, C 69.17, H 9.67; found C 68.90, H 9.58; IR (neat): ṽ = 3301 (brs), 2953 (m), 2871 
(m), 1426 (m), 1248 (m), 1112 (s), 1032 (s), 829 (s), 700 (s); GC (achiral phase), 60 kPa He, 
100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 18.3 min; GC (chiral phase, Brechbühler, β–
cyclodextrin dimethyl-tertbutylsilyl SE54 column (30 m × 0.25 mm × 0.25 μm), 80 kPa He, 
95 °C, 80 min, 10 °C/min, 180 °C, 5 min): tR = 62.9 min (+); tR = 66.3 min (–), 96% ee; [α]D20 
= –9.5 (c = 0.60, CHCl3). 
 
(–)-3-(Dimethyl(phenyl)silyl)-2-methylpropyl acetate (49) 
 
Appearance: pale yellow liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.54–7.49 (m, 2H), 7.38–7.33 (m, 3H), 3.86 (dd, J = 10.6, 5.9 Hz, 1H), 
3.78 (dd, J = 10.6, 7.1 Hz, 1H), 2.02 (s, 3H), 1.99–1.87 (m, 1H), 0.91 (d, J = 6.7 Hz, 4H), 0.65 
(dd, J = 14.9, 9.2 Hz, 1H), 0.31 (d, J = 0.7 Hz, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
171.3, 139.5, 133.6, 129.1, 127.9, 71.6, 29.3, 21.1, 20.4, 20.0, –1.9, –2.1; LRMS (EI, 70 eV) 
m/z (%) 235 (17) [(M–Me)+], 193 (11), 180 (12), 179 (72), 173 (19), 137 (80), 136 (18), 135 
(100), 117 (43), 105 (15), 75 (18); EA: calc. (%) for C14H22O2Si, C 67.15, H 8.85; found C 
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67.00, H 8.73; IR (neat): ṽ = 2957 (brs), 2877 (w), 1742 (s), 1247 (m), 1237 (m), 831 (w), 
673 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 19.7 
min; HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 100:0, 
0.5 mL/min, 20 °C): tR = 60.2 min (+), tR = 64.0 (–), 58% ee; [α]D20 = –4.4 (c = 1.00, CHCl3). 
 
(+)-Dimethyl(phenyl)(1-phenylpropan-2-yl)silane (50) 
 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.59–
7.51 (m, 2H), 7.41–7.34 (m, 3H), 7.29–7.21 (m, 2H), 7.19–7.07 (m, 3H), 
2.87 (dd, J = 13.7, 3.6 Hz, 1H), 2.22 (dd, J = 13.6, 11.8 Hz, 1H), 1.29–1.14 (m, 1H), 0.84 (d, 
J = 7.3 Hz, 3H), 0.30 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 142.6, 138.4, 134.1, 
129.0 (×2), 128.2, 127.9, 125.7, 38.0, 21.8, 13.8, –4.76, –4.84; LRMS (EI, 70 eV) m/z (%) 
254 (1) [M+], 176 (23), 136 (16), 135 (100), 121 (10), 118 (16), 105 (10), 91 (11); EA: calc. 
(%) for C17H22Si, C 80.25, H 8.71 found C 79.94, H 8.57; IR (neat): ṽ = 3023 (w), 2952 (w), 
2862 (w), 1495 (w), 1249 (s), 1111 (s), 979 (w), 828 (s), 811 (s), 769 (m), 699 (s); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 23.1 min; HPLC (chiral, 
Daicel Chiracel OJ, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 0.5 mL/min, 20 °C): tR = 
13.4 min (–), tR = 16.0 (+), 42% ee; [α]D20 = +5.4 (c = 0.60, CHCl3). 
 
(+)-Triethoxy(4-phenylbutan-2-yl)silane (58) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.31–7.26 (m, 2H), 7.22–7.08 (m, 3H), 3.83 (q, J = 7.0 Hz, 6H), 2.83–2.68 
(m, 1H), 2.67–2.51 (m, 1H), 1.99–1.84 (m, 1H), 1.65–1.49 (m, 1H), 1.23 
(t, J = 7.0 Hz, 9H), 1.09 (d, J = 7.4 Hz, 3H), 0.96–0.84 (m, 1H); 13C NMR (100 MHz, CDCl3) δC 
(ppm) = 143.1, 128.6, 128.4, 125.7, 58.6, 34.8, 33.6, 18.5, 16.4, 14.0; LRMS (EI, 70 eV) m/z 
(%) 296 (2) [M+], 205 (30), 164 (17), 163 (100), 119 (28), 91 (22), 79 (17); HRMS (ESI) exact 
mass calculated for C16H28O3SiNa [(M+Na)+], 319.1700, found 319.1701; IR (neat): ṽ = 2972 
(m), 2925 (w), 1389 (w), 1164 (w), 1101 (s), 1075 (s), 954 (s), 778 (m); GC (achiral phase), 
60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 19.6 min; HPLC (chiral, Daicel 
Chiracel OJ, 0.46 cm × 25 cm, n-heptane/isopropanol 100:0, 0.2 mL/min, 20 °C): tR = 23.4 
min (–), tR = 27.9 (+), 70% ee; [α]D20 = +9.2 (c = 1.00, CHCl3). 
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(–)-Trimethoxy(4-phenylbutan-2-yl)silane (60) 
 
 Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.31–7.22 (m, 2H), 7.21–7.09 (m, 3H), 3.58 (s, 9H), 2.85–2.68 (m, 1H), 
2.65–2.47 (m, 1H), 1.97–1.80 (m, 1H), 1.65–1.47 (m, 1H), 1.10 (d, J = 
7.3 Hz, 3H), 1.02–0.74 (m, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 142.9, 128.6, 128.4, 
125.8, 51.0, 34.7, 33.5, 15.8, 13.8; LRMS (EI, 70 eV) m/z (%) 254 (1) [M+], 163 (24), 122 
(11), 121 (100), 91 (43); EA: calc. (%) for C13H22O3Si, C 61.38, H 8.72 found C 61.34, H 8.59; 
IR (neat): ṽ = 2939 (brs), 2841 (m), 2363 (m), 2356 (w), 1601 (w), 1456 (m), 1188 (m), 1078 
(s), 798 (s), 748 (s), 698 (m); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 
°C, 10 min: tR = 18.1 min; HPLC (chiral, Daicel Chiracel OB-H, 0.46 cm × 25 cm, n-
heptane/isopropanol 100:0, 0.2 mL/min, 20 °C): tR = 36.1 min (–), tR = 40.6 (+), 77% ee; 
[α]D20 = –4.9 (c = 0.50, CHCl3). 
 
(–)-(1-Cyclohexylethyl)trimethoxysilane (61) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.58 (s, 
9H), 1.71 (d, J = 11.7 Hz, 2H), 1.63 (d, J = 12.8 Hz, 2H), 1.50–1.35 (m, 1H), 
1.32–1.02 (m, 6H), 1.00 (d, J = 7.5 Hz, 3H), 0.91–0.81 (m, 1H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 50.8, 39.4, 32.6, 31.2, 27.4, 27.1, 26.7, 23.2, 10.8; LRMS (EI, 70 eV) 
m/z (%) 232 (1) [M+], 122 (10), 121 (100), 110 (45), 91 (38); HRMS (ESI) exact mass 
calculated for C11H24O3SiNa [(M+Na)+], 255.1387, found 255.1387; IR (neat): ṽ = 2920 (s), 
2838 (m), 1447 (w), 1189 (w), 1080 (s), 796 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 
min, 7 °C/min, 250 °C, 10 min: tR = 13.4 min; GC (chiral phase, Hydrodex, β-3P column (30 
m × 0.25 mm × 0.25 μm), 60 kPa He, 50 °C, 0 min, 0.5 °C/min, 100 °C, 0 min, 10 °C/min, 
180 °C, 5 min): tR = 99.2 (+), tR = 102.3 (–), 88% ee; [α]D20 = –7.3 (c = 0.50, CHCl3). 
 
(–)-(3,3-Dimethylbutan-2-yl)trimethoxysilane (62) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.58 (s, 
9H), 1.02 (d, J = 7.7 Hz, 3H), 0.97 (s, 9H), 0.82 (dd, J = 15.4, 7.7 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δC (ppm) = 50.7, 32.0, 29.6, 29.0, 10.6; LRMS (EI, 70 eV) m/z (%) 
191 (25) [(M–Me)+], 150 (34), 122 (13), 121 (100), 118 (19), 91 (32); HRMS (ESI) exact mass 
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calculated for C9H20O3SiNa [(M+Na)+], 229.1230, found 229.1233; GC (achiral phase), 60 
kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 7.5 min; GC (chiral phase, Chiraldex, 
γ–cyclodextrin 6-Methyl-2,3-pentyl PS 086 column (30 m × 0.25 mm × 0.25 μm), 120 kPa 
He, 35 °C, 50 min, 10 °C/min, 180 °C, 5 min): tR = 25.7 min (+), tR = 27.3 min (–), 53% ee; 
[α]D20 = –7.2 (c = 0.40, CHCl3). 
 
(–)-1-Methyl-1-(1-phenylethyl)siletane (64) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.30–7.22 
(m, 2H), 7.14–7.06 (m, 3H), 2.41 (q, J = 7.5 Hz, 1H), 2.07–1.81 (m, 2H), 1.44 (d, 
J = 7.5 Hz, 3H), 1.15–0.98 (m, 2H), 0.98–0.92 (m, 2H), 0.15 (s, 3H); 13C NMR (100 
MHz, CDCl3) δC (ppm) = 144.8, 128.2, 126.9, 124.5, 29.6, 17.6, 14.2, 12.9, 12.8, –3.6; LRMS 
(EI, 70 eV) m/z (%) 190 (27) [M+], 162 (41), 149 (10), 148 (20), 147 (56), 145 (16), 121 (12), 
105 (17), 86 (10), 85 (100); IR (neat): ṽ = 3048 (w), 2972 (w), 1495 (w), 1237 (m); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 14.0 min; HPLC (chiral, 
Daicel Chiracel OJ, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 0.5 mL/min, 20 °C): tR = 
7.8 min (–), tR = 8.6 (+), 96% ee; [α]D20 = –13.6 (c = 0.50, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[96]  
 
6.3 Iridium-Catalyzed Asymmetric Hydrogenation of Maleic Acid Dimethyldiester 
6.3.1 Synthesis and analytical data of maleic anhydrides 
 
6.3.2.1 General procedure for the synthesis of maleic anhydrides 
 
3-Cyclohexylfuran-2,5-dione (73b) 
 
The title compound was prepared according to the procedure followed for 
the synthesis of 3-isopropylfuran-2,5-dione (see above). The crude material 
was purified by crystallization (CH2Cl2) to afford 1.04 g (70% yield) of the title compound 
as a white solid.  
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m.p: 109–111 °C; 1H NMR (400 MHz, DMSO-d6) δH (ppm) 5.85 (s, 1H), 2.41 (tt, J = 10.9, 3.2 
Hz, 1H), 1.98–1.87 (m, 4H), 1.85–1.71 (m, 1H), 1.63–1.19 (m, 5H); 13C NMR (100 MHz, 
DMSO-d6) δC (ppm) 169.6, 166.2, 165.5, 116.9, 41.7, 30.8, 25.6, 25.4; LRMS (EI, 70 eV) m/z 
(%) 180 (18) [M+], 153 (22), 152 (100), 139 (16), 135 (21), 134 (22), 124 (20), 112 (48), 107 
(54); HRMS (EI) exact mass calculated for C10H12O3 [(M)+], 180.0786, found 180.0777; IR 
(neat): ṽ = 2924 (w), 2853 (w), 1694 (s), 1638 (s), 1419 (s), 1276 (s), 1246 (s), 1217 (s), 
906.4 (m), 880 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 
10 °C/min, 250 °C, 5 min: tR = 46.7 min. 
 
3-Isopropylfuran-2,5-dione (73c) 
 
To a mixture of dimethyl 2-isopropylmaleate (1.2 g, 6.4 mmol, 1.0 eq. ) in 
THF/H2O (1:1 mixture, 15 mL) a LiOH solution (4 M in water, 25.8 mmol, 6.4 
mL) was added. The reaction was heated at 50 °C and stirred overnight at the same 
temperature. After cooling the mixture to 0 °C, the reaction was quenched with HCl (1 M 
aq., ca. 10 mL) and extracted with MTBE (3×25 mL), washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo to yield a pale yellow liquid, which was purified by 
Kugelrohr distillation (5 mbar at 110 °C) to afford 352 mg (40% yield) of the title compound 
as a colorless liquid. 
 
1H NMR (400 MHz, CDCl3) δH (ppm) 6.55 (d, J = 1.6 Hz, 1H), 2.90 (septd, J = 6.9, 1.6 Hz, 1H), 
1.28 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) 165.4, 164.1, 159.4, 127.1, 
26.8, 20.6; LRMS (EI, 70 eV) m/z (%) 125 (3) [(M–Me)+], 112 (87), 111 (11), 97 (26), 95 (12), 
94 (13), 81 (28), 69 (16), 68 (16), 67 (100), 66 (13), 53 (51); IR (neat): ṽ = 2974 (w), 1837 
(w), 1761 (s), 1635 (w), 1269 (m), 1231 (s), 967 (s), 891 (s), 772 (m); GC (achiral phase), 60 
kPa He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 34.6 min.  
The 1H and 13C NMR data were consistent with the literature data.[186] 
 
3-(tert-Butyl)furan-2,5-dione (73d) 
 
The title compound was prepared according to the procedure followed for 
the synthesis of 3-isopropylfuran-2,5-dione (see above). The crude material 
Chapter 6  
 
114 
 
was purified by Kugelrohr distillation (5 mbar at 140 °C) to afford 390 mg (54% yield) of 
the title compound as a white solid.  
 
m.p: 60–62 °C; 1H NMR (400 MHz, CDCl3) δH (ppm) 6.52 (1H, s), 1.34 (9H, s); 13C NMR (100 
MHz, CDCl3) δC (ppm) 164.3, 163.8, 161.7, 127.1, 33.5, 28.2; LRMS (EI, 70 eV) m/z (%) 139 
(10) [(M–Me)+], 126 (88), 125 (10), 111 (59), 110 (31), 109 (19), 108 (25), 95 (59), 83 (62), 
67 (100); IR (neat): ṽ = 2974 (m), 1829 (m), 1765 (s), 1616 (m), 1508 (s), 1472 (m), 1246 
(m), 1192 (m), 959 (s), 744 (w); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 
°C, 10 min: tR = 11.5 min. 
The 1H and 13C NMR data were consistent with the literature data.[187]  
 
6.3.2 Synthesis and analytical data of maleic acid dimethylesters 
 
6.3.2.1 General procedure for the synthesis of maleic acid dimethylesters 
 
Dimethyl 2-cyclohexylmaleate (76b) 
 
The title compound was prepared according to the procedure published 
by Li.[107] To a cold (–40 °C) solution of cuprous bromide-dimethylsulfide 
complex (4.1 g, 20 mmol, 1.0 eq.) in THF (50 mL) was added dropwise a solution of 
cyclohexylmagnesium chloride (1.3 M in THF/toluene 1:1, 20 mL, 26 mmol, 1.3 eq.). The 
resulting yellow solution was stirred at –40 °C for 2 h and then cooled at –78 °C prior to 
dropwise addition of dimethyl acetylenedicarboxylate (2.45 mL, 20 mmol, 1.0 eq.) in THF 
(15 mL). The resulting dark mixture was stirred at –78 °C for 2 h, quenched with NH4Cl 
(sat. aq., 10 mL) and allowed to warm to rt. The layers were separated and the aqueous 
phase was extracted with MTBE (3×40 mL). The combined organic layers were washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a black oil as a 
24:1 Z/E isomers mixture. Purification by column chromatography (SiO2, 2 cm × 23 cm, 
pentane/EtOAc, 15:1) afforded 2.2 g (50% yield) of the title compound as a pale yellow 
oil. 
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Rf: 0.33 in pentane/EtOAc, 15:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.76 (d, J = 1.3 Hz, 1H), 3.83 (s, 3H), 3.71 (s, 3H), 2.32–2.27 (m, 1H), 1.88–1.64 (m, 5H), 
1.22–1.08 (m, 5H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 169.6, 165.9, 156.5, 117.1, 52.4, 
51.9, 42.6, 31.2, 26.2, 25.9; LRMS (EI, 70 eV) m/z (%) 226 (4) [M+], 194 (47), 167 (80), 135 
(100), 107 (51), 79 (42); EA: calc. (%) for C12H18O4, C 63.70, H 8.02; found C 63.72, H 8.18; 
IR (neat): ṽ = 2931 (m), 2345 (w), 1722 (s), 1643 (m), 1444 (m), 1255 (s), 1202 (m), 1163 
(s); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 250 °C, 
5 min: tR = 47.6 min.  
The 1H and 13C NMR data were consistent with the literature data.[188] 
 
6.3.2.2 Synthesis of Grignard reagents 
 
Grignard reagents that were not commercially available were synthesized according to 
the following procedure: 
 
Procedure for the synthesis of Grignard reagents: 
 
In a flame-dried argon flushed two-neck round bottom flask were added freshly grounded 
magnesium turnings (312 mg, 13 mmol, 1.3 eq.) and Et2O (15 mL). To this mixture a 
solution of the relevant arylbromide (12 mmol, 1.2 eq.) in Et2O (5 mL) was added. To the 
mixture a crystal of iodine was added and the reaction was refluxed for 90 min. After 
cooling to rt, the Grignard solution was used directly as described above in the synthesis 
of dimethyl 2-cyclohexylmaleate.  
 
6.3.2.3 Analytical data  
 
Dimethyl 2-methylbut-2-enedioate ((Z)- and (E)-76a) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using 
methylmagnesium bromide (3 M in diethyl ether, 4.2 mL, 25 mmol, 1.25 eq.) as reagent. 
The crude material consisted of a 6:1 Z/E isomers mixture, which were separated by 
column chromatography (SiO2, 2 cm × 29 cm, pentane/EtOAc, 25:1) to afford 2.1 g (76% 
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yield) of the title compound (Z)-76a and 540 mg (17% yield) of dimethyl 2-methylfumarate 
(E)-76a both as pale yellow liquids.  
 
(Z)-76a: 
Rf: 0.43 in pentane/EtOAc, 15:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.85 (q, J = 3.2, 1.6 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 2.05 (d, J = 1.6 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δC (ppm) = 169.5, 165.5, 145.8, 120.7, 52.5, 51.9, 20.6; LRMS (EI, 70 eV) 
m/z (%) 158 (5) [M+], 128 (26), 127 (100), 126 (17), 99 (42); GC (achiral phase), 60 kPa He, 
50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 18.1 min. 
 
(E)-76a: 
Rf: 0.47 in pentane/EtOAc, 15:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 6.78 (dd, J = 1.4, 1.0 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 2.28 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 167.7, 166.4, 143.9, 126.6, 52.7, 51.8, 14.4; LRMS (EI, 70 eV) m/z (%) 
158 (5) [M+], 128 (26), 127 (100), 126 (17), 99 (42); GC (achiral phase), 60 kPa He, 50 °C, 0 
min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 17.6 min. 
The 1H and 13C NMR data of both isomers were consistent with the literature data.[189] 
 
(Z)-Dimethyl 2-isopropylmaleate (76c) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using 
isopropylmagnesium bromide (2 M in THF, 13.0 mL, 26 mmol, 1.3 eq.) as reagent. The 
crude material consisted of a 20:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 3 cm × 24 cm, pentane/EtOAc, 5:1) to afford 2.85 g (77% yield) of 
the title compound as a pale yellow liquid.  
 
Rf: 0.65 in pentane/EtOAc, 5:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.79 (m, 1H), 3.84 (s, 3H), 3.73 (s, 3H), 2.69–2.62 (m, 1H), 1.16 (d, J = 6.9 Hz, 6H); 13C 
NMR (100 MHz, CDCl3) δC (ppm) = 169.3, 165.7, 157.0, 116.9, 52.2, 51.8, 32.9, 20.7; LRMS 
(EI, 70 eV) m/z (%) 155 (29) [(M–MeO)+], 154 (92), 127 (27), 126 (100), 125 (20), 111 (37), 
96 (15), 95 (41), 94 (15); HRMS (ESI) exact mass calculated for C9H14O4Na [(M+Na)+], 
209.0784, found 209.0785; IR (neat): ṽ = 2968 (w), 2955 (w), 1723 (s), 1647 (m), 1435 (m), 
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1374 (w), 1258 (s), 1196 (m), 1166 (s), 1054 (m), 877 (m); GC (achiral phase), 60 kPa He, 
50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 25.3 min.  
 
(Z)-Dimethyl 2-(tert-butyl)maleate (76d) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using tert-
butylmagnesium chloride (1 M in diethyl ether, 26.0 mL, 26 mmol, 1.3 eq.) as reagent. The 
crude material showed no trace of the corresponding fumarate. Purification by column 
chromatography (SiO2, 3 cm × 29 cm, pentane/EtOAc, 30:1) afforded 1.5 g (38% yield) of 
the title compound as a colorless liquid.  
 
Rf: 0.36 in pentane/EtOAc, 15:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.84 (m, 1H), 3.84 (s, 3H), 3.71 (s, 3H), 1.18 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) 
= 169.2, 165.9, 161.0, 116.0, 52.2, 51.9, 35.8, 29.0; LRMS (EI, 70 eV) m/z (%) 185 (8) [(M–
Me)+], 169 (29), 153 (22), 141 (100), 140 (18), 125 (25), 109 (78), 81 (40); HRMS (ESI) exact 
mass calculated for C10H16O4Na [(M+Na)+], 223.0941, found 223.0945; IR (neat): ṽ = 2955 
(w), 1724 (s), 1688 (m), 1640 (m), 1434 (m), 1348 (m), 1260 (m), 1236 (m), 1193 (m), 1165 
(s), 1161 (m), 1028 (w), 874 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 
°C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 40.0 min.  
 
(Z)-Dimethyl 2-butylmaleate (76e) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using n-
butylmagnesium chloride (14.6 mL of a 20% wt solution in THF/toluene, 25 mmol, 1.25 
eq.) as reagent. The crude material consisted of a 12:1 Z/E isomers mixture, which were 
separated by column chromatography (SiO2, 3 cm × 26 cm, pentane/EtOAc, 30:1) to afford 
3.5 g (88% yield) of the title compound as a yellow oil.  
 
Rf: 0.30 in pentane/EtOAc, 15:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.80 (m, 1H), 3.83 (d, J = 0.7 Hz, 3H), 3.72 (d, J = 0.7 Hz, 3H), 2.38–2.29 (m, 2H), 1.53–
1.42 (m, 2H), 1.42–1.30 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) 
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169.6, 165.9, 151.2, 119.1, 52.5, 51.9, 34.2, 29.2, 22.2, 13.9; LRMS (EI, 70 eV) m/z (%) 200 
(2) [M+], 185 (6), 169 (100), 153 (9), 141 (40), 140 (46), 126 (83), 125 (34), 113 (20), 109 
(24), 98 (30), 81 (55); EA: calc. (%) for C10H16O4, C 59.98, H 8.05; found C 59.46, H 7.96; IR 
(neat): ṽ = 2931 (m), 2345 (w), 1722 (s), 1643 (m), 1444 (m), 1255 (s), 1202 (m), 1163 (s); 
GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 250 °C, 5 
min: tR = 42.5 min. 
 
(Z)-Dimethyl 2-isobutylmaleate (76f) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using 
isobutylmagnesium chloride (2 M in diethyl ether, 13.0 mL, 26 mmol, 1.3 eq.) as reagent. 
The crude material showed no trace of the corresponding fumarate. Purification by 
column chromatography (SiO2, 2 cm × 24 cm, pentane/EtOAc, 40:1) afforded 1.25 g (31% 
yield) of the title compound as a pale yellow liquid.  
 
Rf: 0.19 in pentane/EtOAc, 25:1 (visualization: KMnO4); 1H NMR (400 MHz, CDCl3) δH (ppm) 
= 5.79 (t, J = 1.2 Hz, 1H), 3.82 (s, 3H), 3.72 (s, 3H), 2.22 (dd, J = 7.2, 1.3 Hz, 2H), 1.89–1.70 
(m, 1H), 0.93 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3) = δC (ppm) 169.5, 165.5, 150.2, 
120.4, 52.4, 51.9, 44.1, 26.6, 22.3; LRMS (EI, 70 eV) m/z (%) 185 (2) [(M–Me)+], 169 (16), 
127 (11), 126 (100), 98 (36), 69 (11); EA: calc. (%) for C10H16O4, C 59.98, H 8.05; found C 
59.68, H 8.05; IR (neat): ṽ = 2956 (m), 2339 (w), 1722 (s), 1645 (w), 1369 (w), 1262 (m), 
1165 (s); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 
250 °C, 5 min: tR = 27.5 min. 
 
(Z)-Dimethyl 2-(phenyl)maleate (76g) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using 
phenylmagnesium bromide (2.8 M in diethyl ether, 2.25 mL, 6.25 mmol, 1.25 eq.) as 
reagent. The crude material consisted of a 4.6:1 Z/E isomers mixture, which were 
separated by column chromatography (SiO2, 2 cm × 33 cm, pentane/EtOAc, 23:1) to afford 
248 mg (24% yield) of the title compound as a colorless liquid.  
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Rf: 0.24 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.52–7.49 (m, 2H), 7.44–7.38 (m, 3H), 6.34 (s, 1H), 3.97 (s, 3H), 3.81 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δC (ppm) = 168.5, 165.6, 149.1, 133.3, 130.8, 129.2, 126.9, 117.2, 
52.9, 52.2; LRMS (EI, 70 eV) m/z (%) 220 (67) [M+], 219 (26), 205 (68), 189 (50), 161 (100), 
118 (12), 115 (51), 102 (50); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 
0 min, 10 °C/min, 250 °C, 5 min: tR = 35.6 min. 
The 1H and 13C NMR data were consistent with the literature data. [190] 
 
(Z)-Dimethyl 2-(p-tolyl)maleate (76h) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using p-tolylmagnesium bromide (0.5 M in diethyl ether, 24 
mL, 12 mmol, 1.2 eq.) as reagent. The crude material consisted of a 3:1 Z/E isomers 
mixture, which were separated by column chromatography (SiO2, 2 cm × 29 cm, 
pentane/EtOAc, 12:1) to afford 330 mg (14% yield) of the title compound as a yellow solid.  
 
m.p.: 35–37 °C; Rf: 0.36 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.38–7.36 (2H, d, J = 8.2 Hz), 7.21–7.19 (2H, d, J = 8.2 Hz), 6.29 
(1H, s), 3.95 (3H, s), 3.78 (3H, s), 2.37 (3H, s); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.7, 
165.7, 149.1, 141.3, 130.4, 130.0, 126.8, 116.0, 52.8, 52.2, 21.5; LRMS (EI, 70 eV) m/z (%) 
234 (90) [M+], 219 (62), 203 (27), 176 (17), 175 (100), 132 (18), 119 (21), 116 (46), 115 
(76), 91 (29); HRMS (ESI) exact mass calculated for C13H14O4Na [(M+Na)+], 257.0784, found 
257.0784; IR (neat): ṽ = 2953 (w), 2361 (w), 1725 (s), 1512 (w), 1433 (m), 1302 (m), 1149 
(s), 955 (m), 868 (m), 783 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 
°C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 37.6 min. 
 
(Z)-Dimethyl 2-(m-tolyl)maleate (76i) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using m-
tolylmagnesium bromide (12.5 mmol, 1.25 eq.) as reagent, which was 
synthesized according to the procedure for the synthesis of Grignard reagents. The crude 
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material consisted of a 6:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 3 cm × 28 cm, pentane/EtOAc, 19:1) to afford 360 mg (15% yield) 
of the title compound as a yellow oil.  
 
Rf: 0.43 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.31–7.21 (m, 4H), 6.30 (s, 1H), 3.95 (s, 3H), 3.79 (s, 3H), 2.37 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δC (ppm) = 168.6, 165.6, 149.3, 139.0, 133.2, 131.6, 129.0, 127.5, 124.1, 
117.0, 52.9, 52.2, 21.6; LRMS (EI, 70 eV) m/z (%) 234 (70) [M+], 233 (22), 220 (13), 219 
(100), 203 (34), 176 (13), 175 (85), 132 (15), 119 (15), 116 (45), 115 (72), 91 (30); HRMS 
(ESI) exact mass calculated for C13H14O4Na [(M+Na)+], 257.0784, found 257.0787; IR 
(neat): ṽ = 2951 (w), 2361 (w), 1734 (s), 1718 (s), 1621 (m), 1433 (m), 1347 (m), 1294 (m), 
1230 (m), 1160 (s), 1036 (m), 790 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 
150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 37.0 min. 
 
(Z)-Dimethyl 2-(o-tolyl)maleate (76j) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using o-
tolylmagnesium bromide (12.5 mmol, 1.25 eq.) as reagent, which was 
synthesized according to the Procedure for the synthesis of Grignard reagents. The crude 
material consisted of a 4:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 2 cm × 34 cm, pentane/EtOAc, 15:1) to afford 210 mg (9% yield) of 
the title compound as pale yellow liquid.  
 
Rf: 0.40 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.22–7.18 (m, 2H), 7.15–7.12 (m, 2H), 5.94 (s, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 2.29 
(s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.0, 165.4, 148.3, 136.1, 134.8, 131.0, 
129.4, 128.7, 126.1, 123.4, 52.7, 52.2, 20.2; LRMS (EI, 70 eV) m/z (%) 234 (9) [M+], 204 
(14), 202 (25), 175 (23), 174 (64), 129 (24), 116 (27), 115 (100), 91 (13); HRMS (ESI) exact 
mass calculated for C13H14O4Na [(M+Na)+], 257.0784, found 257.0789; IR (neat): ṽ = 2952 
(w), 2920 (w), 2852 (w), 2362 (w), 1722 (s), 1635 (w), 1434 (mw, 1345 (w), 1271 (w), 1196 
(m), 1165 (m), 888 (w); GC (achiral phase) 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 
10 °C/min, 250 °C, 5 min: tR = 35.2 min. 
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(Z)-Dimethyl 2-(4-methoxyphenyl)maleate (76k) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above,) using 4-methoxyphenylmagnesium bromide (1 M in THF, 
12.5 mL, 12.5 mmol, 1.25 eq.) as reagent. The crude material consisted of a 4.6:1 Z/E 
isomers mixture, which were separated by column chromatography (SiO2, 3 cm × 30 cm, 
pentane/EtOAc, 15:1) to afford 248 mg (24% yield) of the title compound as a colorless 
liquid.  
 
Rf: 0.24 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.43–7.41 (m, 2H), 6.93–6.88 (m, 2H), 6.23 (s, 1H), 3.95 (s, 3H), 3.83 (s, 3H), 3.77 
(s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.8, 165.8, 161.8, 148.8, 128.6, 125.6, 
114.6, 114.5, 55.6, 52.8, 52.1; LRMS (EI, 70 eV) m/z (%) 250 (100) [M+], 219 (18), 192 (19), 
191 (78), 135 (25), 132 (29), 117 (14), 89 (18); HRMS (ESI) exact mass calculated for 
C13H14O5Na [(M+Na)+], 273.0733, found 273.0735; IR (neat): ṽ = 2952 (w), 2361 (w), 1734 
(s), 1715 (s), 1598 (s), 1513 (m), 1435 (w), 1356 (m), 1289 (m), 1254 (m), 1164 (s), 1031 
(m), 997 (m), 833 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 
10 °C/min, 250 °C, 5 min: tR = 28.7 min. 
 
(Z)-Dimethyl 2-(4-fluorophenyl)maleate (76l) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using 4-fluorophenylmagnesium bromide (0.8 M in THF, 15 
mL, 12 mmol, 1.2 eq.) as reagent. The crude material consisted of a 4:1 Z/E isomers 
mixture, which were separated by column chromatography (SiO2, 2 cm × 35 cm, 
pentane/EtOAc, 15:1) to afford 680 mg (28% yield) of the title compound as a white solid.  
 
m.p.: 50–51 °C; Rf: 0.47 in pentane/EtOAc, 5:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.49–7.45 (m, 2H), 7.11–7.07 (m, 2H), 6.26 (s, 1H), 3.94 (s, 3H), 
3.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.3, 165.4, 164.3 (d, JCF = 252 Hz), 
148.0, 129.5 (d, JCF = 3.4 Hz), 129.0 (d, JCF = 8.6 Hz), 117.2 (d, JCF = 1.8 Hz), 116.4 (d, JCF = 
OMe
O
MeO O
MeO
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22.0 Hz), 53.0, 52.2; 19F NMR (376 MHz, CDCl3) δF (ppm) = –109.1; LRMS (EI, 70 eV) m/z 
(%) 238 (86) [M+], 210 (22), 207 (48), 180 (15), 179 (100), 133 (19), 123 (14), 120 (47), 115 
(24), 109 (17); EA: calc. (%) for C12H11FO4, C 60.50, H 4.65; found C 60.89, H 4.87; IR (neat): 
ṽ = 2968 (w), 2371 (w), 1724 (s), 1718 (s) 1627 (w), 1601 (w), 1508 (m), 1430 (m), 1352 
(m) 1164 (s), 1025 (m), 995 (m), 837 (s), 808 (s); GC (achiral phase), 60 kPa He, 50 °C, 0 
min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 35.3 min. 
 
(Z)-Dimethyl 2-(3-fluorophenyl)maleate (76m) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of dimethyl 2-cyclohexylmaleate (see above) using 3-
fluorophenylmagnesium bromide (1 M in THF, 12,5 mL, 12.5 mmol, 1.25 
eq.) as reagent. The crude material consisted of a 10:1 Z/E isomers 
mixture, which were separated by column chromatography (SiO2, 2 cm × 30 cm, 
pentane/EtOAc, 15:1) to afford 298 mg (13% yield) of the title compound as a colorless 
liquid.  
 
Rf: 0.40 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.42–7.34 (m, 1H), 7.29–7.24 (m, 1H), 7.22–7.16 (m, 1H), 7.16–7.10 (m, 1H), 6.31 
(s, 1H), 3.94 (s, 3H), 3.79 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.0, 165.3, 163.1 
(d, JCF = 248 Hz), 147.7 (d, JCF = 2.5 Hz), 135.5 (d, JCF = 7.9 Hz), 130.8 (d, JCF = 8.3 Hz), 122.7 
(d, JCF = 3.0 Hz), 118.6, 117.6 (d, JCF = 21.3 Hz), 113.9 (d, JCF = 23.2 Hz), 53.0, 52.3; 19F NMR 
(376 MHz, CDCl3) δF (ppm) = –111.6; LRMS (EI, 70 eV) m/z (%) 238 (89) [M+], 207 (55), 180 
(15), 179 (100), 136 (15), 120 (50), 115 (29), 109 (19); EA: calc. (%) for C12H11FO4, C 60.50, 
H 4.65; found C 60.45, H 4.69; IR (neat): ṽ = 2963 (w), 2379 (w), 1718 (s), 1626 (w), 1583 
(m), 1351 (m), 1196 (s), 1160 (s); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 
150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 33.5 min. 
 
(Z)-Dimethyl 2-(4-chlorophenyl)maleate (76n) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using 4-chlorophenylmagnesium bromide (1 M in diethyl 
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ether, 12.5 mL, 12.5 mmol, 1.25 eq.) as reagent. The crude material consisted of a 5:1 Z/E 
isomers mixture, which were separated by column chromatography (SiO2, 3 cm × 33 cm, 
pentane/EtOAc, 20:1) to afford 205 mg (8% yield)of the title compound as a white solid.  
 
m.p: 54–57 °C; Rf: 0.28 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.42–7.36 (m, 4H), 6.29 (s, 1H), 3.95 (s, 3H), 3.79 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δC (ppm) = 168.1, 165.4, 147.8, 137.0, 131.8, 129.5, 128.2, 117.8, 53.0, 
52.3; LRMS (EI, 70 eV) m/z (%) 254 (88) [M+], 226 (25), 225 (17), 223 (51), 197 (34), 195 
(100), 152 (11), 137 (12), 136 (49), 116 (37), 115 (41); HRMS (ESI) exact mass calculated 
for C12H11ClO4Na [(M+Na)+], 277.0238, found 277.0240; IR (neat): ṽ = 2965 (w), 2371 (w), 
1725 (s), 1710 (s), 1624 (m), 1435 (m), 1347 (m), 1196 (s), 1169 (s), 1090 (m), 844 (m), 821 
(m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 
°C, 5 min: tR = 38.3 min.  
 
(Z)-Dimethyl 2-(4-(trifluoromethyl)phenyl)maleate (76o) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using (4-(trifluoromethyl)phenyl)magnesium bromide (12.5 
mmol, 1.25 eq.) as reagent, which was synthesized according to procedure A. The crude 
material consisted of a 5:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 3 cm × 30 cm, pentane/EtOAc, 19:1) to afford 110 mg (4% yield) of 
the title compound as a yellow oil.  
 
Rf: 0.47 in pentane/EtOAc, 5:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.69–7.53 (m, 4H), 6.36 (s, 1H), 3.95 (s, 3H), 3.81 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 167.7, 165.1, 147.4, 136.9, 132.4 (q, JCF = 32.9 Hz), 127.3, 126.1 (q, JCF = 
3.8 Hz), 123.8 (d, JCF = 272.4 Hz), 119.8, 53.0, 52.4; 19F NMR (376 MHz, CDCl3) = –63.0; 
LRMS (EI, 70 eV) m/z (%) 288 (62) [M+], 287 (26), 257 (76), 230 (14), 229 (98), 219 (23), 
170 (23), 165 (16), 151 (27), 120 (14); HRMS (ESI) exact mass calculated for C13H11O4F3Na 
[(M+Na)+], 311.0502, found 311.0506; IR (neat): ṽ = 2955 (w), 2361 (w), 1722 (s), 1630 
(w), 1436 (m), 1322 (s), 1285 (m), 1167 (s), 1115 (s), 1068 (s), 844 (m); GC (achiral phase), 
60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 34.6 min. 
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(Z)-Dimethyl 2-[(1,1'-biphenyl) -4-yl]maleate (76p) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using 4-biphenylmagnesium bromide (0.5 M in THF, 24 mL, 
12 mmol, 1.2 eq.) as reagent. The crude material consisted of a 6:1 Z/E isomers mixture, 
which were separated by column chromatography (SiO2, 2 cm × 32 cm, pentane/EtOAc, 
12:1) to afford 350 mg (12% yield) of the title compound as a crystalline white solid.  
 
m.p.: 106–110 °C; Rf: 0.32 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.66–7.54 (m, 6H), 7.48–7.44 (m, 2H), 7.41–7.37 (m, 1H), 6.37 (s, 
1H), 3.98 (s, 3H), 3.81 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.5, 165.6, 148.7, 
143.7, 140.0, 132.1, 129.1, 128.2, 127.8, 127.4, 127.2, 116.8, 52.9, 52.2; LRMS (EI, 70 eV) 
m/z (%) 296 (100) [M+], 281 (15), 265 (13), 237 (41), 179 (11), 178 (42), 176 (12); EA: calc. 
(%) for C18H16O4, C 72.96, H 5.44; found C 72.70, H 5.25; IR (neat): ṽ = 2950 (w), 2361 (w), 
1718 (s), 1622 (w), 1431 (w), 1350 (w), 1291 (w), 1196 (s), 1171 (s), 769 (m); GC (achiral 
phase), 100 kPa He, 100 °C, 0 min, 6 °C/min, 250 °C, 10 min: tR = 36.8 min. 
 
(Z)-Dimethyl 2-(4-(trimethylsilyl)phenyl)maleate (76q) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using (4-(trimethylsilyl)phenyl)magnesium bromide (12.5 
mmol, 1.25 eq.) as reagent, which was synthesized according to procedure A. The crude 
material consisted of a 4:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 2 cm × 33 cm, pentane/EtOAc, 25:1) to afford 155 mg (5% yield)of 
the title compound as a white solid.  
 
m.p.: 40–42 °C; Rf: 0.47 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.57–7.53 (m, 2H), 7.46–7.44 (m, 2H), 6.33 (s, 1H), 3.94 (s, 3H), 
3.79 (s, 3H), 0.30 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.5, 165.6, 149.3, 144.3, 
134.1, 133.5, 126.0, 117.1, 52.8, 52.2, –1.2; LRMS (EI, 70 eV) m/z (%) 292 (12) [M+], 278 
(20), 277 (100), 230 (14), 229 (98), 219 (23), 170 (23), 165 (16), 151 (27), 120 (14); HRMS 
OMe
O
MeO O
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(ESI) exact mass calculated for C15H20O4SiNa [(M+Na)+], 315.1023, found 315.1024; IR 
(neat): ṽ = 2953 (w), 2358 (w), 1721 (s), 1624 (m), 1434 (m), 1353 (m), 1289 (s), 1168 (brs), 
991 (m), 842 (s), 818 (s), 760 (m); GC (achiral phase), 100 kPa He, 100 °C, 0 min, 6 °C/min, 
250 °C, 15 min: tR = 24.0 min. 
 
(Z)-Dimethyl 2-(4-(methylthio)phenyl)maleate (76r) 
 
The title compound was prepared according to the procedure 
followed for the synthesis of dimethyl 2-cyclohexylmaleate (see 
above) using 4-(methylthio)phenylmagnesium bromide (0.5 M in 
THF, 24 mL, 12 mmol, 1.2 eq.) as reagent. The crude material consisted of a 10:1 Z/E 
isomers mixture, which were separated by column chromatography (SiO2, 3 cm × 29 cm, 
pentane/EtOAc, 12:1) to afford 401 mg (15% yield) of the title compound as a pink solid.  
 
m.p.: 63–65 °C; Rf: 0.35 in pentane/EtOAc, 5:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.39–7.37 (m, 2H), 7.24–7.21 (m, 2H), 6.28 (s, 1H), 3.94 (s, 3H), 
3.78 (s, 3H), 2.49 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.5, 165.7, 148.6, 142.9, 
129.4, 127.2, 126.1, 115.8, 52.9, 52.1, 15.2; LRMS (EI, 70 eV) m/z (%) 266 (100) [M+], 208 
(12), 207 (37), 148 (23), 147 (11), 133 (11), 115 (12), 89 (14); EA: calc. (%) for C13H14O4S, C 
58.63, H 5.30; found C 58.65, H 5.34; IR (neat): ṽ = 2956 (w), 2349 (w), 1727 (m), 1708 (s), 
1587 (m), 1434 (w), 1354 (w), 1169 (m), 1091 (m), 993 (w), 843 (w), 817 (w); GC (achiral 
phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 36.7 
min. 
 
(Z)-Dimethyl 2-(thiophen-3-yl)maleate (76s) 
 
In a flame-dried argon flushed two-neck round bottom flask a solution 
of 3-bromothiophene (0.62 mL, 6.6 mmol, 1.1 eq.) in THF (6 mL) and 
isoproylmagnesium chloride-lithium chloride complex solution (1.3 M 
in THF, 4.6 mL, 6 mmol, 1.0 eq.) were added. After stirring for 2 h at rt, the reaction 
mixture was cooled at –40 °C, and a solution of cuprous bromide-dimethylsulfide complex 
(1.23 g, 6 mmol, 1.0 eq.) in THF (6 mL) was added, causing the mixture’s color to turn from 
white to dark brown. The reaction mixture was allowed to stir for 2 h, prior to addition of 
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a solution of dimethylacetylenedicarboxylate (0.74 mL, 6 mmol, 1.0 eq.) in THF (4 mL) at 
–78 °C. The resulting black mixture was then allowed to warm up to rt overnight. The 
reaction was then quenched with NH4Cl (sat. aq., 10 mL) the layers were separated and 
the aqueous phase was extracted with MTBE (3×15 mL). The combined organic layers 
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude 
material consisted of a 7.5:1 Z/E isomers mixture, which were separated by column 
chromatography (SiO2, 3 cm × 30 cm, pentane/EtOAc, 15:1) to afford 190 mg (13% yield) 
of the title compound as a pale yellow solid. 
 
m.p.: 40–42 °C; Rf: 0.22 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.47–7.44 (m, 1H) 7.38–7.34 (m, 1H), 7.26–7.22 (m, 1H), 6.24 (s, 
1H), 3.95 (s, 3H), 3.77 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 168.4, 165.8, 143.6, 
135.3, 127.4, 127.1, 125.1, 115.6, 52.9, 52.2; LRMS (EI, 70 eV) m/z (%) 226 (33) [M+], 195 
(16), 168 (12), 167 (100), 108 (18); HRMS (ESI) exact mass calculated for C10H10O4SNa 
[(M+Na)+], 249.0192 found 249.0195; IR (neat): ṽ = 3116 (s), 3089 (s), 2946 (w), 2360 (w), 
1724 (s), 1710 (s), 1617 (m), 1432 (m), 1328 (m), 1279 (m), 1234 (m), 1194 (m), 1164 (s), 
1012 (m), 963 (w), 923 (w), 879 (w), 857 (m), 804 (s), 681 (s); GC (achiral phase), 60 kPa 
He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 36.4 min. 
6.3.3 Analytical data of the hydrogenation products 
 
(R)-(+)-3-Methyldihydrofuran-2,5-dione (74a) 
 
Appearance: colorless liquid; m.p.: 38–39 °C; 1H NMR (400 MHz, CDCl3) 3.24–
3.10 (m, 2H), 2.70–2.53 (m, 1H), 1.46 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) 174.4, 169.9, 36.2, 35.7, 16.4; IR (neat): ṽ = 2961 (w), 2365 (w), 1771 (m), 
1693 (m), 1405 (m), 1219 (bm), 1062 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 1 
°C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 58.2 min; GC (chiral phase, Macherey-
Nagel, Capillary column, Lipodex E (25 m × 0.25 mm × 0.25 μm), 60 kPa H2, 70 °C, 0 min, 
1 °C/min, 145 °C, 0 min, 20 °C/min, 180 °C, 5 min): tR = 41.5 min (R, +), tR = 44.4 min (S, –
), 90% ee; [α]D20 +25.2 (c = 0.40, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[103] 
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(R)-(+)-3-Isopropyldihydrofuran-2,5-dione (74c) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) 3.07 (1H, ddd, J = 
10.2, 5.5, 4.8 Hz), 2.97 (1H, dd, J = 18.7, 10.0 Hz), 2.73 (1H, dd, J = 18.7, 5.6 
Hz), 2.37–2.25 (1H, m), 1.05 (3H, d, J = 6.9 Hz), 0.99 (3H, t, J = 7.9 Hz); 13C NMR (100 MHz, 
CDCl3) δC (ppm) 173.0, 170.4, 46.9, 30.8, 29.4, 19.9, 18.2; LRMS (EI, 70 eV) m/z (%) 127 (2) 
[(M–Me)+], 100 (34), 97 (14), 70 (77), 55 (100), 43 (17), 42 (29), 41 (24); IR (neat): ṽ = 2966 
(w), 1859 (w), 1773 (s), 1690 (m), 1469 (w), 1258 (w), 1190 (w), 1061 (m), 913 (s), 895 (s), 
728 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 
250 °C, 5 min: tR = 41.3 min; GC (chiral phase, Macherey-Nagel, Capillary column, Lipodex 
E (25 m × 0.25 mm × 0.25 μm), 80 kPa He, 70 °C, 0 min, 0.2 °C/min, 110 °C, 0 min, 10 
°C/min, 180 °C, 5 min): tR = 145.1 min (R, +), tR = 151.8 min (S, –), 90% ee; [α]D20 +15.8 (c 
= 0.80, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[191] 
 
(+)-Dimethyl 2-methylsuccinate (77a) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.70 
(s, 3H), 3.68 (s, 3H), 2.99–2.87 (m, 1H), 2.74 (dd, J = 16.5, 8.1 Hz, 1H), 2.41 
(dd, J = 16.5, 6.1 Hz, 1H), 1.22 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) = δC (ppm) 175.9, 172.5, 52.1, 51.9, 37.6, 35.9, 17.2; LRMS (EI, 70 eV) m/z (%) 129 
(63) [(M–MeO)+], 128 (41), 101 (35), 100 (31), 87 (18), 69 (20); IR (neat): ṽ = 2960 (w), 
2358 (w), 1718 (s), 1370 (w), 1204 (w), 1150 (s), 1004 (w); GC (achiral phase), 60 kPa He, 
50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 18.8 min; GC (chiral 
phase, Chiraldex G-TA, γ–cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 80 kPa 
He, 50 °C, 0 min, 1 °C/min, 90 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 34.2 min (–), tR = 
35.3 min (+), 98% ee; [α]D20 = +5.8 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[189,192] 
 
(+)-Dimethyl 2-cyclohexylsuccinate (77b) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.69 
(s, 3H) 3.66 (s, 3H), 2.68–2.77 (m, 2H), 2.44–2.49 (m, 1H), 1.75–1.56 (m, 
OMe
O
MeO O
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6H), 1.25–1.00 (m, 5H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 175.1, 173.2, 51.9, 51.8, 
47.2, 40.1, 33.4, 30.8, 30.3, 26.4, 26.3; LRMS (EI, 70 eV) m/z (%) 197 (14) [(M–MeO)+], 155 
(20), 146 (91), 137 (13), 114 (100), 95 (15), 87 (12); IR (neat): ṽ = 2926 (m), 2853 (w), 2360 
(s), 1728 (s), 1435 (w), 1159 (s); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 2 °C/min, 120 
°C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 46.7 min; GC (chiral phase, Brechbühler SE54 β-
cyclodextrin DEtTButSil (25 m × 0.25 mm × 0.25 μm)) 80 kPa H2, 60 °C, 0 min, 1 °C/min, 
130 °C, 0 min, 20 °C/min, 160 °C, 5 min): tR = 63.4 min (+), tR = 63.8 min (–), 99% ee; [α]D20 
= +22.9 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[193] 
 
(+)-Dimethyl 2-isopropylsuccinate (76c) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.70 
(s, 3H), 3.67 (s, 3H), 2.76–2.71 (m, 2H), 2.46–2.38 (m, 1H), 2.03–1.93 (m, 
1H), 0.93 (d, J = 5.8 Hz, 3H), 0.92 (d, J = 5.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
175.1, 173.1, 51.9, 51.8, 47.6, 33.1, 30.3, 20.2, 19.7; LRMS (EI, 70 eV) m/z (%) 157 (34) 
[(M–MeO)+], 146 (40), 128 (12), 115 (46), 114 (100), 113 (14), 97 (33), 87 (27), 83 (15); 
HRMS (ESI) exact mass calculated for C9H16O4Na [(M+Na)+], 211.0941, found 211.0941; IR 
(neat): ṽ = 2960 (w), 1731 (s), 1463 (w), 1437 (m), 1371 (w), 1253 (m), 1160 (s), 1000 (w), 
846 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 
250 °C, 5 min: tR = 24.1 min; GC (chiral phase, Chiraldex G-TA, γ–cyclodextrin TFA column 
(30 m × 0.25 mm × 0.25 μm), 80 kPa He, 50 °C, 0 min, 1 °C/min, 105 °C, 0 min, 10 °C/min, 
160 °C, 5 min): tR = 47.0 min (–), tR = 48.2 min (+), 99% ee; [α]D20 = +13.7 (c = 0.80, CHCl3). 
 
(+)-Dimethyl 2-(tert-butyl)succinate (76d) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.69 (s, 
3H) 3.66 (s, 3H), 2.79 (dd, J = 16.5, 11.8 Hz, 1H), 2.64 (dd, J = 11.8, 3.0 Hz, 
1H), 2.48 (dd, J = 16.5, 3.0 Hz, 1H), 0.96 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
174.9, 173.3, 51.9, 51.5, 51.4, 32.8 (2C), 27.9; LRMS (EI, 70 eV) m/z (%) 171 (18) [(M–
MeO)+], 155 (22), 146 (55), 114 (100), 95 (10), 87 (11), 85 (15), 83 (14); IR (neat): ṽ = 2955 
(w), 2362 (w), 1728 (s), 1370 (w), 1207 (w), 1155 (s), 1004 (w); GC (achiral phase), 60 kPa 
He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 39.1 min; GC (chiral 
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phase, Brechbühler SE54 β-cyclodextrin DEtTButSil (25 m × 0.25 mm × 0.25 μm)) 80 kPa 
H2, 60 °C, 0 min, 1 °C/min, 90 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 26.4 min (+), tR = 
26.6 min (–), 98% ee; [α]D20 = +13.8 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[192] 
 
(+)-Dimethyl 2-butylsuccinate (76e) 
 
Appearance: pale yellow liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.72 
(s, 3H), 3.70 (s, 3H), 2.92–2.81 (m, 1H), 2.74 (dd, J = 16.4, 9.3 Hz, 1H), 2.46 
(dd, J = 16.4, 5.1 Hz, 1H), 1.74–1.61 (m, 1H), 1.61–1.47 (m, 1H), 1.41–1.21 (m, 4H), 0.91 (t, 
J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 175.7, 172.6, 51.9, 51.9, 41.3, 36.0, 
31.8, 29.2, 22.6, 14.0; LRMS (EI, 70 eV) m/z (%) 171 (33) [(M–MeO)+], 146 (46), 138 (20), 
129 (71), 127 (13), 114 (100), 111 (34), 110 (24), 101 (10), 97 (11), 87 (18), 83 (27); IR 
(neat): ṽ = 2954 (w), 2862 (w), 1730 (s), 1437 (w), 1160 (brs); GC (achiral phase), 60 kPa 
He, 50 °C, 0 min, 2 °C/min, 120 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 41.2 min; GC (chiral 
phase, Chiraldex G-TA, γ–cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 60 kPa 
He, 50 °C, 0 min, 1 °C/min, 120 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 62.1 min (–), tR = 
62.9 min (+), 95% ee; [α]D20 = +13.2 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[192] 
 
(+)-Dimethyl 2-isobutylsuccinate (76f) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 3.69 
(s, 3H), 3.67 (s, 3H), 2.96–2.84 (m, 1H), 2.69 (dd, J = 16.5, 9.4 Hz, 1H), 2.42 
(dd, J = 16.5, 5.0 Hz, 1H), 1.65–1.50 (m, 2H), 1.37–1.20 (m, 1H), 0.92 (d, J = 6.2 Hz, 3H), 
0.89 (d, J = 6.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 176.0, 172.6, 52.0, 51.9, 
41.4, 39.6, 36.5, 26.0, 22.7, 22.4; LRMS (EI, 70 eV) m/z (%) 171 (26) [(M–OMe)+], 146 (42), 
129 (53), 127 (34), 114 (100), 111 (24), 87 (15), 85 (16); EA: calc. (%) for C10H18O4,C 59.39, 
H 8.97; found C 59.05, H 8.89; IR (neat): ṽ = 2956 (w), 2356 (w), 1733 (s), 1440 (w), 1239 
(w), 1161 (s), 1045 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 
min, 10 °C/min, 250 °C, 5 min: tR = 26.2 min; GC (chiral phase, Chiraldex G-TA, γ–
cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 60 kPa He, 50 °C, 0 min, 1 °C/min, 
Chapter 6  
 
130 
 
135 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 56.1 min (–), tR = 57.0 min (+), 94% ee; [α]D20 
= +17.3 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[192] 
 
(+)-Dimethyl 2-phenylsuccinate (77g) 
 
Appearance: white crystalline solid; m.p.: 53–55 °C; 1H NMR (400 MHz, 
CDCl3) δH (ppm) = 7.35–7.25 (m, 5H), 4.09 (dd, J = 10.1, 5.2 Hz, 1H), 3.68 
(s, 3H), 3.67 (s, 3H), 3.21 (dd, J = 17.0, 10.1 Hz, 1H), 2.67 (dd, J = 17.0, 5.3 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δC (ppm) = 173.6, 172.1, 137.8, 129.0, 127.9, 127.8, 52.5, 52.0, 47.2, 
37.8; LRMS (EI, 70 eV) m/z (%) 191 (17) [(M–OMe)+], 190 (72), 163 (23), 162 (80), 131 (13), 
121 (100), 104 (22), 103 (34), 91 (14); IR (neat): ṽ = 2958 (w), 2362 (w), 1724 (s), 1434 (m), 
1307 (m), 1150 (m), 994 (m), 868 (w), 726 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 
4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 33.4 min; GC (chiral phase, 
Brechbühler SE54 β-cyclodextrin DEtTButSil (25 m × 0.25 mm × 0.25 μm)) 80 kPa H2, 60 °C, 
0 min, 1 °C/min, 150 °C, 0 min, 20 °C/min, 160 °C, 5 min): tR = 63.0 min (+), tR = 63.6 min 
(–), 95% ee; [α]D20 = +110.7 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[192,194] 
 
(+)-Dimethyl 2-(p-tolyl)succinate (77h) 
 
Appearance: white crystalline solid; m.p.: 29–31 °C; 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.20–7.10 (m, 4H), 4.06 (dd, J = 10.1, 5.3 Hz, 
1H), 3.67 (6H, s), 3.19 (dd, J = 16.9, 10.1 Hz, 1H), 2.65 (dd, J = 16.9, 5.3 
Hz, 1H), 2.32 (3H, s); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.7, 172.2, 137.6, 134.8, 
129.7, 127.7, 52.5, 52.0, 46.8, 37.8, 21.2; LRMS (EI, 70 eV) m/z (%) 236 (1) [M+], 205 (12), 
204 (65), 177 (28), 176 (90), 136 (11), 135 (100), 118 (16), 117 (42), 115 (14), 91 (17); 
HRMS (ESI) exact mass calculated for C13H16O4Na [(M+Na)+], 259.0941, found 259.0943; 
IR (neat): ṽ = 2953 (w), 2361 (w), 1725 (s), 1512 (w) 1433 (m), 1302 (s), 1196 (w), 1149 (s), 
995 (m), 868 (m), 783 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 
min, 10 °C/min, 250 °C, 5 min: tR = 34.9 min; GC (chiral phase, Chiraldex G-TA, γ–
cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 90 kPa He, 60 °C, 0 min, 1 °C/min, 
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150 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 86.7 min (–), tR = 87.2 min (+), 96% ee; [α]D20 
= +136.3 (c = 1.00, CHCl3).  
The 1H and 13C NMR data were consistent with the literature data.[194] 
 
(+)-Dimethyl 2-(m-tolyl)succinate (77i) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.24–
7.18 (m, 1H), 7.12–7.02 (m, 3H), 4.05 (dd, J = 10.2, 5.1 Hz, 1H), 3.679 (s, 
3H), 3.676 (s, 3H), 3.20 (1H, dd, J = 17.0, 10.2 Hz), 2.65 (1H, dd, J = 17.0, 
5.1 Hz), 2.34 (3H, s); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.7, 172.2, 138.8, 137.7, 
128.9, 128.6, 128.5, 124.9, 52.5, 52.0, 47.2, 37.8, 21.5; LRMS (EI, 70 eV) m/z (%) 236 (2) 
[M+], 205 (26), 204 (83), 177 (21), 176 (98), 145 (11), 136 (11), 135 (100), 118 (18), 117 
(44), 115 (16), 91 (18); HRMS (ESI) exact mass calculated for C13H16O4Na [(M+Na)+], 
259.0941, found 259.0941; IR (neat): ṽ = 2952 (w), 1731 (s), 1607 (w), 1435 (m), 1260 (m), 
1152 (brs), 1004 (w), 886 (w), 785 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 
°C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 34.7 min; HPLC (chiral, Daicel Chiracel 
OD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 92:8, 1.0 mL/min, 20 °C): tR = 8.5 min (+), 
tR = 12.5 min (–), 96% ee; [α]D20 = +123.2 (c = 1.00, CHCl3). 
 
(+)-Dimethyl 2-(4-methoxyphenyl)succinate (77k) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.23–7.17 (m, 2H), 6.88–6.82 (m, 2H), 4.04 (dd, J = 9.9, 5.5 Hz, 1H), 
3.79 (s, 3H), 3.670 (s, 3H), 3.666 (s, 3H), 3.17 (dd, J = 16.9, 10.0 Hz, 
1H), 2.65 (dd, J = 16.9, 5.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.8, 172.2, 
159.2, 129.9, 128.9, 114.4, 55.4, 52.5, 52.0, 46.4, 37.9; LRMS (EI, 70 eV) m/z (%) 252 (5) 
[M+], 220 (41), 193 (36), 192 (100), 134 (21), 133 (22), 119 (10), 91 (15); IR (neat): ṽ = 2953 
(w), 2361 (w), 1728 (s), 1513 (m), 1245 (m), 1156 (brs), 1031 (m); GC (achiral phase), 60 
kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 37.6 min; HPLC 
(chiral, Daicel Chiracel OJ, 0.46 cm × 25 cm, n-heptane/isopropanol 92:8, 1.0 mL/min, 20 
°C): tR = 36.8 min (–), tR = 42.4 min (+), 95% ee; [α]D20 = +112.3 (c = 0.50, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[194] 
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(+)-Dimethyl 2-(4-fluorophenyl)succinate (77l) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.31–
7.26 (m, 2H), 7.07–7.00 (m, 2H), 4.10 (dd, J = 9.7, 5.6 Hz, 1H), 3.71 (s, 
3H), 3.69 (s, 3H), 3.20 (dd, J = 16.9, 9.8 Hz, 1H), 2.69 (dd, J = 16.9, 5.6 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.4, 171.9, 162.4 (d, JCF = 246.4 Hz), 133.5 
(d, JCF = 3.3 Hz), 129.5 (d, JCF = 8.1 Hz), 115.8 (d, JCF = 21.5 Hz), 52.6, 52.1, 46.5, 37.8; 19F 
NMR (376 MHz, CDCl3) δF (ppm) = –114.6; LRMS (EI, 70 eV) m/z (%) 209 (13) [(M–OMe)+], 
208 (71), 181 (29), 180 (80), 140 (11), 139 (100), 122 (23), 121 (29), 109 (11), 101 (13); IR 
(neat): ṽ = 2954 (w), 1730 (s), 1605 (w), 1508 (s), 1437 (m), 1224 (m), 1156 (brs), 1006 (m), 
836 (m), 807 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 
°C/min, 250 °C, 5 min: tR = 33.3 min; GC (chiral phase, Chiraldex G-TA, γ–cyclodextrin TFA 
column (30 m × 0.25 mm × 0.25 μm), 80 kPa He, 80 °C, 0 min, 1 °C/min, 145 °C, 0min, 10 
°C/min, 160 °C, 5 min): tR = 58.7 min (–), tR = 59.1 min (+), 95% ee; [α]D20 = +103.0 (c = 
1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[194] 
 
(+)-Dimethyl 2-(3-fluorophenyl)succinate (77m) 
 
Appearance: white crystalline solid; m.p.: 31–32 °C; 1H NMR (400 MHz, 
CDCl3) δH (ppm) = 7.33–7.26 (m, 1H), 7.08–6.94 (m, 3H), 4.09 (dd, J = 9.9, 
5.5 Hz, 1H), 3.69 (s, 3H), 3.68 (s, 3H), 3.18 (dd, J = 17.0, 9.9 Hz, 1H), 2.67 
(dd, J = 17.0, 10.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.0, 
171.8, 163.1 (d, JCF = 246.8 Hz), 140.1 (d, JCF = 7.4 Hz), 130.5 (d, JCF = 8.3 Hz), 123.6 (d, JCF = 
3.0 Hz), 115.0 (d, JCF = 14.1 Hz), 114.8 (d, JCF = 13.1 Hz), 52.7, 52.1, 46.9, 37.6; 19F NMR 
(376 MHz, CDCl3) δF (ppm) = –112.2; LRMS (EI, 70 eV) m/z (%) 209 (23) [(M–OMe)+], 208 
(41), 180 (69), 139 (100), 122 (23), 121 (24), 109 (11), 101 (14); EA: calc. (%) for C12H13FO4, 
C 60.00, H 5.45; found C 59.64, H 5.56; IR (neat): ṽ = 2951 (w), 2360 (w), 1729 (s), 1590 
(m), 1437 (m), 1158 (brs), 1007 (w); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 
150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 33.3 min; GC (chiral phase, Brechbühler SE54 
β-cyclodextrinDEtTButSil (25 m × 0.25 mm × 0.25 μm)) 80 kPa H2, 80 °C, 0 min, 1 °C/min, 
130 °C, 0 min, 20 °C/min, 180 °C, 5 min): tR = 47.4 min (+), tR = 48.2 min (–), 95% ee; [α]D20 
= +119.0 (c = 1.00, CHCl3).  
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(+)-Dimethyl 2-(4-chlorophenyl)succinate (77n) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.33–7.27 (m, 2H), 7.24–7.19 (m, 2H), 4.07 (dd, J = 9.7, 5.6 Hz, 1H), 
3.68 (s, 3H), 3.67 (s, 3H), 3.17 (dd, J = 16.9, 9.7 Hz, 1H), 2.66 (dd, J = 
16.9, 5.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.2, 171.8, 136.3, 133.8, 129.3, 
129.2, 52.6, 52.1, 46.6, 37.6; LRMS (EI, 70 eV) m/z (%) 256 (1) [M+], 226 (21), 225 (12), 224 
(63), 199 (11), 198 (36), 197 (33), 196 (100), 157 (28), 155 (87), 139 (12), 138 (22), 137 
(23), 103 (22), 102 (12); IR (neat): ṽ = 2952 (w), 1730 (s), 1491 (m), 1436 (m), 1156 (brs), 
1090 (m), 1010 (m), 847 (m), 764 (m); GC (achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 
150 °C, 0 min, 10 °C/min 250 °C, 5 min: tR = 36.4 min; HPLC (chiral, Daicel Chiracel OD-H, 
0.46 cm × 25 cm, n-heptane/isopropanol 98:2, 1.0 mL/min, 20 °C): tR = 9.1 min (+), tR = 
12.3 min (–), 93% ee; [α]D20 = +114.1 (c = 1.00, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[194] 
 
(+)-Dimethyl 2-(4-(trifluoromethyl)phenyl)succinate (77o) 
 
Appearance: white crystalline solid; m.p.: 32–33 °C; 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.59 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.1 Hz, 
2H), 4.16 (dd, J = 9.6, 5.7 Hz, 1H), 3.69 (s, 3H), 3.68 (s, 3H), 3.21 (dd, 
J = 17.0, 9.6 Hz, 1H), 2.69 (dd, J = 17.0, 5.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
172.7, 171.5, 141.6 (q, JCF = 1.3 Hz), 130.1 (q, JCF = 32.6 Hz), 128.3, 125.9 (q, JCF = 3.8 Hz), 
125.4, 52.7, 52.2, 47.1, 37.5; 19F NMR (376 MHz, CDCl3) δF (ppm) = –62.7; LRMS (EI, 70 eV) 
m/z (%) 259 (21) [(M–OMe)+], 258 (75), 231 (18), 230 (76), 199 (16), 189 (100), 172 (19), 
171 (21), 151 (12), 103 (11); HRMS (ESI) exact mass calculated for C13H13O4F3Na [(M+Na)+], 
313.0658, found 313.0662; IR (neat): ṽ = 2962 (w), 2360 (w), 1730 (s), 1618 (w), 1438 (m), 
1327 (brs), 1304 (s), 1151 (s), 1108 (s), 1068 (m), 991 (m), 869 (m), 843 (m), 815 (w); GC 
(achiral phase), 60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: 
tR = 33.0 min; HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 
99:1, 1.0 mL/min, 20 °C): tR = 11.3 min (+), tR = 13.8 min (–), 93% ee; [α]D20 = +108.5 (c = 
1.00, CHCl3). 
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(+)-Dimethyl 2-[(1,1'-biphenyl)-4-yl]succinate (77p) 
 
Appearance: white crystalline solid; m.p.= 97–99 °C; 1H NMR (400 
MHz, CDCl3) δH (ppm) = 7.61–7.52 (m, 4H), 7.47–7.40 (m, 2H), 7.39–
7.30 (m, 3H), 4.15 (dd, J = 10.0, 5.3 Hz, 1H), 3.71 (s, 3H), 3.69 (s, 3H), 
3.25 (dd, J = 17.0, 10.0 Hz, 1H), 2.72 (dd, J = 17.0, 5.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 173.5, 172.1, 140.8, 140.7, 136.8, 128.9, 128.3, 127.8, 127.5, 127.2, 52.6, 52.1, 
46.9, 37.7; LRMS (EI, 70 eV) m/z (%) 298 (5) [M+], 267 (10), 266 (47), 239 (29), 238 (100), 
197 (45), 180 (17), 179 (22), 178 (14), 165 (11); HRMS (ESI) exact mass calculated for 
C18H18O4Na [(M+Na)+], 321.1097, found 321.1096; IR (neat): ṽ = 2950 (w), 2361 (w), 1720 
(s), 1487 (w), 1437 (m), 1407 (w), 1377 (w), 1326 (m), 1194 (m), 1160 (brs), 1001 (w), 851 
(w), 832 (m), 756 (m), 699 (m); GC (achiral phase), 100 kPa He, 100 °C, 0 min, 6 °C/min, 
250 °C, 15 min: tR = 30.8 min; HPLC (chiral, Daicel Chiracel IC, 0.46 cm × 25 cm, n-
heptane/isopropanol 95:5, 1.0 mL/min, 20 °C): tR = 46.1 min (–),tR = 50.5 min (+), 97% ee; 
[α]D20 = +141.1 (c = 1.00, CHCl3). 
 
(+)-Dimethyl 2-(4-(trimethylsilyl)phenyl)succinate (77q) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.48 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 4.09 (dd, J = 10.3, 
5.1 Hz, 1H), 3.68 (s, 6H), 3.21 (dd, J = 17.0, 10.3 Hz, 1H), 2.66 (dd, J 
= 17.0, 5.1 Hz, 1H), 0.25 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.6, 172.2, 140.0, 
138.2, 134.1, 127.2, 52.5, 52.0, 47.2, 37.7, –1.0; LRMS (EI, 70 eV) m/z (%) 279 (39) [(M–
Me)+], 263 (25), 262 (92), 235 (17), 234 (37), 220 (10), 219 (49), 210 (18), 209 (100), 193 
(28), 161 (27), 89 (30); HRMS (ESI) exact mass calculated for C15H22O4SiNa [(M+Na)+], 
317.1185, found 317.1188; IR (neat): ṽ = 2953 (w), 2360 (w), 1735 (s), 1436 (w), 1246 (m), 
1158 (brs), 1006 (w), 837 (s), 735 (w), 638 (w); GC (achiral phase), 100 kPa He, 100 °C, 0 
min, 6 °C/min, 250 °C, 15 min: tR = 22.9 min; HPLC (chiral, Daicel Chiracel OD-H, 0.46 cm × 
25 cm, n-heptane/isopropanol 99.5:0.5, 1.0 mL/min, 20 °C): tR = 23.4 min (+), tR = 31.9 min 
(–), 96% ee; [α]D20 = +90.4 (c = 0.90, CHCl3). 
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(+)-Dimethyl 2-(thiophen-3-yl)succinate (77s) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.28 (dd, 
J = 5.0, 3.0 Hz, 1H), 7.16–7.13 (m, 1H), 7.03 (d, J = 5.0 Hz, 1H), 4.22 (dd, 
J = 10.0, 5.3 Hz, 1H), 3.70 (s, 3H), 3.68 (s, 3H), 3.17 (dd, J = 16.9, 10.0 Hz, 
1H), 2.71 (dd, J = 16.9, 5.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 173.2, 172.0, 
137.7, 127.0, 126.4, 122.3, 52.5, 52.1, 42.6, 37.4; LRMS (EI, 70 eV) m/z (%) 228 (2) [M+], 
197 (12), 196 (60), 169 (29), 168 (88), 127 (100), 110 (27), 109 (26); HRMS (ESI) exact mass 
calculated for C10H12O4SNa [(M+Na)+], 251.0349, found 251.0351; IR (neat): ṽ = 2952 (w), 
1729 (s), 1436 (m), 1337 (s), 1263 (m), 1154 (brs), 1002 (m), 778 (m); GC (achiral phase), 
60 kPa He, 50 °C, 0 min, 4 °C/min, 150 °C, 0 min, 10 °C/min, 250 °C, 5 min: tR = 36.5 min; 
GC (chiral phase, Chiraldex G-TA, γ–cyclodextrin TFA column (30 m × 0.25 mm × 0.25 μm), 
80 kPa He, 80 °C, 0 min, 1 °C/min, 145 °C, 0 min, 10 °C/min, 160 °C, 5 min): tR = 61.6 min 
(–), tR = 62.2 min (+), 80% ee; [α]D20 = +71.8 (c = 0.90, CHCl3). 
 
 
6.4 Iridium-Catalyzed Asymmetric Hydrogenation of 3,3-Disubstituted Allylic 
Alcohols  
6.4.1 Synthesis and analytical data of 3,3-disubstituted α,β-unsaturated esters 
 
Ethyl (E)-4-methyl-3-phenylpent-2-enoate (85b) 
 
To a cold (0 °C) solution of triethylphosphonoacetate (2.0 mL, 10 mmol, 
1.0 eq.) in CH2Cl2 (10 mL) was added dropwise a solution of nBuLi (1.6 M 
in hexane, 5.0 mL, 8 mmol, 0.8 eq.). The mixture was stirred at 0 °C for 
45 min prior to addition of isobutyrophenone (1.5 mL, 10 mmol, 1.0 eq.) at 0 °C. The 
reaction was refluxed overnight and quenched with NaHCO3 (sat. aq., 10 mL). The layers 
were separated and the aqueous phase was extracted with methyl-tert-butylether (2×15 
mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo to give a pale yellow liquid. Purification by column chromatography 
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(SiO2, 3 cm × 30 cm, pentane/EtOAc, 50:1) afforded 1.41 g (65% yield) of the title 
compound as a colorless liquid. 
 
Rf: 0.51 in pentane/EtOAc, 30:1 (visualization: UV, KMnO4); 1H NMR (500 MHz, CDCl3) δH 
(ppm) = 7.35–7.29 (m, 3H), 7.22–7.18 (m, 2H), 5.70 (s, 1H), 4.20 (q, J = 7.1 Hz, 2H), 4.11 
(sept, J = 7.0 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.09 (d, J = 7.0 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δC (ppm) = 167.3, 166.4, 140.9, 127.9, 127.8, 127.7, 118.7, 60.0, 29.7, 21.5, 14.4; 
LRMS (EI, 70 eV) m/z (%) 218 (100) [M+], 173 (40), 172 (55), 171 (23), 157 (31), 145 (87), 
143 (35), 131 (25), 130 (20), 129 (57), 128 (45), 117 (20), 115 (23), 103 (18), 91 (35). 
The 1H and 13C NMR data were consistent with the literature data[195] 
6.4.2 Synthesis and analytical data of 3,3-disubstituted allylic alcohols 
 
The general procedure for the synthesis of 3,3-disubtituted primary allylic alcohols by 
DIBAL-H reduction of the corresponding α,β-unsaturated esters using a work up 
procedure developed by Nelson,[196] is described for the synthesis of (E)-3-phenylbut-2-
en-1-ol (86a). 
 
(E)-3-Phenylbut-2-en-1-ol (86a) 
 
To a cold (0 °C) solution of 3,3-disubstituted ester 85a (1.2 g, 6.3 mmol, 
1.0 eq.) in CH2Cl2 (30 mL) was added dropwise a solution of DIBAL-H (1.0 
M in CH2Cl2, 14 mL, 14 mmol, 2.3 eq.). The mixture was stirred at 0 °C for 30 min, and then 
for 2 h at rt. After this time the reaction mixture was cooled again to 0 °C and the excess 
of DIBAL-H quenched with sequential addition of H2O (2.06 mL), NaOH (10% aq., 2.06mL) 
and H2O (4.14 mL). The ice bath was removed and the suspension stirred for 1 h at rt. 
Afterwards, the suspension was filtered, dried over Na2SO4, filtered and concentrated in 
vacuo to give an oil that was purified by column chromatography (SiO2, 2 cm × 25 cm, 
pentane/EtOAc, 3:1) to afford 888 mg (95% yield) of the title compound as a colourless 
liquid. 
 
Rf: 0.59 in pentane/EtOAc, 30:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.44–7.39 (m, 2H), 7.36–7.31 (m, 2H), 7.29–7.22 (m, 1H), 5.98 (td, J = 6.8, 1.4 Hz, 
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1H), 4.37 (d, J = 6.7 Hz, 2H), 2.09 (d, J = 1.3 Hz, 3H), 1.42 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δC (ppm) = 143.0, 138.1, 128.4, 127.4, 126.6, 125.9, 60.1, 16.2; LRMS (EI, 70 eV) m/z (%) 
148 (65) [M+], 147 (22), 145 (22), 134 (10), 133 (100), 130 (57), 129 (46), 128 (26), 127 
(11), 117 (12), 116 (16), 115 (89), 106 (48), 105 (78), 103 (31), 91 (81), 79 (28), 78 (28), 77 
(40); EA: calc. (%) for C10H12O, C 81.04, H 8.16; found C 80.65, H 8.15; IR (neat): ṽ = 3362 
(brs), 2927 (w), 2876 (w), 1715 (s), 1675 (s), 1654 (s), 1445 (m), 1369 (m), 1266 (m), 1153 
(m), 1015 (m), 1003 (s), 757 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 
250 °C, 10 min): tR = 16.9 min. 
The 1H and 13C NMR data were consistent with the literature data.[197]  
 
(E)-4-methyl-3-phenylpent-2-en-1-ol (86b) 
 
The title compound was prepared according to the procedure followed 
for the synthesis of (E)-3-phenylbut-2-en-1-ol (86a) starting from 3,3-
disubstituted unsaturated ester 85b. The crude material was purified by 
column chromatography (SiO2, 1 cm × 16 cm, pentane/EtOAc, 4:1) to afford 202 mg (93% 
yield) of the title compound as a colorless liquid.  
 
Rf: 0.38 in pentane/EtOAc, 5:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.32–7.23 (m, 3H), 7.19–7.14 (m, 2H), 5.48 (t, J = 6.7 Hz, 1H), 4.36 (d, J = 6.7 Hz, 
2H), 3.02 (quin, J = 7.0 Hz, 1H), 1.36 (s, 1H), 1.05 (d, J = 7.0 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 150.2, 142.4, 128.5, 127.8, 127.5, 126.8, 59.1, 29.9, 22.1; LRMS (EI, 70 
eV) m/z (%) 176 (19) [M+], 158 (11), 145 (14), 143 (37), 134 (19), 133 (100), 132 (38), 131 
(11), 129 (15), 128 (27), 117 (34), 116 (16), 115 (55), 105 (45), 103 (18), 92 (15), 91 (41), 
77 (20); IR (neat): ṽ = 3337 (brs), 2924 (s), 1851 (m), 1651 (w), 1597 (w), 1491 (w), 1447 
(m), 1011 (m), 891 (w), 766 (w), 702 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 
°C/min, 250 °C, 10 min): tR = 17.2 min. 
The 1H and 13C NMR data were consistent with the literature data.[198]  
 
(E)-2-Methyl-4-phenylpent-3-en-2-ol (88) 
 
This compound was synthesized using the procedure described by 
Weinreb.[134] To a cold (–78 °C) solution of 3,3-disubstituted ester 85a 
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(0.55 mL, 3.0 mmol, 1.0 eq.) in THF (15 mL) was added dropwise a solution of 
methyllithium (1.6 M in Et2O, 15 mL, 24 mmol, 8.0 eq.). The reaction was stirred at –78 °C 
for 3 h and then for 12 h at rt. After this time the mixture was cooled again to –78 °C and 
quenched with NaHCO3 (sat. aq., 10 mL) and allowed to warm to rt. The layers were 
separated and the aqueous phase was extracted with EtOAc (2×15 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo to give a pale yellow liquid. Purification by column chromatography (SiO2, 2 cm × 
23 cm, pentane/EtOAc, 15:1) afforded 443 mg (84% yield) of the title compound as a 
colorless liquid. 
 
Rf: 0.23 in pentane/EtOAc, 12:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.39–7.34 (m, 2H), 7.34–7.28 (m, 2H), 7.26–7.21 (m, 1H), 5.86 (q, J = 1.4 Hz, 1H), 
2.29 (d, J = 1.4 Hz, 3H), 1.54 (s, 1H), 1.48 (s, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
144.8, 137.4, 135.4, 128.3, 127.1, 126.0, 71.5, 31.4, 17.0; LRMS (EI, 70 eV) m/z (%) 159 (2) 
[(M–OH)+], 258 (18), 144 (11), 143 (97), 142 (23), 141 (22), 129 (26), 128 (100), 127 (23), 
115 (53), 102 (13), 91 (12); EA: calc. (%) for C12H16O, C 81.77, H 9.15; found C 81.50, H 
9.09; IR (neat): ṽ = 3365 (brs), 2971 (m), 2373 (w), 1378 (w), 1139 (w), 951 (w); GC (achiral 
phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR = 17.1 min. 
6.4.3 Synthesis and analytical data of 3,3-disubstituted unsaturated aldehydes 
 
(E)-3-Phenylbut-2-enal (87a) 
 
The title compound was prepared according to the procedure published 
by Swern et al.[133] To a cold (–60 °C) solution of oxalyl chloride (0.81 mL, 
9.3 mmol, 1.1 eq.) in CH2Cl2 (20 mL) was added dropwise a solution of 
dimethylsulfoxide (1.3 mL, 19 mmol, 2.2 eq.) in CH2Cl2 (5 mL). The reaction was stirred at 
–60 °C for 10 min prior to dropwise addition of a solution of allylic alcohol 86a (1.26 g, 8.5 
mmol, 1.0 eq.) in CH2Cl2 (9 mL). Upon addition the mixture was stirred for 45 min and 
triethylamine (5.9 mL, 43 mmol, 5.0 eq.) was added. The reaction was allowed to warm 
up to 0 °C in 2 h. After this time the solvent was removed in vacuo and the resulting 
mixture partitioned between H2O (15 mL) and CH2Cl2 (15 mL). The layers were separated 
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and the aqueous phase was extracted with CH2Cl2 (2×15 mL). The combined organic layers 
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a 
pale yellow liquid. Purification by column chromatography (SiO2, 3 cm × 20 cm, 
pentane/EtOAc, 10:1) afforded 960 mg (78% yield) of the title compound as a colorless 
liquid. 
 
Rf: 0.42 in pentane/EtOAc, 10:1 (visualization: UV, KMnO4); 1H NMR (250MHz, CDCl3) δH 
(ppm) = 10.19 (d, J = 7.8 Hz, 1H), 7.61–7.49 (m, 2H), 7.47–7.34 (m, 3H), 6.40 (d, J = 7.9 Hz, 
1H), 2.58 (s, 3H); 13C NMR (125 MHz, CDCl3) δC (ppm) = 191.4, 157.8, 140.7, 130.2, 128.9, 
127.4, 126.4, 16.5; GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: 
tR = 16.4 min. 
The 1H and 13C NMR data were consistent with the literature data.[199] 
6.4.3 Analytical data of the hydrogenation products 
 
(R)-(–)-3-phenylbutanal (92a) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 9.63 (s, 
1H), 7.29–7.13 (m, 5H), 3.33–3.24 (m, 1H), 2.70 (m, 1H), 2.58 (m, 1H), 1.23 
(d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 201.8, 145.3, 
128.9, 127.1, 126.8, 52.0, 34.3, 22.5; LRMS (EI, 70 eV) m/z (%) 148 (35) [M+], 133 (30), 115 
(11), 106 (28), 105 (100), 91 (56), 79 (37), 78 (34), 77 (49); GC (achiral phase), 60 kPa He, 
100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 17.2 min; GC (chiral phase, Gamma CD-
Trifluoroacetyl GTA, 60 KPa, 90 °C, 35 min, 10 °C/min, 160 °C, 5 min): tR = 30.7 min (S, +), 
tR = 31.7 min (R, –). 
The 1H and 13C NMR data were consistent with the literature data.[198]  
 
(R)-(–)-3-Phenylbutan-1-ol (93a) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 7.34–
7.27 (m, 2H), 7.24–7.17 (m, 3H), 3.56 (qt, J = 10.6, 6.6 Hz, 2H), 2.89 (sext, 
J = 7.1 Hz, 1H), 1.86 (dt, J = 7.9, 6.5 Hz, 2H), 1.34 (brs, 1H), 1.28 (d, J = 7.0 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 147.0, 128.6, 127.1, 126.3, 61.4, 41.1, 36.6, 
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22.6; LRMS (EI, 70 eV) m/z (%) 150 (11) [M+], 117 (51), 105 (100); EA: calc. (%) for C10H14O, 
C 79.96, H 9.39; found C 79.71, H 9.44; GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 
°C/min, 250 °C, 10 min): tR = 15.6 min; GC (chiral phase, Chiraldex (Gamma CD-6-Methyl-
2,3-pentyl PS086, 60 KPa, 110 °C, 20 min, 10 °C/min, 180 °C, 10 min): tR = 14.3 min (S, +), 
tR = 15.9 min (R, –). 
The 1H and 13C NMR data were consistent with the literature data.[200]  
 
(S)-(–)-3-Phenylbutan-1-ol (93b) 
 
Appearance: colorless liquid;1H NMR (400 MHz, CDCl3) δH (ppm) = 7.32–
7.25 (m, 2H), 7.22–7.16 (m, 1H), 7.15–7.11 (m, 2H), 3.48 (ddd, J = 10.5, 
7.4, 4.9 Hz, 1H), 3.39 (ddd, J = 10.5, 7.7, 6.7 Hz, 1H), 2.41 (ddd, J = 11.6, 7.8, 3.9 Hz, 1H), 
2.13–2.05 (m, 1H), 1.91–1.75 (m, 2H), 1.28 (brs, 1H), 0.97 (d, J = 6.7 Hz, 3H), 0.73 (d, J = 
6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 144.0, 128.6, 128.4, 126.3, 61.8, 49.8, 
36.1, 33.7, 21.1, 20.9; LRMS (EI, 70 eV) m/z (%) 178 (10) [M+], 135 (25), 118 (10), 117 (25), 
106 (10), 105 (100), 92 (10), 91 (68); EA: calc. (%) for C12H18O, C 80.85, H 10.18; found C 
80.54, H 10.12; GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min): tR 
= 16.4 min; HPLC (chiral phase, Daicel Chiracel OD-H, 0.46 cm × 25 cm, n-
heptane/isopropanol 97:3, 0.5 mL/min, 20 °C): tR = 23.2 min (S, –), tR = 25.9 min (R, +); 
[α]D20 = –13 (c = 0.3, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[201]  
 
(–)-2-Methyl-4-phenylpentan-2-ol (94) 
 
Appearance: colorless oil;1H NMR (400 MHz, CDCl3) δH (ppm) = 7.34–
7.27 (m, 2H), 7.27–7.22 (m, 2H), 7.21–7.15 (m, 1H), 2.97 (dqd, J = 9.0, 
7.0, 4.6 Hz, 1H), 1.99 (dd, J = 14.3, 8.9 Hz, 1H), 1.78 (dd, J = 14.3, 4.6 Hz, 
1H), 1.28 (d, J = 7.0 Hz, 3H), 1.16 (s, 3H), 1.14 (s, 3H), 1.08 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δC (ppm) = 148.2, 128.8, 127.2, 126.3, 71.6, 51.4, 36.6, 30.1, 30.1, 25.3; LRMS (EI, 
70 eV) m/z (%) 161 (1) [(M–OH)+], 160 (10), 145 (26), 143 (20), 118 (12), 117 (9), 105 (100), 
103 (10); HRMS (ESI) exact mass calculated for C12H18ONa [(M+Na)+], 201.1250 found 
201.1252; GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 14.1 
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min; GC (chiral phase, Gamma CD-Trifluoroacetyl GTA), 60 kPa, 50 °C, 1 °C/min, 105 °C, 10 
°C/min, 180 °C, 10 min): tR = 56.2 min (+),tR = 57.0 min (−). 
The 1H and 13C NMR data were consistent with the literature data.[202] 
 
6.5 Chiral N-Heterocyclic Carbene/Pyridine Ligands for the Iridium-Catalyzed 
Asymmetric Hydrogenation of Olefins  
6.5.1 Synthesis and analytical data of the substrates 
 
(E)-(3-(Methoxymethoxy)-2-methylprop-1-en-1-yl)benzene (111) 
 
In a two-necked round bottom flask equipped with a magnetic stirring 
bar, allylic alcohol 107 (445 mg, 3.00 mmol, 1.00 eq.), lithium bromide 
(52.0 mg, 0.60 mmol, 0.2 eq.) and PTSA (51.0 mg, 0.30 mmol, 0.10 eq.) were dissolved in 
dimethoxyethane (6.00 mL, 67.8 mmol, 22.6 eq.). The mixture was stirred at rt for 3 h and 
after this time it was diluted with H2O (5 mL), and extracted with MTBE (2×5 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by column chromatography (SiO2, 2 cm × 22 cm, 
pentane/EtOAc, 40:1) afforded 300 mg (53% yield) of the title compound as a colorless 
liquid. 
 
Rf: 0.65 in pentane/EtOAc, 40:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.36–7.29 (m, 4H), 7.26–7.23 (m, 1H), 6.55 (s, 1H), 4.71 (s, 2H), 4.12 (s, 2H), 3.43 
(s, 3H), 1.92 (s, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 137.6, 134.8, 129.0, 128.2, 
127.3, 126.6, 95.7, 73.5, 55.5, 15.8; LRMS (EI, 70 eV) m/z (%) 192 (10) [M+], 134 (42), 132 
(31), 131 (49), 130 (28), 129 (25), 119 (16), 118 (10), 117 (38), 116 (14), 115 (36), 91 (98); 
HRMS (EI) exact mass calculated for C12H16O2 [M+], 192.1150, found 192.1149; IR (neat): 
ṽ = 2931 (w), 2884 (w), 1599 (w), 1491 (w), 1444 (w), 1212 (w), 1149 (s), 1101 (s), 1039 
(s), 917 (s), 745 (m), 698 (s); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 
°C, 10 min: tR = 16.9 min. 
 
 
 
Chapter 6  
 
142 
 
(E)-tert-Butyl(2-methyl-3-phenylallyl)carbonate (113) 
 
In a two-necked round bottom flask equipped with a magnetic stirring 
bar, allylic alcohol 107 (445 mg, 3.00 mmol, 1.00 eq.), di-tert-butyl 
dicarbonate (0.76 mL, 3.30 mmol, 1.10 eq.) and Zn(OAc)2 (55 mg, 0.30 mmol, 0.10 eq.) 
were dissolved in CH2Cl2 (4 mL). The mixture was stirred and refluxed for 3 h and after this 
time it was diluted with H2O (5 mL) and extracted with CH2Cl2 (2×5 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo to give a colorless liquid. Purification by column chromatography (SiO2, 2 cm × 25 
cm, pentane/EtOAc, 70:1) afforded 430 mg (58% yield) of the title compound as a 
colorless liquid. 
 
Rf: 0.42 in pentane/EtOAc, 40:1 (visualization: UV, KMnO4); 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 7.34–7.29 (m, 2H), 7.28–7.18 (m, 3H), 6.53 (s, 1H), 4.61 (s, 2H), 1.90 (d, J = 1.3 Hz, 
3H), 1.50 (s, 9H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 153.6, 137.2, 132.6, 129.1, 128.7, 
128.3, 126.9, 82.3, 72.8, 27.9, 15.7; IR (neat): ṽ = 2980 (w), 2934 (w), 1736 (s), 1368 (m), 
1273 (s), 1250 (s), 1156 (s), 1088 (m), 845 (m), 699 (m); GC (achiral phase), 60 kPa He, 100 
°C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 21.5 min.  
The 1H and 13C NMR data were consistent with the literature data.[173]  
 
tert-Butyl (E)-2-(4-methoxy-3-(3-methoxypropoxy)benzylidene)-3-methylbutanoate 
(115) 
 
The title compound was obtained by column 
chromatography (SiO2, pentane/EtOAc, 15:1) of a batch 
containing both stereoisomers of compound 115 which 
was previously synthesized by Esther Hörmann.[119] 
 
Appearance: colorless oil; Rf: 0.31 in pentane/EtOAc, 8:1 (visualization: UV, KMnO4); 1H 
NMR (400 MHz, CDCl3) δH (ppm) = 7.34 (s, 1H), 6.94–6.80 (m, 3H), 4.11 (d, J = 6.5 Hz, 2H), 
3.88 (s, 3H), 3.57 (t, J = 6.2 Hz, 2H), 3.35 (s, 3H), 3.15 (sept, J = 6.9 Hz, 1H), 2.10 (quin, J = 
6.3 Hz, 2H), 1.55 (s, 9H), 1.24 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 
167.8, 149.3, 148.2, 139.7, 136.6, 129.1, 122.1, 114.4, 111.5, 80.7, 69.4, 66.2, 58.9, 56.1, 
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29.7, 28.5, 27.7, 21.4; LRMS (EI, 70 eV) m/z (%) 364 (35) [M+], 308 (46), 290 (14), 217 (15), 
190 (10), 73 (100); HRMS (ESI) exact mass calculated for C21H32O5Na [(M+Na)+], 387.2142, 
found 387.2144; GC (achiral phase), 100 kPa He, 100 °C, 0 min, 6 °C/min, 250 °C, 15 min): 
tR = 30.5 min. 
The 1H and 13C NMR data were consistent with the literature data.[119] 
6.5.2 Analytical data of the hydrogenation products 
 
(–)-(3-(Methoxymethoxy)-2-methylpropyl)benzene (111) 
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.32–7.27 (m, 2H), 7.23–7.18 (m, 3H), 4.64 (s, 2H), 3.46–3.37 (m, 5H), 
2.81 (dd, J = 13.4, 6.0 Hz, 1H), 2.41 (dd, J = 13.5, 8.3 Hz, 1H), 2.13–1.95 (m, 1H), 0.92 (d, J 
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) = 140.8, 129.3, 128.3, 126.0, 96.8, 72.7, 
55.3, 40.1, 35.7, 17.0; LRMS (EI, 70 eV) m/z (%) 163 (5) [(M–OMe)+], 162 (32), 132 (31), 
131 (18), 117 (44), 105 (12), 92 (32), 91 (100); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 
7 °C/min, 250 °C, 10 min: tR = 15.0 min; HPLC (chiral phase, Daicel Chiracel OJ, 0.46 cm × 
25 cm, n-heptane/isopropanol 99:1, 0.5 mL/min, 20 °C): tR = 15.2 min (+), tR = 16.9 min (–
), 70% ee; [α]D20 = –4 (c = 0.20, CHCl3). 
 
(+)-tert-Butyl (2-methyl-3-phenylpropyl)carbonate (114)  
 
Appearance: colorless liquid; 1H NMR (400 MHz, CDCl3) δH (ppm) = 
7.31–7.27 (m, 2H), 7.23–7.12 (m, 3H), 3.97 (dd, J = 10.5, 6.1 Hz, 1H), 
3.90 (dd, J = 10.5, 6.5 Hz, 1H), 2.77 (dd, J = 13.5, 6.1 Hz, 1H), 2.44 (dd, J = 13.5, 8.3 Hz, 1H), 
2.22–2.07 (m, 1H), 1.50 (s, 9H), 0.93 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC (ppm) 
= 153.9, 140.0, 129.3, 128.4, 126.2, 82.0, 71.5, 39.8, 34.8, 28.0, 16.6; LRMS (EI, 70 eV) m/z 
(%) 150 (2) [M+], 133 (26), 132 (100), 131 (23), 117 (85), 92 (14), 91 (84); HRMS (ESI) exact 
mass calculated for C15H22O3Na [(M+Na)+], 273.1461, found 273.1462; IR (neat): ṽ = 2975 
(w), 2931 (w), 1737 (s), 1455 (w), 1369 (w), 1275 (s), 1252 (s), 1159 (s), 1094 (w), 862 (w), 
701 (m); GC (achiral phase), 60 kPa He, 100 °C, 2 min, 7 °C/min, 250 °C, 10 min: tR = 20.0 
min; HPLC (chiral phase, Daicel Chiracel OJ, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 
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0.5 mL/min, 20 °C): tR = 14.6 min (+), tR = 16.9 min (–), 70% ee; [α]D20 = +9.1 (c = 0.20, 
CHCl3). 
 
(+)-tert-Butyl 2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate (116) 
 
Appearance: colorless oil; 1H NMR (400 MHz, CDCl3) δH 
(ppm) = 6.86–6.64 (m, 3H), 4.08 (t, J = 6.5 Hz, 2H), 3.82 (s, 
3H), 3.56 (t, J = 6.2 Hz, 2H), 3.35 (s, 3H), 2.92–2.63 (m, 2H), 
2.31 (ddd, J = 9.7, 7.2, 5.8 Hz, 1H), 2.09 (quin, J = 6.3 Hz, 2H), 1.87 (dq, J = 13.7, 6.9 Hz, 1H), 
1.29 (s, 9H), 0.94 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δC 
(ppm) = 173.4, 148.3, 148.9, 133.0, 121.4, 114.4, 111.8, 80.1, 69.6, 66.2, 58.8, 56.2, 55.4, 
35.8, 31.0, 29.8, 28.2, 20.7, 20.3; LRMS (EI, 70 eV) m/z (%) 366 (37) [M+], 311 (14), 293 
(14), 210 (16), 209 (88), 177 (20), 151 (13), 138 (17), 137 (57), 73 (100); HRMS (ESI) exact 
mass calculated for C21H34O5Na [(M+Na)+], 389.2298, found 389.2301; GC (achiral phase), 
100 kPa He, 100 °C, 0 min, 6 °C/min, 250 °C, 15 min: tR = 28.2 min; HPLC (chiral phase, 
Daicel Chiracel AD-H, 0.46 cm × 25 cm, n-heptane/isopropanol 99:1, 0.6 mL/min, 20 °C): 
tR = 18.2 min (–), tR = 19.3 min (+), 49% ee; [α]D20 = +3.5 (c = 0.30, CHCl3). 
The 1H and 13C NMR data were consistent with the literature data.[119] 
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